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General introduction
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THE URINARY TRACT
The urinary tract encompasses an upper tract (the renal pelvis and ureters) and a lower 
tract (the bladder and urethra) (figure 1). The function of the urinary tract is to collect 
and to dispose urine. Urine produced by the kidneys is collected in the renal pelvis, 
and then flows via the ureters into the urinary bladder. Here, the urine is stored until 
urination. On average an adult person will urinate 1.4 liters of urine per 24 hours 1. In 
a clinical setting, a urine output of at least 0.5mL/kg body weight/hour is considered 
adequate. The largest component of urine is water (91-96%), therefore the variation 
in total urine output is primarily due to fluid intake. Several chemical components of 
urine are: Nitrogen (mostly in the form of urea), Phosphorus, Potassium, Calcium and 
Creatinine 1. Lastly, urine also contains organic components, e.g. inflammatory cells, 
urothelial cells and sometimes bacteria.
The urinary tract is histologically made up of different cell layers; its inner lining 
consists of a specialized epithelium of urothelial cells, referred to as urothelium and 
is approximately 3-6 cells thick 3. The urothelial cell layer that is in contact with urine 
consists of large and flat umbrella cells that prevent components from urine to enter 
the bladder wall (figure 2) 3. The urothelium maintains the tissue barrier as the bladder 
expands and contracts. The urothelium is a regenerative cell layer and is separated from 
the lamina propria by a basement membrane (figure 2). The lamina propria consists of 
connective tissue containing stromal cells, small blood vessels and occasional smooth 
muscle fibers. The small bundles of smooth muscle fibers in the lamina propria are 
referred to as the muscularis mucosae 3. Beneath the lamina propria lie large bundles 
of muscle fibers. The thickness of this muscularis propria or musculus detrusor varies 
at different locations in the bladder wall. Normally, the muscle is relaxed allowing 
expansion of the bladder enabling it to fill with urine 4. During urination, the musculus 
detrusor contracts (figure 2) and the bladder is emptied. The outer most layer of the 
urinary bladder, the perivesical tissue, is a layer of fat.
The urinary bladder is a unique organ to study, since it is hollow and able to store a 
body fluid for a number of hours. Because of these features, the urinary bladder can be 
inspected via the urethra using a cystoscope and operations of the bladder can often 
be done transurethrally. Moreover, the urinary bladder can be flushed with therapeutic 
agents thereby avoiding systemic treatment. Finally, the urine provides doctors and 
researchers with a nearly endless supply of study material.
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Figure 1. A schematic representation of the upper urinary tract (the renal pelvis and ureters) 
and the lower urinary tract (the bladder and urethra) 2. Reprinted with permission from the 
European Association of Urology.
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Figure 2. Cross-sectional histology slides with hematoxylin and eosin (H&E) staining showing 
the different cell layers of the urinary bladder wall at 20x magnification (A) and at 100x 
magnification (B). 
BLADDER CANCER
The incidence of bladder cancer has increased more than 1.5-fold since the 1990s, with 
currently over 7,000 new cases each year in The Netherlands 5, 6. The incidence increases 
with age and peaks between 50-70 years of age 7. The male-female ratio is 3:1, making it 
the fourth most common solid cancer in males, with only prostate, lung and colorectal 
cancer occurring more frequently 8, 9. Besides gender and age, tobacco smoking is the 
most important risk factor; current cigarette smokers have a three times higher risk 
than never-smokers 9, 10. Most bladder cancers (>95%) arise from the inner lining of the 
urinary tract; the urothelium 7. Bladder cancer is therefore also referred to as urothelial 
carcinoma. A small percentage of cancers in the bladder originate from other cell types. 
Since the urothelium lines the entire urinary tract, urothelial cancer can occur in the 
lower urinary tract but also in the upper urinary tract. 
14
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Diagnosis
Symptoms of bladder cancer may include dysuria (unpleasant sensation during 
urination), frequency and urgency (sudden urge to urinate). However, by far most 
patients present with hematuria: blood cells in their urine. Hematuria can be either 
microscopic (not visible to the eye) or macroscopic (visible to the eye). Patients with 
microscopic hematuria are usually identified by coincidence, because of routine urine 
analysis. In women, the differentiation between hematuria and vaginal bleeding as the 
cause of blood cells in the urine is sometimes difficult to make.
In general, causes of hematuria can be benign or malignant. Examples of benign 
causes include; trauma, exercise induced hematuria, stones, urinary tract infections, 
vascular malformations or benign prostate hyperplasia. Malignant causes of hematuria 
include kidney cancer, prostate cancer or bladder cancer 11. Only 3–28% of the patients 
presenting with hematuria will be diagnosed with bladder cancer 12, 13. Hence, more 
than 70% of the patients have different causes of hematuria and most of these are non-
malignant causes.
Cystoscopy accompanied by histological confirmation of the presence of tumor cells 
in a biopsy is considered the gold standard in bladder cancer diagnostics 8. During a 
cystoscopy, the urologist visually inspects the bladder by inserting a flexible or rigid 
scope through the urethra into the bladder. Urine cytology is used in high-risk patients 
to confirm suspicion of the presence of a bladder tumor. In cytology, the pathologist 
inspects cells obtained from urine under a microscope. In addition, imaging of the 
upper urinary tract by computed tomography (CT) scan or ultrasound can aid in the 
diagnosis of upper urinary tract abnormalities.
Treatment
Patients found to have a suspicious lesion in their bladder will undergo a transurethral 
resection (TUR). During this procedure instruments are inserted through the urethra 
and the urologist will scrape the bladder tumor off the bladder wall. A pathologist will 
analyze the removed tissue in order to confirm the diagnosis of bladder cancer and to 
determine the histological subtype of the bladder tumor. 
The treatment and follow-up of a bladder tumor is dependent on the pathological 
diagnosis, which is described according to the Tumor, Node, Metastasis (TNM) 
classification system (table 1, figure 3) 14. If a bladder tumor is confined to the urothelium 
(stage Tis or Ta) or the tumor shows micro-invasive growth into the lamina propria of the 
bladder (T1), the tumor is called a non-muscle-invasive bladder cancer (NMIBC). When 
the tumor grows deeper into the bladder wall, invading the musculus detrusor (T2), the 
15
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perivesical tissue (T3) or invades surrounding organs (T4), the bladder tumor is called a 
muscle-invasive bladder cancer (MIBC). Positive nodal disease can be in a single lymph 
node (N1) or multiple locoregional lymph nodes (N2), or more distant from the bladder 
(N3). Distant metastases (e.g. lung, bone, liver or brain metastasis) are classified as being 
absent (M0) or present (M1) (table 1) 14.
Table 1. TNM classification of malignant tumors of the urinary bladder 14.
T - Primary Tumor
Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
Ta Non-invasive papillary carcinoma
Tis Carcinoma in situ: “flat tumor”
T1 Tumor invades subepithelial connective tissue
T2 Tumor invades muscle
  T2a Tumor invades superficial muscle (inner half )
  T2b Tumor invades deep muscle (outer half )
T3 Tumor invades perivesical tissue:
  T3a microscopically
  T3b macroscopically (extravesical mass)
T4 Tumor invades any of the following: prostate stroma, seminal vesicles, uterus, vagina, pelvic wall, 
abdominal wall
  T4a Tumor invades prostate stroma, seminal vesicles, uterus, or vagina
  T4b Tumor invades pelvic wall or abdominal wall
N - Regional Lymph Nodes
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph-node metastasis
N1 Metastasis in a single lymph node in the true pelvis (hypogastric, obturator, external iliac, or 
presacral)
N2 Metastasis in multiple lymph nodes in the true pelvis (hypogastric, obturator, external iliac, or 
presacral)
N3 Metastasis in common iliac lymph node(s)
M - Distant Metastasis
M0 No distant metastasis
M1 Distant metastasis
16
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Figure 3. A schematic representation of the invasion depth of different T-stages of bladder 
cancer 15. Reprinted with permission from the European Association of Urology.
Over two thirds of new patients are diagnosed with NMIBC, the remaining one third 
of patients are diagnosed with MIBC 8. Patients diagnosed with NMIBC are treated 
by TUR and sometimes additional intravesical instillation of chemotherapeutic or 
immunotherapeutic drugs 8. If the bladder tumor has grown deeper into the detrusor 
muscle, additional more invasive treatment modalities are indicated.
The preferred curative treatment for MIBC is radical cystectomy with pelvic lymph node 
dissection, which is sometimes preceded by four courses of systemic cisplatin-based 
neoadjuvant chemotherapy (NAC) 16. During a radical cystectomy, the whole urinary 
bladder is removed and a continent or incontinent urinary diversion is created from the 
small bowel. NAC results in only 6% increase in 10-year survival, because the response to 
treatment differs highly between patients. Only 20-38% of patients are without residual 
disease after NAC (ypT0N0) 17, 18. Patients who do not respond to NAC experience 
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a delay in time to potentially curative surgery and in addition may suffer from toxic 
side effects of chemotherapy. Compared to non-NAC treated patients, NAC treated 
patients with no response to NAC (f.i. pT2-T4 versus ypT2-T4) have worse survival after 
radical cystectomy 19. Other potentially curative treatments include chemo-radiation, 
partial cystectomy with brachytherapy, or external beam radiotherapy, however, these 
treatment modalities are reserved for a selected group of patients. 
Prognosis and surveillance
The overall and cancer-specific survival of NMIBC is >90%, however the recurrence 
rate is high (>50%) and these recurrences may progress to MIBC (in approximately 
5-10% of cases) 8, 20. The survival of MIBC is highly dependent on radical surgery and 
accompanying lymph node status. The 5-year survival rate for stage pT2N0 is around 
73.5% but it drops to a mere 46.1% for stage pT4N0. Patients with node-positive disease 
at radical cystectomy have a poor outcome with a 5-year disease specific survival of 
only 22.4% 21. A large study on recurrence after cystectomy showed that around 80% of 
the cases with pathological node-positive disease (pN1-3) recurred versus only 20% of 
pathological node-negative organ-confined disease 22.
Surveillance of NMIBC patients is based on their European Association of Urology (EAU) 
risk stratification for recurrence and progression (low, intermediate or high risk) (table 2) 
8, 20. Risk stratification is based on clinico-pathological parameters and was first proposed 
by the European Organisation for Research and Treatment of Cancer (EORTC) (table 3 
and 4). These patients follow different surveillance schemes, ranging from cystoscopic 
evaluation every year to 3-monthly cystoscopies. Besides cystoscopy, cytology is 
sometimes used in the follow-up of bladder cancer patients. Also, ultrasound or CT 
imaging to visualize the upper urinary tract may be necessary. Finally, some patients 
will undergo random biopsies of their bladder wall to exclude the presence of Tis, which 
is sometimes difficult to detect by cystoscopic inspection only 8.
MIBC patients have a very different surveillance schedule. These patients will undergo 
frequent CT scans and blood tests to analyze their physical well-being and disease 
status 16. More and more attention is given to the mental and emotional challenges of 
having to undergo a radical cystectomy and the difficulties accompanied by living with 
a urinary diversion. Specialized uro-oncology nurses provide practical and emotional 
guidance. Also, the impact on the sexuality of patients treated for bladder cancer (e.g. 
due to urine leakage or erectile dysfunction) is addressed. 
Overall, surveillance of both NMIBC and MIBC will take at least 5 years but mostly far 
longer.
18
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Table 2. European Association of Urology (EAU) guidelines on non-muscle invasive urothelial 
carcinoma, risk group stratification 13.
Low-risk tumors Primary, solitary, Ta, LG/G1, < 3 cm, no CIS
Intermediate-risk tumors All tumors not defined in the two adjacent categories (between the category 
of low and high risk)
High-risk tumors Any of the following:
• T1 tumor
• HG/G3 tumor
• CIS
• Multiple and recurrent and large (>3 cm) Ta G1G2 tumors (all conditions 
must be present in this point)
CIS = carcinoma in situ; HG = high grade; LG = low grade.
Table 3. European Organisation for Research and Treatment of Cancer (EORTC) nomogram, 
weights used to calculate the recurrence and progression scores 19.
Factor Recurrence Progression
Number of tumors  
  Single 0 0
  2 to 7 3 3
  ≥ 8 6 3
Tumor size  
  < 3 cm 0 0
  ≥ 3 cm 3 3
Prior recurrence rate  
  Primary 0 0
  ≤ rec/yr 2 2
  > 1 rec/yr 4 2
T category  
  Ta 0 0
  T1 1 4
CIS 
  No 0 0
  Yes 1 6
Grade  
  G1 0 0
  G2 1 0
  G3 2 5
Total score 0–17 0–23
19
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Table 4. Probability of recurrence and progression according to the total EORTC risk scores 19. 
Recurrence score
Probability of recurrence
1 year % (95% CI) 5 years % (95% CI)
0 15 (10 - 19) 31 (24 - 37)
1–4 24 (21 - 26) 46 (42 - 49)
5–9 38 (35 - 41) 62 (58 - 65)
10–17 61 (55 - 67) 78 (73 - 84)
Progression score
Probability of progression
1 year % (95% CI) 5 years % (95% CI)
0 0.2 (0 - 0.7) 0.8 (0 - 1.7)
2–6 1.0 (0.4 - 1.6) 6 (5 - 8)
7–13 5 (4 - 7) 17 (14 - 20)
14–23 17 (10 - 24) 45 (35 - 55)
Costs and awareness
The long duration of surveillance, combined with (sometimes) invasive surgical 
procedures, frequent imaging and invasive cystoscopies contribute to bladder cancer 
being one of the costliest cancers in western countries. Bladder cancer accounts for 
3% of the entire cancer care costs in the European Union (€ 143 billion in 2012) 23. The 
high incidence and recurrence rate of NMIBC, together with the poor survival rate of 
MIBC and the immense costs make bladder cancer a serious public health problem. Still, 
bladder cancer is desperately understudied and awareness in the general population 
is shortcoming. A lack of funding opportunities is a major cause of this problem 24. For 
the future, this absence of awareness and the shortage of research funding implicate 
an important responsibility and challenge for all people involved in the field of urology.
BASIC GENETICS
The entire genetic information of an organism is stored in the DNA (deoxyribonucleic 
acid). DNA consists of two complementary strands of millions of bases on a backbone 
of deoxyribose sugar and phosphate groups 25. The four bases are: Adenine (A), Thymine 
(T), Guanine (G) and Cytosine (C). A base combined with its ribose and phosphate group 
is called a nucleotide. The double stranded structure of DNA is achieved by the formation 
of G-C and A-T pairs. The human genome consists of 3,000,000,000 of these base pairs 
and codes for ~25.000 genes. Each gene encompasses a unique sequence of bases. 
20
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The DNA is situated in the cell nucleus, consisting of 23 chromosome pairs 25. When 
active, genes are transcribed and mRNA is produced, a process called transcription. The 
mRNA also consists of bases that are copied based on the DNA sequence but it is single 
stranded. The mRNA is subsequently translated into a protein (translation). A protein 
is a string of amino acids. A sequence of 3 bases in the DNA (and mRNA) codes for one 
amino acid in a protein. This is called the genetic code. Proteins function as the cell’s 
work force and also as signaling molecules within and between cells.
The influence of genes can be altered by turning the gene on or off via activating or 
inhibitory proteins. Other ways to influence gene expression may be activating or 
silencing mutations. Different types of point mutations are: silent mutations, missense 
mutations, or nonsense mutations. In silent mutations the nucleotide alteration does 
not change the amino acid and thus does not change the protein structure. In missense 
mutations the nucleotide alteration results in a different amino acid, leading to a 
different protein. In a nonsense mutation, the nucleotide alteration leads to a premature 
stop codon, leading to an incomplete and usually nonfunctional protein. Hence, DNA 
mutations can lead to changes that increase activity of the produced proteins; gain-of 
function mutations. On the contrary, mutations may also lead to a reduction of activity 
or complete inactivity of the produced proteins; loss-of-function mutations.
Furthermore, the DNA sequence can be altered by deletion of nucleotides or (parts of ) 
genes. All genes occur in diploid in a cell (positioned on paired chromosomes), one 
maternal copy and one paternal copy, referred to as alleles. Sometimes a whole section 
of a chromosome or gene is lost, a process referred to as Loss of Heterozygosity (LOH). In 
contrast, in healthy cells, large numbers of sections of the genome are repeated. These 
sections of repeats can be short repeats or long repeats. Copy Number Variation (CNV) is 
a phenomenon that describes the differences in the length of repeats between different 
individuals 25, 26. The differences in repeats lead to variety in the population and may also 
be altered in cancer cells. 
Methylation is another way to influence gene expression. It is an epigenetic process in 
which a methyl-group (CH3-group) is added to a Cytosine in the DNA by the enzyme 
DNA-methyltransferase 27. A Cytosine followed by a Guanine often cluster in very CG-
rich regions in the DNA, called CpG islands. Hypermethylation of certain CpG islands is 
thought to alter gene expression by, for instance, preventing the transcription complex 
from binding to the promotor site 27. Hypermethylation may lead to Allelic Imbalance 
(AI), a process that leads to different expression levels of a certain allele or gene in a cell 
25, 28. Besides hypermethylation also other alterations in f.i. regulatory regions of genes 
may cause AI. 
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CANCER EVOLUTION
Human life starts with one fertilized egg cell. For development during pregnancy and 
adulthood, cells need to divide and generate daughter cells. The daughter cells start 
to differ from each other, divide further and form the different organs and tissues. 
Eventually over 200 differentiated cell types form the organs, tissues and blood cells. An 
adult human body contains about 40,000,000,000 cells. In the adult certain cells, such 
as brain cells do not divide anymore and in other tissues there is a certain level of cell 
renewal, which is required for the function of the organ. However, it is mandatory that 
the number of cells in an adult does not increase further. Tightly regulated processes of 
cell division and cell death accomplish this. A cancer develops when cells start to divide 
uncontrollably or do not die when necessary, leading to tumor formation or overgrowth 
of normal cells and eventually destruction of normal architecture of tissues and 
dissemination throughout the body. Cells have to overcome certain safety mechanisms 
and barriers in order to become a cancer-cell. The capabilities a cell has to acquire to 
develop into a cancer are referred to as the hallmarks of cancer. Six hallmarks of cancer 
have been formulated by D. Hanahan and R.A. Weinberg in 2000 29. Ever since, new 
discoveries have unveiled an increasing complexity of cancer development, leading to 
the recently expanded hallmarks of cancer 30. Some important hallmarks are:
Sustained proliferative signaling: Growth factors bind to cell-surface receptors (growth 
factor receptors), which stimulate intracellular signaling pathways that stimulate 
progression through the cell cycle 30. In normal cells, the presence of growth signals is 
strictly controlled by adjusting the production and release of growth factors.  Cancer 
cells are able to disturb these signals by for instance: stimulation of surrounding cells 
to release more growth factors, upregulation of the number of receptors on the cell 
surface, or structurally alter receptors to render them independent of the growth factor 
ligand 29. In cancer cells, activating mutations are often found in genes coding for growth 
factor signaling molecules, so called gain-of-function mutations. 
Evading growth suppressors: A way to maintain a good balance between cell renewal and 
the total number of cells in healthy tissues, tumor suppressor genes produce growth 
suppressors 29. Cancer cells can circumvent these genes in order to sustain proliferation. 
Two well-known tumor suppressor genes are TP53 and RB. Nicknamed the guardian of 
the genome, TP53 receives input from stress and cell damage. If damage occurs, TP53 
will either initiate a repair mechanism or it will trigger apoptosis (cell death)29. In cancer 
cells, inactivating mutations can be found in tumor suppressor genes, so called loss-of-
function mutations.
22
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Enabling replicative immortality: Normally, cells only have a limited number of cell 
cycles until division stops: this is called the Hayflick limit 30. Telomeres are protective 
repetitive nucleotide sequences at the end of a chromosome and shorten at every cell 
cycle. Telomerase is crucial for cancer cell survival; it increases telomere length at the 
chromosome ends. Without telomerase replicative senescence and genomic instability 
would occur. In normal cells, telomerase is active in stem cells but becomes inactive in 
differentiated cells 31. 
Invasion and metastases: During cancer progression, tumors alter in shape and slowly 
lose their connection to surrounding cells and extracellular matrix 32, leading to local 
invasion and cell spread throughout the circulatory system (blood or lymphatic vessels). 
At a distant organ site, the tumor cells may exit from the vessels (extravasation) and 
metastases will start to form 32.      
GENETIC ALTERATIONS IN BLADDER CANCER
On a DNA level, bladder cancer is known to have a high mutational burden. This 
means, that most bladder cancer tumor cells harbor many different mutations. Of all 
cancer types, the mutational burden in bladder cancer is amongst the highest, only 
slightly lower than in lung cancer and melanoma 33, 34. Besides DNA mutations, other 
DNA alterations can occur in bladder cancer, such as; copy number alterations (CNAs, 
deletions or gain of (parts) of a gene) and genomic rearrangements (coupling of two 
unrelated genes).  
Oncogenic mutations
Some of the most affected signaling pathways in cancer are the RTK-RAS-MAPK pathway 
and the RTK-PI3K-Akt pathway (figure 4) 35. RTK stands for Receptor Tyrosine Kinase. 
Specific growth factors (for example, cytokines or hormones) bind to the extracellular 
domain of an RTK, thereby activating the intracellular kinase domain of the receptor. 
The activation results in the stimulation of downstream cascades that affect cell 
proliferation and growth resulting in cell division. Many different types of RTKs exist, of 
which Fibroblast Growth Factor Receptor 3 (FGFR3) is especially important in bladder 
cancer. Approximately two-thirds of all NMIBCs have activating FGFR3 mutations 36. In 
MIBC, <15% of tumors have FGFR3 mutations, although >40% of MIBCs overexpress 
FGFR-3 37. Tumors with an FGFR3 mutation have a favorable disease course; they grow 
slowly and are less likely to progress to MIBC than FGFR3 wild type tumors 4, 37-39. 
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Figure 4. Flow diagram of the most affected signaling pathways in cancer, including the RTK-
RAS-MAPK pathway and the RTK-PI3K-Akt pathway 35. 
There are three known RAS genes, which code for KRAS, NRAS and HRAS. All RAS proteins 
are small GTPases that are involved in signal transduction. RAS proteins can be either 
bound to guanosine diphosphate (GDP); resulting in an inactivated state, or can be 
bound to guanosine triphosphate (GTP); resulting in an activated state 40. Oncogenic 
mutations result in a permanently activated state, leading to persistent downstream 
signaling activation (figure 4). In general, KRAS mutations are most frequent in cancer. 
For instance, KRAS is mutated in 90% of pancreatic cancers and 45% of colorectal cancers 
41. Although in general HRAS mutations occur less frequently in cancer, in bladder cancer 
HRAS is the most commonly mutated RAS gene. Still, mutations in the RAS family of 
genes are rare in bladder cancer; HRAS mutations are present in only 5% of bladder 
tumors 34. 
Approximately 20% of (N)MIBC tumors have a mutation in the PIK3CA gene 34. PI3K 
stands for phosphatidylinositol-3-kinase, and consists of a regulatory subunit and a 
catalytic subunit. This catalytic subunit (phosphatidylinositol-4,5-bisphosphate-3-
kinase catalytic subunit alpha) is encoded by the PIK3CA gene 42. PI3K is activated by 
24
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RTKs, but can also be activated via crosstalk with the activated RTK-RAS-MAPK pathway. 
Downstream signaling of PIK3CA, via Akt and mTOR results in cell growth and cell 
survival (figure 4). 
In 2014, the importance of the Telomerase reverse transcriptase (TERT) gene in bladder 
cancer became clear, >70% of bladder tumors were found to harbor a TERT promotor 
mutation 31. The presence of a TERT mutation was not associated with stage or grade 
of the tumors, but was found to be more frequent in tumors that also harbored FGFR3 
mutations 31. The presence of mutations in these genes is thus not always mutually 
exclusive; in fact significant overlap between different mutations occurs. 
Gene hypermethylation
Genome-wide methylation analyses have identified several genes that are significantly 
hypermethylated in bladder cancer cells versus normal urothelial cells 43. Bladder cancer 
specific methylation of OTX1, ONECUT2, TWIST1 and several other genes was found 
to be useful for the diagnosis of bladder cancers 44-46. A combination of methylation 
markers OTX1, ONECUT2, and OSR1 together with mutation marker FGFR3 could detect 
the presence of bladder cancer cells in urine samples with 74% sensitivity 44. Another 
combination of methylation markers OTX1, ONECUT2, OSR1 with SIM2 and MEIS1 showed 
that these methylation markers combined with age, gender and type of hematuria 
could detect bladder cancer cells in urine samples with a sensitivity of 82% 45. Finally, 
TWIST1 and NID2 gene were identified to be hypermethylated in urine sediments. The 
two-gene panel was 90% sensitive for detecting primary bladder cancer 46. 
In addition, hypermethylation of the GATA2, TBX2, TBX3, and ZIC4 genes was shown to be 
associated with progression of NMIBC to MIBC 43. Furthermore, methylation of TBX2 and 
TBX3 can, for instance, be used to stratify Ta tumors into three distinct molecular grades, 
with different risks of progression 47, with a 5-year progression rate of 8% for the low 
molecular grade group versus 29% and 63% for the intermediate and high molecular 
grade groups. Finally, hypermethylation of ZIC4 was shown to be an independent 
predictor of progression to MIBC in patients with Ta bladder tumors 47. 
Gene expression
In recent years, our knowledge of the molecular alterations in bladder cancers has 
increased substantially. Several research groups in the world have identified genetically 
distinct tumors that appeared associated with different clinical behaviors and therapy 
responsiveness 33, 48-50. In NMIBCs, one group described three different classes based on 
gene expression analyses 51. Another group found two different classes of tumors based 
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on copy-number variations and loss of chromosome 9q 52. Both groups reported an overall 
lower mutational burden in NMIBC tumors compared to MIBC tumors (approximately 
3-fold).  Also, both groups described an enrichment of APOBEC mutational signatures in 
high-risk NMIBC tumors 51, 52.
The Cancer Genome Atlas (TCGA) initiative strived to analyze a large set of multiple 
tumor types, in order to provide a better overview of frequently occurring DNA, RNA and 
protein alterations. In 412 chemo-naïve non-metastatic MIBC from 36 different tissue 
source sites a total of 58 frequently mutated genes was identified 34. Different mutational 
signatures were found to be related to differences in tumor behavior. Interestingly in 
MIBC, an APOBEC gene signature was correlated to a favorable prognosis. Furthermore, 
clustering of MIBC tumors based on their gene expression profile revealed five different 
gene expression subclasses. The five identified subclasses were ‘luminal-infiltrated’, 
‘luminal-papillary’, ‘luminal’, ‘basal/squamous’, and ‘neuronal’ 34. These findings will 
certainly play a major role in upcoming clinical trials and future research to optimize 
personalized management of both NMIBC and MIBC patients.  
BIOMARKERS AND BLADDER CANCER
A biomarker is a feature (like a molecule or gene) that can be detected and measured 
in a patient to identify certain pathological or physiological processes in the body. In 
bladder cancer patients, biomarkers can aid in the diagnosis, prognosis, treatment and 
surveillance. We identified biomarkers in either tissue derived DNA, tissue derived RNA 
or urine derived DNA and evaluated their use in bladder cancer management.
LABORATORY TECHNIQUES
In the research described in this thesis, different laboratory techniques were used. In 
short the most important features of these techniques are described below.
Snapshot assay, single-nucleotide extension reaction 
In a Snapshot assay one can interrogate a single nucleotide on a specific position on 
the DNA strand. First, the DNA sequence of interest (containing the specific nucleotide 
position you wish to interrogate) is multiplied by polymerase chain reaction (PCR), 
using specific primers. Then, specific probes will bind to the DNA adjacent to the 
nucleotide under interrogation. Next, fluorescently labelled nucleotides (called 
dideoxynucleotides or ddNTPs) are added. Only one of such nucleotides can bind to 
the probe. Then, all excess DNA and ddNTPs are removed and the remaining DNA is 
26
General introduction
analyzed on a sequencer. The fluorescent label will tell which nucleotide was able to 
bind to the probe, and thus which nucleotide is present at the opposite specific position 
on the amplified DNA (figure 5). This technique is used to identify hotspot mutations or 
methylation of specific CGs.
Figure 5. Output from a Snapshot analysis of methylation of the OTX1 gene (upper panel, the 
C-peak depicts the methylated Cytosine, the T-peak depicts the unmethylated Cytosine) and 
mutation analysis of the FGFR3 gene (lower panel, showing a wild type gene = no mutation 
present). 
Methylation Specific Polymerase Chain Reaction (MSP)
MSP is a technique that uses methylation specific primers to amplify the DNA. The 
DNA is first treated with bisulfite. During the bisulfite conversion, methylated cytosines 
are protected from bisulfite modification because of their methyl-group, whereas 
unmethylated cytosines will be affected and transformed to uracils. After a PCR to amplify 
the DNA region of interest, the uracils will be transformed into thymines. Primers for 
MSP are specifically designed to cover regions of a chosen CpG island (region with many 
CG nucleotides). If a majority of the DNA of interest is unmethylated, the methylation-
specific primer cannot anneal to the DNA and no PCR product (amplified DNA) will be 
formed. This technique is used to identify a region of methylated CGs in the DNA.
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Quantitative real-time polymerase chain reaction (qRT-PCR)
A qRT-PCR is used to quantitatively measure the amount of a certain mRNA (product 
of a certain gene). In a qRT-PCR the enzyme reverse transcriptase is first employed to 
generate complementary DNA (cDNA) from the mRNA. Next, a PCR is used to multiply 
the cDNA. By comparing expression of genes of interest to household genes, differences 
in gene expression can be measured, expressed as delta Ct (ΔCt). This indicates the 
difference between the number of PCR cycles between the product of the gene of 
interest and the household gene standard. In figure 6 an example of an output of a 
dilution series of a qRT-PCR reaction is given. This figure nicely shows that a smaller 
number of templates require more cycles to reach the threshold value. Note that 
duplicate samples completely overlap. 
Figure 6. Dilution series of pooled T24 cell line RNA qRT-PCR.
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AIMS OF THIS THESIS
The general aim of this thesis is to evaluate and validate the use of (epi)genetic 
biomarkers in personalized bladder cancer management; including diagnosis of 
primary disease, prognosis of disease, tools for treatment allocation and their use in 
individualized surveillance regimens. More specifically the aims of this thesis are: 
• To develop and validate a non-invasive diagnostic urine assay for the primary 
diagnosis of bladder cancer
• To optimize NMIBC risk stratification for progression using molecular biomarkers
• To evaluate biomarker tools for the prediction of response to chemotherapy and 
the risk of disease progression in MIBC 
• To provide insight into both the challenges and promises of the preclinical 
development of new targeted therapies for bladder cancer patients
• To evaluate the feasibility of implementing urine analysis for NMIBC surveillance
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SCOPE OF THE THESIS
The research performed is outlined in the following parts.
Part I. Diagnosis of bladder cancer.
Almost all patients that present with hematuria to the urologist will undergo a cystoscopy 
to evaluate the cause of hematuria. A cystoscopy is invasive, uncomfortable and costly. 
Since, bladder cancer is only found in a minority of patients presenting with hematuria, 
biomarkers could aid in optimizing the current diagnostic protocol. In chapter 2, the 
development of a methylation and mutation based urine assay is explored to improve 
the selection of patients who should undergo a cystoscopy. We validated this urine 
assay in a retrospective international cohort, as described in chapter 3. In chapter 4, 
we elaborate on the validation of the assay in a large prospective regional cohort. 
Part II. Prognosis of patients diagnosed with bladder cancer.
NMIBC patients can be stratified into different risk categories according to clinico-
pathological parameters described in the EAU guidelines. This risk stratification does 
not include any molecular biomarkers of recurrence or progression (table 2 and 3). 
In chapter 5, we investigate the added effect of four different methylation markers 
(GATA2, TBX2, TBX3 and ZIC4) and four different mutation markers (FGFR3, TERT, PIK3CA 
and RAS) to the EAU NMIBC risk stratification.
NAC results in a modest 6% increase in 10-year survival, because the response to 
treatment differs highly between patients. Patients who do not respond to NAC 
experience a delay in time to curative surgery and might experience toxic side effects of 
chemotherapy. Tools for the prediction of disease progression could potentially aid in 
the decision whether or not to offer NAC. In chapter 6, we investigate the neutrophil-
to-lymphocyte ratio as a predictor of poor outcome in MIBC patients treated with pre-
operative chemotherapy. Furthermore, in chapter 7 we attempted to evaluate the 
clinical applicability a previously published gene expression model designed to predict 
the presence of lymph node positive disease at radical surgery in MIBC patients that 
were preoperatively staged as being clinically node negative. 
Part III. Treatment and surveillance of bladder cancer patients.
Targeted therapies target specific molecules in different cellular processes of cancer 
cells to stop the cells from dividing or even stimulate cell death (figure 7). Numerous 
targeted therapies are available for the treatment of many different types of cancer. 
However, for bladder cancer, up to January 2017, no targeted therapies were approved. 
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Figure 7. Different cellular processes involved in cancer development. The different processes 
show the diversity of potential targets for therapies 35.
In chapter 8, we reviewed studies published since 2009 reporting on the evaluation 
and the development of targeted therapies in animal bladder cancer models (in vivo 
studies). In this systematic review, we tried to analyze the reasons for the scarcity of new 
targeted therapies for bladder cancer patients.
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Due to the high recurrence rate of NMIBC and the risk of progression to MIBC, patients 
treated for NMIBC are kept under strict surveillance. Reducing the amount of invasive 
cystoscopies in the surveillance of NMIBC could be a fruitful strategy to reduce the 
care costs for bladder cancer. In chapter 9, we performed a cost-effectiveness study 
to evaluate the safety and potential cost-reduction of implementing urine based 
surveillance strategies that would partially replace cystoscopies. 
Part IV. General discussion and summary
In chapter 10, a bird’s eye view of the thesis is given and where possible, overall 
conclusions are drawn. Finally, challenges for the research field, implications for clinical 
practice, future perspectives and aspirations are discussed.
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ABSTRACT
Purpose: Many patients enter the care cycle with gross or microscopic hematuria and 
undergo cystoscopy to rule out bladder cancer. Sensitivity of this invasive examination 
is limited, leaving many patients at risk for undetected cancer. To improve current 
clinical practice more sensitive and noninvasive screening methods should be applied.
Materials and methods: A total of 154 urine samples were collected from patients 
with hematuria, including 80 without and 74 with bladder cancer. DNA from cells in 
the urine was epigenetically profiled using 2 independent assays. Methylation specific 
polymerase chain reaction was performed on TWIST1. SNaPshot methylation analysis 
was done for different loci of OTX1 and ONECUT2. Additionally, all samples were analyzed 
for mutation status of TERT (telomerase reverse transcriptase), PIK3CA, FGFR3 (fibroblast 
growth factor receptor 3), HRAS, KRAS and NRAS.
Results: The combination of TWIST1, ONECUT2 (2 loci) and OTX1 resulted in the best 
overall performing panel. Logistic regression analysis on these methylation markers, 
mutation status of FGFR3, TERT and HRAS, and patient age resulted in an accurate model 
with 97% sensitivity, 83% specificity and an AUC of 0.93 (95% CI 0.88e0.98). Internal 
validation led to an optimism corrected AUC of 0.92. With an estimated bladder cancer 
prevalence of 5% to 10% in a hematuria cohort the assay resulted in a 99.6% to 99.9% 
negative predictive value.
Conclusions: Epigenetic profiling using TWIST1, ONECUT2 and OTX1 results in a high 
sensitivity and specificity. Accurate risk prediction might result in less extensive and 
invasive examination of patients at low risk, thereby reducing unnecessary patient 
burden and health care costs.
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INTRODUCTION
Hematuria, which accounts for up to 20% of all urological visits, is the presence of red 
blood cells in urine.1 Urological cancer is found to be the cause of hematuria in 5% of 
patients with microscopic hematuria and in up to 20% with macroscopic hematuria.2,3 
Therefore, it is an important clinical question to discriminate between a malignant and 
nonmalignant cause of hematuria since early detection of bladder cancer correlates 
with an increased likelihood of bladder preservation and improved overall survival.4
The typical diagnostic analysis of hematuria includes cystoscopy, which has 68% to 
83% sensitivity to detect BC recurrence. For the primary diagnosis of BC sensitivity 
was described to be 87% in patients with gross hematuria.5 Cystoscopy is invasive and 
causes pain and discomfort.6 Cytology is considered specific but with low sensitivity and 
it is typically used in combination with cystoscopy.7 Patients diagnosed with early stage 
BC undergo frequent monitoring currently based on cystoscopy and cytology, resulting 
in Ba becoming one of the most costly of all cancers to manage.8
To improve current clinical practice noninvasive and more sensitive screening methods 
should be applied to improve patient treatment and reduce the cost, morbidity and 
mortality of the sixth most common cancer.9 Much effort has focused on trying to 
identify urine based markers for the diagnosis of BC. While urine cytology is specific but 
lacks sensitivity, especially for low grade BC,10,11 and with cystoscopy being only 68% to 
83% sensitive and invasive as well as costly and often associated with discomfort12 an 
accurate, noninvasive assay could complement current clinical practice.
Cancer results from interactions between the environment, and genetic and epigenetic 
factors. Although genetic mutations are often the subject of investigation,13 such 
genetic alterations account for only a small percent of most cancers.14 The epigenetic 
component of cancer represents the most frequent DNA alteration that can lead to the 
development and progression of cancer.15 More specifically DNA hypermethylation 
occurs when DNA becomes methylated at CpG-rich regions located in the gene 
promoter regions, leading to gene inactivation. DNA methylation of critical genes such 
as tumor suppressors is a frequent and early event in neoplastic development.16
MSP is widely used to detect hypermethylated genes originating from cancer cells in 
tissues and body fluids such as serum, urine, stool and saliva.17 A large number of studies 
have identified methylated genes linked to BC.18-24
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The aim of the current study was to combine 2 previously published methylation 
marker panels to assess their complementarity and validate the minimal panel with the 
best clinical performance. Detection of the methylated TWIST1 gene in urine sediments 
using MSP provides a greater than 90% sensitive and specific noninvasive approach to 
detect primary BC.20,21,25,26 Methylation of OSR1, SIM2, OTX1, MEIS1 and ONECUT2 was 
shown to be a significant predictor of the presence of urothelial cell carcinoma.27
MATERIALS AND METHODS
Patients and urine samples
Voided urine samples were collected from 154 patients undergoing cystoscopy for the 
diagnostic evaluation of hematuria. Urine samples were collected at Erasmus Medical 
Center, The Netherlands, between 2006 and 2013. These samples were used according 
to The Code for Proper Secondary Use of Human Tissues in the Netherlands (http://
www.federa.org/). All patients were primary referrals with no history of any urinary tract 
malignancy. Of these 154 patients 74 were diagnosed with BC and 80 had a benign 
cause of hematuria (table 1).
Table 1. Characteristics of patients and tumors included in analysis.
 Urothelial Carcinoma Benign 
No. pts 74 80
Age (range) Mean 68 (38-91) 58 (21-86)
N (%) N (%)
Gender (%) Male 59 (80) 50 (63)
Female 15 (20) 30 (37)
Stage (%) Ta 36 (49)
T1 14 (19)
T2-4 24 (32)
Grade G1 11 (13)
G2 29 (39)
G3 34 (46)
Urine samples were collected prior to cystoscopy and stored at 4°C. The samples 
were centrifuged at 3,000 rpm. The cell pellets were washed with 10 ml phosphate 
buffered saline twice and spun down for 10 minutes at 3,000 rpm. The cells were then 
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resuspended in 1 ml phosphate buffered saline, transferred to an Eppendorf vial and 
centrifuged for another 5 minutes. Supernatant was discarded and the cell pellet was 
stored at -80°C until DNA isolation.
ANALYSES
Methylation 
DNA was isolated from urine sediments using the QIAamp® DNA Micro Kit and 
quantified with the Quant-iT™ PicoGreen® dsDNA Quantification Kit according to 
manufacturer instructions. DNA (100ng) was used for bisulfite modification with the EZ 
DNA Methylation-Lightning™ Kit. Modified DNA was eluted into 20μl tris-HCl (1mM, pH 
8.0) and stored at -80°C for further processing.
Blinded MSP analyses were performed using a multiplex reaction for TWIST1 on the 
antisense chain (Integrated DNA Technologies, Coralville, Iowa). Supplementary table 
1 lists the sequences. Quantitative PCR mix (Quantitect® Multiplex Mastermix) was 
used and reactions were run on a Rotor-Gene® Q. Copy numbers were calculated based 
on linear regression of a standard curve obtained from plasmid DNA containing the 
bisulfite modified sequences of interest (GeneArt™ Gene Synthesis).
SNaPshot assays consisted of multiple probes covering 4 CpG sites in OTX1 and 5 sites 
in ONECUT2. After bisulfite specific PCR for the sites of interest for ONECUT2 and OTX1 
SNaPshot analysis was performed using primers that annealed to the PCR product 
adjacent to the cytosine (in a CpG dinucleotide) of interest and the SNaPshot Multiplex 
Kit. Probes were extended with labeled dideoxynucleotides and the products were 
analyzed on an automatic sequencer (ABI PRISM® 3100 Genetic Analyzer). The label 
indicated the presence or absence of a methylated cytosine as previously described. 
Supplementary table 1 lists details of the primers and probes used. The Supplementary 
Appendix A shows a more detailed description of the methods.
SNaPshot methylation data were also normalized for each gene by calculating a 
methylation percent. We divided the height of the methylated peak by the sum of the 
heights of the methylated and unmethylated peaks multiplied by hundred.
Mutation 
DNA from cell pellets was analyzed for mutations in FGFR3, TERT, PIK3CA, HRAS, NRAS 
and KRAS as described previously.28 Supplementary table 2 lists details of the primers 
and probes used.
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Statistical 
Statistical analyses were performed with SPSS® and R (https://www.r-project.org). 
Univariate and multivariate logistic regression analyses were done to calculate the 
association between BC and predictor variables. A limited number of variables were 
entered on multivariate analysis, selected based on performance on univariate analysis. 
The optimal probe combination for the genes OTX1 and ONECUT2 was selected based on 
overall performance on univariate logistic regression analysis. An average methylation 
ratio was calculated for this optimal probe combination per gene and then entered 
in the multivariate logistic regression model to account for multicollinearity of the 
different probes in each gene. Cutoffs to dichotomize the methylation marker results 
were chosen based on the desired sensitivity-specificity tradeoff as visualized by the 
ROC curve. The predictive accuracy of the multivariate model was determined by the 
AUC. The bootstrap procedure was used to internally validate the predictive model with 
p <0.05 considered statistically significant. Different cutoffs (ie a patient was or was not 
selected for cystoscopy) of the optimal multivariate model were used to calculate the 
effect on sensitivity, specificity and NPV.
RESULTS
Assay robustness
Six urine samples (4%) with fewer than 750 copies of the neutral TWIST1 assay were 
removed from the data set since the DNA yield was too low to be considered for accurate 
methylation or mutation analysis. All other methylation assays produce a valid result in 
more than 97% of samples. Similar robustness was observed for all 6 mutation assays 
with a dropout rate less than 3%.
Univariate logistic regression
On univariate analysis all variables were significantly associated with the presence of 
BC (table 2). Adding multiple probes in the OTX1 assay did not add to the predictive 
capacity of the marker. Probe 2 performed best (OR 12.49, 95% CI 5.691-27.429). For 
the ONECUT2 assay combining probes 1 and 4 enhanced the marker slightly, increasing 
maximal sensitivity from 84% to 85%. Because of high specificity, the best mutation 
assays were combined into a single mutation index. This index included FGFR3, TERT 
and HRAS mutation status, which resulted in 72% sensitivity and 93% specificity.
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Cytology and mutations
Urine cytology was available for 56% of all urine samples. While cytology proved to 
be specific in this cohort, ie 97%, sensitivity was lacking at 60%. Despite missing data 
best case scenarios (all samples with unknown cytology predicted correctly) and worst 
case scenarios (all samples with unknown cytology predicted falsely) could be made. It 
was determined that when combining the methylation assay with cytology, sensitivity 
would range from 91% to 97%.
With regard to mutation analyses 1 FGFR3 and 2 TERT mutations were detected in 3 
Ta samples. Mutations in these 2 genes were observed 5 times for TERT and once for 
FGFR3 in urine samples from control patients (supplementary table 3). Not a single NRAS 
mutation assay was positive in cases or controls (supplementary table 3).
Stage specific analyses
Table 3 shows stage specific analyses of the methylation assay and mutations of FGFR3, 
TERT and HRAS. Interestingly methylation and mutation seem to perform best in T1 or 
higher stage tumors. In general methylation performs better in higher stage disease 
than in Ta tumors, although the difference is minor. However, mutation analyses 
contributed most in stage Ta tumors.
Multivariate logistic regression
Multivariate regression analysis resulted in a predictive model including age, mutation 
status of FGFR3, TERT and HRAS, and the methylation markers OTX1, ONECUT2 (2 loci) 
and TWIST1 (table 4). NPV ranged from 99.9% at a 5% cancer prevalence in a general 
hematuria population to 99.6% at a 10% prevalence in a more macroscopic hematuria 
population. The predictive capacity of the overall model was 0.93 as represented by the 
AUC (fig. 1). Bootstrapping showed the robustness of the model with an AUC of 0.92 
(table 4). Although methylation and mutation assays each performed well, combining 
them increased the predictive capacity of the model. 
By choosing different cutoffs for the optimal model the optimal sensitivity could be 
chosen (table 5 and fig. 1), preferably maximizing sensitivity without a major reduction 
in specificity. The lowest cutoff was selected based on the optimal sensitivity-specificity 
tradeoff as visualized by the ROC curve. The higher cutoffs were chosen based on visual 
inspection of the ROC curve while maximizing sensitivity. The preferred cutoff, defined 
as missing the least amount of bladder cancers based on optimal sensitivity-specificity, 
would result in overall sensitivity of 97% and specificity of 83%, ie sensitivity of 91% for 
Ta and 91% for T1 or higher stage tumors (table 5 and fig. 2).
47
Epigenetic profile for detection of bladder cancer
2
Table 3. Stage specific multivariate logistic regression analysis including methylation and 
mutation variables 
Model (variables) OR (95% CI) P value AUC (95% CI)
Ta tumors, methylation only 
ONECUT2 probes 1+4 14.005 (3.687-53.199) 0.000 0.871 (0.785-0.958)
OTX1 probe 2 1.597 (0.434-5.883) 0.481
TWIST 3.507 (0.923-13.329 0.065
Ta tumors, methylation + mutation
ONECUT2 probes 1+4 9.660 (2.286-40.822) 0.002 0.900 (0.827-0.973)
OTX1 probe 2 1.424 (0.345-5.886) 0.625
TWIST 1.226 (0.227-6.616) 0.813
FGFR3/TERT/HRAS 7.886 (1.600-38.862) 0.011
T1 + T2-4  tumors, methylation only 
ONECUT2 probes 1+4 12.992 (2.992-57.557) 0.001 0.927 (0.866-0.988)
OTX1 probe 2 4.616 (1.036-20.564) 0.045
TWIST 3.863 (0.949-15.729) 0.059
T1 + T2-4 tumors, methylation + mutation
ONECUT2 probes 1+4 6.698 (1.257-35.689) 0.026 0.923 (0.860-0.987)
OTX1 probe 2 3.184 (0.635-15.964) 0.159
TWIST 3.014 (0.692-13.127) 0.142
FGFR3/TERT/HRAS 4.245 (0.849-21.227) 0.078
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Table 4. Multivariate logistic regression analyses 
Model (variables) OR (95% CI) P value AUC (95% CI)
Optimism 
corrected AUC
Optimal model
Age 1.044 (0.997-1.093) 0.067 0.930 (0.883-0.978) 0.91665
FGFR3/TERT/HRAS 8.574 (2.176-33.780) 0.002
ONECUT2 probes 1 + 4 6.802 (1.881-24.589) 0.003
OTX1 probe 2 1.569 (0.434-5.670) 0.492
Twist 1.796 (0.464-6.948) 0.396
Optimal model without mutation
Age 1.033 (0.992-1.075) 0.115 0.918 (0.870-0.965) 0.9031
ONECUT2 probes 1 + 4 11.886 (3.589-39.360) 0.000
OTX1 probe 2 2.070 (0.641-6.683) 0.224
Twist 3.587 (1.094-11.759) 0.035
Optimal model without methylation
Age 1.065 (1.023-1.108) 0.002 0.898 (0.844-0.953) 0.8974
FGFR3/TERT/HRAS 37.197 (11.945-15.837) 0.000
Methylation only
ONECUT2 probes 1 + 4 14.569 (4.531-46.851) 0.000 0.900 (0.843-0.956) 0.8926
OTX1 probe 2 2.034 (0.641-6.456) 0.228
Twist 3.680 (1.131-11.971) 0.030
Table 5. Effect on sensitivity, specificity, Positive Predictive Value (PPV) and Negative Predictive 
Value (NPV) at optimal multivariable model cutoffs
Optimal multivariable cutoff 0.1213372 0.1917196 0.3547327 0.4975214
Sensitivity (%) 98.5 97.0 90.9 86.4
Specificity (%) 57.7 83.1 85.9 90.1
PPV 5% prevalence 11.1 23.4 25.7 46.8
PPV 10% prevalence 20.7 39 41.9 49.4
NPV 5% prevalence 1 99.9 99.5 99.3
NPV 10% prevalence 99.8 99.6 98.9 98.4
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Figure 1. ROC curve with different cutoff values of optimal multivariable prediction model 
result, including cutoffs 0.1213372 (blue dotted line), 0.1917196 (red dashed line), 0.3547327 
(green dotted and dashed line) and 0.4975214 (orange dashed line)
Figure 2. ROC curves with optimal cutoff values, and resulting sensitivity and specificity for 
stages Ta (A) and T1-T4 (B) disease
 A     B
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DISCUSSION
Epigenetic biomarker panels were generated and evaluated based on overall accuracy. A 
combination of the 3 genes TWIST1, ONECUT2 (2 loci) and OTX1 combined with mutation 
analyses of FGFR3, TERT and HRAS as well as the age parameter resulted in the best overall 
performance with 97% sensitivity and 83% specificity. The methylation assay performed 
with high sensitivity across all stages (table 2). Including mutation analyses of FGFR3, 
TERT and HRAS, and age the sensitivity was 91% for Ta and higher stage tumors (T1-T4). 
The prevalence of BC was estimated to range from 3% in microscopic hematuria cases 
to 20% in gross hematuria cases. As a general prevalence in a population of patients 
with hematuria at risk for BC, a 5% prevalence rate was assumed. In this population 
a NPV of 99.2% was reached with the methylation assay alone. When mutations were 
added in and the effect of cytology was estimated, the NPV could further increase to 
99.9%. With low prevalence rates it is of crucial importance to obtain a high NPV to 
better diagnose patients so as to not subject them to unnecessary and potentially 
harmful invasive procedures.
Several urine biomarker assays have been suggested over the years (eg NMP22® , 
Immunocyt™ , Aura Tek FDP Test™ , BTA stat® , etc). Many have been proposed for 
surveillance of patients treated for BC. Most assays have not proved to be sufficiently 
sensitive and/or specific to be able to replace cystoscopy.29 In the primary diagnostic 
setting patients must be ruled in for cystoscopy. Therefore, high sensitivity of the 
biomarker assay is desired. Our proposed biomarker assay showed convincing results 
with 97% sensitivity and 83% specificity, supporting the clinical usefulness of the assay 
in reducing superfluous cystoscopy in patients presenting with hematuria.
While the combination of FGFR3, TERT and HRAS mutations combined could detect 72% 
of all tumors with high specificity, sensitivity was insufficient for the combination to be 
used alone as a diagnostic tool. Multivariate analysis confirmed these results. However, 
while mutations of TERT or FGFR3 showed a higher OR than the methylation assays, 
this could be assigned to the high specificity of mutations. Methylation remains the 
most significant risk factor and the complementarity of the methylation and mutation 
markers was validated in the multivariate logistic regression model. In addition, age had 
a small but significant contribution, serving as a risk factor in the multivariate model.
Limitations of the study were the relatively small sample size, limited cytology data and 
lack of data on the type of hematuria. Furthermore, the patient cohort was enriched for 
cases to enable sufficient events to reach statistical significance. We will now perform a 
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prospective validation study in a natural cohort of patients presenting with hematuria. 
We strongly believe that the data described in the current work is sufficiently promising 
to embark on this prospective study.
CONCLUSIONS
Epigenetic profiling in noninvasive urine samples based on the biomarkers TWIST1, 
ONECUT2 and OTX1 resulted in high sensitivity and specificity. The methylation assays 
yielded high predictive potential in a cohort of patients with hematuria. While the 
methylation assay was the best diagnostic tool, it could be further improved when 
complemented with the detection of mutation of FGFR3, TERT and HRAS, and the 
clinical parameter age, resulting in 97% sensitivity and 83% specificity. Further, cytology 
could potentially add to the model. However, neither mutations nor cytology have the 
diagnostic potential of epigenetics when considered alone. Accurate risk prediction 
might result in less extensive and invasive examination of patients at low risk, thereby 
reducing the unnecessary patient burden and health care costs.
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SUPPLEMENTARY APPENDIX A
Methods 
Methylation analysis
DNA was isolated from urine sediments using the QIAamp DNA micro kit (Qiagen, Venlo, The 
Netherlands) and quantified using the Quant-iT PicoGreen dsDNA Quantification Kit (Molecular 
Probes, Eugene, OR, USA) according to the manufacturer’s instructions. One hundred ng of DNA 
was used for the bisulfite modification using a commercially available kit (EZ DNA Methylation-
Lightning Kit, Zymo D5030, ZymoResearch, Orange, CA, USA). This reaction selectively deaminates 
unmethylated cytosine residues, resulting in a conversion to uracil, while 5-methyl cytosine 
residues are not modified. The modified DNA was eluted into 20 μl Tris-HCl (1mM, pH 8.0), then 
stored at -80°C for further processing.
Blinded, MSP analyses were performed using a multiplex reaction for TWIST1, on the antisense 
chain. The multiplex also contained a methylation-neutral region without CpG-sites in the TWIST1 
promoter region, allowing for normalization relative to an input control. The reactions were 
performed in a total volume of 20 μl using methylation-specific primers and probes for each 
analyte (Integrated DNA Technologies, see table 2 for the sequences). A commercially available 
qPCR mix was used (Quantitect multiplex mastermix, Qiagen, 204745), with an input of 2 μl of 
bisulfite converted DNA. Reactions were run on a Rotor-Gene Q (Qiagen), under the following 
conditions 95°C for 15 minutes, 45 cycles of 95°C for 30 seconds, 57°C for 30 seconds, 72°C for 
30 seconds. Copy numbers were calculated based on linear regression of a standard curve 
obtained from plasmid DNA containing the bisulfite-modified sequences of interest (GeneArt 
Gene Synthesis, Life Technologies). In vitro methylated DNA (Chemicon,S7821, Temecula, CA, 
USA) and the HCT116 DKO cell line (lacking methylation) were included in each run as positive 
and negative controls, respectively. HL60 and LNCAP cell lines with known methylation status for 
TWIST1 served as a positive and negative control.
SNaPshot assays consisted of multiple probes covering four CpG-sites in OTX1 and five sites 
in ONECUT2.  DNA was treated with sodium bisulfite, followed by bisulfite-specific PCR for the 
sites of interest for ONECUT2 and OTX1. For each reaction 20 ng of input DNA and a PCR primer 
concentration of 20 pM was used. After PCR, a SNaPshot analysis was performed, using primers 
that annealed to the PCR product adjacent to the cytosine (in a CpG dinucleotide) of interest 
(ABI PRISM SNaPshot Multiplex kit, Applied Biosystems). Probes were extended with labeled 
dideoxynucleotides and the products were analyzed on an automatic sequencer (ABI PRISM 
3100 Genetic Analyzer, Applied Biosystems), with the label indicating the presence or absence 
of a methylated cytosine, as previously described (See supplementary table S1 for details on the 
primers and probes used). SNaPshot methylation data was also normalized for each gene, by 
calculating a methylation percentage by dividing the height of the methylated peak by the sum 
of the heights of the methylated and unmethylated peaks multiplied by hundred.
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Supplementary table 1. Sequences of the primers and the probes used in the methylation 
assays and size of the generated amplicons
TWIST Forward primer 5’-GTTAGGGTTCGGGGGCGTTGTT-3’
Reverse primer 5’-CCGTCGCCTTCCTCCGACGAA-3’
Amplicon size 77 bp
Probe 5’-/FAM/CGGCGGGGAAGGAAATCGTTTC/BHQ1/-3’
TWIST 
Neutral
Forward primer 5’-GTGGAAGGAAATTTAGTTTATGGGAAAGGT-3’
Reverse primer 5’-CCACAAAATCTCTCCCTTAAATTAACATTACC-3’
Amplicon size 113 bp
Probe 5’-/ROXN/TAGAGTTAGAGGGGGGTAG/BHQ2/-3’
OTX1 Forward primer 5'-TTTTGAGAGGTATAGAGAGGGGTAGT-3'
Reverse primer 5'-CCCCTAACAAACCCAAATCTC-3'
Amplicon size 172 bp
Probe 1 5’-TTTTTTTTTTTTTTTTTTATAGAGAGGGGTAGTTTT-3’
Probe 2 5’-TTTTTTTTTTTTTTTTTTTTTATTTGTGGTTTTTTAGGTT-3’
Probe 3 5’-TTTTTTTTTTTTTTTTTTTTTTTTTGGAGATATTGGTTTTTAGT-3’
Probe 4 5’-TTTTTTTTTTTTTTTTTTTTTTTTTTTTGGAGTTTTTTTTATTTTTAGTT-3’
ONECUT2 Forward primer 5'-GGGGTTTTTTGTTTTTTGTATTTTT-3'
Reverse primer 5'-TCATTTTCAAACTTAAACTTAATCACC-3'
Amplicon size 206 bp
Probe 1 5’-TTTTTTTTTTTTTGTTTGGGYGGTTGGGTT-3’
Probe 2 5’-TTTTTTTTTTTTTTTTTTGTATTATTTGTTTTTGTG-3’
Probe 3 5’-TTTTTTTTTTTTTTTTTTTTTTCAAAATAATTAAAAAAACTC-3’
Probe 4 5’-TTTTTTTTTTTTTTTTTTTTTTTTTTTGTGYGTATATATTGTTATTTG-3’
Probe 5 5’-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGTATATATTGTTATTTGYGTTTT-3’
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Supplementary table 2. Sequences of the primers and the probes used in the mutation assays 
and size of the generated amplicons
Pan-RAS PCR Primer mix
Primer Sequence (5'->3') Product size (bp) Concentration in PCR mix (μM)
HRAS exon1 Fw CAGGAGACCCTGTAGGAGG 139 0.6
HRAS exon1 Rev TCGTCCACAAAATGGTTCTG 0.6
HRAS exon2 Fw GGAGACGTGCCTGTTGGA 140 0.3
HRAS exon2 Rev GGTGGATGTCCTCAAAAGAC 0.3
KRAS exon1 Fw GGCCTGCTGAAAATGACTG 163 0.3
KRAS exon1 Rev GGTCCTGCACCAGTAATATG 0.3
KRAS exon2 Fw CCAGACTGTGTTTCTCCCTT 155 0.3
KRAS exon2 Rev CACAAAGAAAGCCCTCCCCA 0.3
NRAS exon1 Fw GGTGTGAAATGACTGAGTAC 128 0.3
NRAS exon1 Rev GGGCCTCACCTCTATGGTG 0.3
NRAS exon2 Fw GGTGAAACCTGTTTGTTGGA 103 0.3
NRAS exon2 Rev ATACACAGAGGAAGCCTTCG 0.3
PIK3CA PCR Primer mix
Primer Sequence (5'->3') Product size (bp) Concentration in PCR mix (μM)
PIK3CA ex9-Fw AGTAACAGACTAGCTAGAGA 139 1
PIK3CA ex9-Rev ATTTTAGCACTTACCTGTGAC 1
PIK3CA ex20-Fw GACCCTAGCCTTAGATAAAAC 109 0.7
PIK3CA ex20-Rev GTGGAAGATCCAATCCATTT 0.7
FGFR3 PCR Primer mix
Primer Sequence (5'->3') Product size (bp) Concentration in PCR mix (μM)
FGFR3 RI Fw AGTGGCGGTGGTGGTGAGGGAG 115 1.2
FGFR3 RI Rev GCACCGCCGTCTGGTTGG 1.2
FGFR3 RII Fw CAACGCCCATGTCTTTGCAG 138 0.7
FGFR3 RII Rev AGGCGGCAGAGCGTCACAG 0.7
FGFR3 RIII Fw GACCGAGGACAACGTGATG 160 0.7
FGFR3 RIII Rev GTGTGGGAAGGCGGTGTTG 0.7
TERT PCR Primer mix
Primer Sequence (5'->3') Product size (bp) Concentration in PCR mix (μM)
hTERT Fw AGCGCTGCCTGAAACTCG 155 0.5
hTERT Rev CCCTTCACCTTCCAGCTC 0.5
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Supplementary table 3. Outcomes of the mutation analyses 
Variable (N) Urothelial carcinoma Benign % Sensitivity % Specificity
FGFR3 (146) Mutant 21 1 30.4 98.7
Wild Type 48 76
TERT (142) Mutant 42 5 61.8 93.2
Wild Type 26 69
PIK3CA (144) Mutant 9 0 13.0 100
Wild Type 60 75
HRAS (147) Mutant 4 0 5.7 100
Wild Type 66 77
NRAS (147) Mutant 0 0 - -
Wild Type 70 77
KRAS (147) Mutant 1 0 1.4 100
Wild Type 69 77
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ABSTRACT
Purpose: Only 3% to 28% of patients referred to the urology clinic for hematuria are 
diagnosed with bladder cancer. Cystoscopy leads to high diagnostic costs and a high 
patient burden. Therefore, to improve the selection of patients for cystoscopy and 
reduce costs and over testing we aimed to validate a recently developed diagnostic 
urine assay.
Materials and methods: Included in study were 200 patients from a total of 3 European 
countries who underwent cystoscopy for hematuria, including 97 with bladder cancer 
and 103 with nonmalignant findings. Voided urine samples were collected prior to 
cystoscopy. DNA was extracted and analyzed for mutations in FGFR3, TERT and HRAS, 
and methylation of OTX1, ONECUT2 and TWIST1. Logistic regression was used to analyze 
the association between predictor variables and bladder cancer.
Results: Combining the methylation and mutation markers with age led to an AUC 
of 0.96 (95% CI 0.92-0.99) with 93% sensitivity and 86% specificity, and an optimism 
corrected AUC of 0.95. The AUC was higher for T1 or greater tumors compared to Ta 
tumors (0.99 vs 0.93). The AUC was also higher for high grade tumors compared to low 
grade tumors (1.00 vs 0.93). Overall negative predictive value was 99% based on the 5% 
to 10% prevalence of bladder cancer in patients with hematuria. This would lead to a 
77% reduction in diagnostic cystoscopy.
Conclusions: Analyzing hematuria patients for the risk of bladder cancer using novel 
molecular markers may lead to a reduction in diagnostic cystoscopy. Combining 
methylation analysis (OTX1, ONECUT2 and TWIST1) with mutation analysis (FGFR3, TERT 
and HRAS) and patient age resulted in a validated accurate prediction model.
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INTRODUCTION
Approximately 20% of all patients presenting to a urology clinic are referred for 
macroscopic or persistent microscopic hematuria.1 The origin of hematuria can be renal 
(e.g. benign and malignant renal masses, pyelonephritis and nephropathies) or from 
the upper and/or lower urinary tract (e.g. cystitis, bladder or prostate malignancies 
and benign prostatic hyperplasia). More general causes may be trauma, urolithiasis or 
infection. 
Only 3% to 28% of the patients presenting with hematuria will be diagnosed with BC.2 
Risk factors for urinary tract malignancies in patients with hematuria include male 
gender, age greater than 35 years and smoking.3-5 Most urological guidelines recommend 
performing cystoscopy in nearly all patients with hematuria.1,2,4,6-8 An exception is the 
Swedish guideline, which advocates its use only in macroscopic hematuria cases.9 
The AUA (American Urological Association) and ACR (American College of Radiology) 
guidelines advise cystoscopy and abdominal computerized tomography in all patients 
with risk factors4,6.
The Canadian guidelines recommend cystoscopy and upper urinary tract imaging 
in all patients with risk factors as well.7 This leads to many negative cystoscopies and 
subsequent upper urinary tract imaging procedures, resulting in high diagnostic costs 
and substantial patient burden. In the United Kingdom Rodgers et al estimated that 
by reducing negative cystoscopies approximately US$627 per patient could be saved.10 
To better select patients for diagnostic cystoscopy and thereby decrease cost and over 
testing, there is a clear clinical need for new noninvasive diagnostic tests.
Oncogene mutations play an important role in the malignant transformation of urothelial 
cells. However, not all bladder tumors harbor mutations in the most commonly altered 
oncogenes.11-15 Thus, to reach satisfactory sensitivity a new diagnostic test should 
include multiple biomarkers. Cancer associated hypermethylation of cytosines in CpG 
islands of genes shows great potential to identify the presence of malignant cells, and 
numerous studies in BC have been performed and led to the proposal of candidate 
markers.16-18 Previously we described a diagnostic urine test that showed high sensitivity 
(97%) and specificity (83%).19 The mutation assay included the FGFR3, TERT and HRAS 
genes, and the methylation assay included the OTX1, ONECUT2 and TWIST1 genes. 
In the current study we aimed to validate the previously published diagnostic urine 
assay in an independent, international, multicenter cohort.
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PATIENTS AND METHODS
Patients and urine samples
Any patient referred to the urology clinic and who underwent cystoscopy for microscopic 
or macroscopic hematuria with no prior history of bladder cancer was eligible for 
study inclusion. A total of 200 patients were prospectively, nonconsecutively included 
in the study, of whom 97 were diagnosed with BC and 103 were considered to have 
nonmalignant hematuria. Patients included in the previous development study of the 
assay were excluded from the current study.19 
The DNA yield and quality of 163 patients (81.5%) were sufficient to complete all assays. 
Otherwise part of the assays were run with a result for FGFR3 in 97% of patients, for TERT 
in 97.5%, for HRAS in 94%, for TWIST1 in 92.5%, for OTX1 in 93.5% and for ONECUT2 in 
96%. Samples were collected at Uppsala University Hospital, Sweden, Hospital del Mar, 
Barcelona, Spain, the Spanish National Cancer Research Centre, Madrid, Spain, and the 
Erasmus University Medical Center, The Netherlands. Informed consent was obtained 
from all Swedish and Spanish patients. Urine sampling at Erasmus Medical Center was 
done according to the code of conduct for responsible use of leftover materials.20
Voided urine samples were collected prior to cystoscopy and stored at 4°C. Within 
12 hours after collection, the urine samples were processed in the laboratories at the 
participating centers. Cells were pelleted by centrifugation for 10 minutes at 2,500 
rpm. Cells were then resuspended in 1 ml phosphate buffered saline, transferred to an 
Eppendorf vial and spun down for 5 minutes at 6,000 rpm. Supernatant was discarded 
and the cell pellet was stored at -80°C until DNA isolation. Cell pellets were shipped 
to Erasmus Medical Center for molecular analyses. TWIST1 methylation analysis was 
performed at MDxHealth.
DNA isolation and molecular analyses
DNA was isolated using the QIAmp® DNA Mini-Kit according to the manufacturer 
protocol. Samples were analyzed for hotspot mutations in FGFR3, TERT and HRAS as 
described previously.14,15,21,22 Supplementary table 1 shows primer and probe sequences. 
For methylation analysis DNA was first treated with sodium bisulfite using the EZ DNA 
Methylation-Gold™ Kit according to the manufacturer protocol. After PCR for OTX1 and 
ONECUT2, a multiplex SNaPshot® assay using the SNaPshot Multiplex Kit was performed 
per gene with probes for OTX1 and ONECUT2 that annealed adjacent to the different 
CpGs to be interrogated. Supplementary table 1 lists the sequences of the primers and 
probes used in the assay. 
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The methylation ratios of each CpG were calculated by dividing the height of the 
methylated peak by the sum of the height of the methylated and unmethylated peaks 
multiplied by 100. We have previously reported that reproducibility of the interpretation 
of the methylation assays is good (R2 = 0.99 for OTX1 and R2 = 0.98 for ONECUT2).23 
For TWIST1 methylation specific PCR was done via a multiplex reaction (IDT®) using 
QuantiTect® Multiplex PCR Master Mix for quantitative PCR (supplementary table 1). 
Reactions were run on a Rotor-Gene® Q. Copy numbers were calculated based on linear 
regression of a standard curve obtained from plasmid DNA containing the bisulfite 
modified sequences of interest using GeneArt® Gene Synthesis.
Statistical analyses
Statistical analyses were performed using IBM® SPSS® Statistics for Windows®, version 
22.0 and R statistical software (https://www.r-project.org/foundation/). Characteristics 
of the urine samples were compared between patients with malignant and 
nonmalignant hematuria using the Mann-Whitney U test and the Fisher exact test. 
Previously determined cutoff values were used to dichotomize the methylation markers 
(supplementary table 2).19 Univariable and multivariable logistic regression analysis was 
done to calculate the association between outcome and variables. The AUC was used 
to determine the predictive accuracy of the model and compare predictive accuracy 
to that of the model previously developed.19 The optimism corrected AUC was used to 
illustrate model robustness.
RESULTS
Patient characteristics, and mutation and methylation analyses
Supplementary table 3 lists patient characteristics. Patients with a nonmalignant 
diagnosis were younger than patients diagnosed with BC (mean age 62 vs 71 years, 
p <0.01, supplementary table 3). Men were also more commonly represented among 
subjects without BC (p <0.01). Of the BCs diagnosed 83% were noninvasive, 8% were 
invasive and T stage was unknown in 9%. The average DNA concentration was 26.1 
ng/μl (range 1.17 to 110) for tumor-positive urine samples and 16.7 ng/μl (range 1.29 
to 104) for nonmalignant samples (p = 0.02). The average DNA concentration did not 
significantly differ between males and females (20.3 ng/μl, range 1.17 to 110 and 30.9, 
range 3.49 to 110, respectively, p = 0.30). TERT mutations were most prevalent, with 
70 of 96 positive assays (73%) in BC urine samples and 3 of 99 positive assays (3%) in 
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the urine samples of patients without BC (supplementary table 3). The second most 
prevalent mutations were FGFR3 mutations with 33 of 95 positive results (35%) in urine 
samples from patients with BC. Only 2 samples had a HRAS mutation. 
The combined mutation data from FGFR3, TERT and HRAS were highly informative (OR 
107.7, AUC 0.87, p <0.01). When dichotomized, a positive result of the methylation 
assays was significantly more frequent in urine samples from patients with BC (68% 
to 89% for the different genes) than in the urine samples from patients without BC 
(10% to 44%) (supplementary table 3 and fig. 1). Supplementary table 2 shows cutoffs 
for dichotomization. On univariate analysis methylation and mutation analysis had 
comparable predictive capacity (AUC 0.88, 95% CI 0.83-0.94 and AUC 0.87, 95% CI 0.81-
0.93, respectively, table 1).
Figure 1. Percent methylation in nonmalignant hematuria samples versus malignant hematuria 
samples for OTX1, ONECUT2 and TWIST1. 
Table 1. Univariate logistic regression analysis of the association between predictor variables 
and bladder cancer in voided urine samples from patients presenting with hematuria (p<0.01).
Variable OR (95% CI) AUC (95% CI)
Age 1.10 (1.07-1.14) 0.75 (0.68-0.82)
Mutation combined 107.67 (30.76-376.84) 0.87 (0.81-0.93)
Methylation combined 6.15 (3.78-9.99) 0.88 (0.83-0.94)
Supplementary table 2 lists dichotomization cutoffs.
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Multivariable analyses
The previously published optimal multivariable model19 was applied to this independent 
cohort. The variables included in this model were age, combined mutation and combined 
methylation status. Supplementary table 4 shows the algorithm and overall results per 
sample and per marker. The ORs of the original model and the current model proved to 
be similar (table 2). Mutation status alone and methylation status alone predicted the 
presence of BC well but combining mutation status with methylation status increased 
predictive capacity, as depicted by the AUC (table 2). The AUC of the optimal model was 
0.96 compared to 0.93 in the previous study.19 Internal validation using the bootstrap 
procedure showed the robustness of each model as shown by the optimism corrected 
AUCs (table 2). 
Table 2. Multivariable logistic regression analysis validating the optimal combination of best 
performing predictor variables from previous studies and bladder cancer in voided urine 
samples from patients presenting with hematuria with bladder cancer in 97 and no malignancy 
in 103 (p<0.01).
OR (95% CI) AUC (95% CI) Optimism corrected AUC
Optimal model
Age 1.12 (1.05-1.19) 0.96 (0.92-0.99) 0.95
Mutation combined 69.46 (11.06-436.22)
Methylation combined 2.47 (1.30-4.70)
Optimal model, no mutation
Age 1.11 (1.06-1.17) 0.92 (0.88-0.97) 0.92
Methylation combined 5.95 (3.49-10.14)
Optimal model, no methylation
Age 1.11 (1.05-1.17) 0.93 (0.89-0.98) 0.93
Mutation combined 183.08 (35.75-937.66)
Methylation only
Methylation combined 6.15 (3.78-9.99) 0.88 (0.83-0.94) 0.88
To be able to select appropriate patients for initial cystoscopy, the outcome of the 
multivariable model has to be dichotomized (cancer vs no cancer). Using the cutoffs 
of the previously published optimal model, the multivariable model could predict the 
presence of bladder cancer with 93.2% sensitivity and 85.6% specificity in this cohort 
(table 3 and fig. 2). Depending on the estimated prevalence of 5% to 10% BCs in a 
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cohort of patients referred for hematuria, the NPV was 99.2% to 99.6%. These results 
were similar to those of the previously published model (AUC 0.93, 97% sensitivity, 83% 
specificity and 99.6% to 99.9% NPV).19 
Figure 2. ROC curve of the optimal multivariable prediction model. Red dashed lines indicate 
cutoff of 93.2% sensitivity of 93.2% and 85.6% specificity (see table 3).
Stage and grade specific analyses
On the stage specific univariate and multivariable analyses the mutation and 
methylation markers seemed to show an increasing trend in AUC toward higher stage 
disease (AUC 0.87 for Ta tumors vs 0.98 for T1 and T2-4 tumors, supplementary table 5). 
The clinical parameters age and gender performed equally over all stages on univariate 
analysis. Based on overall accuracy, the proposed optimal model also performed better 
toward higher stage disease (AUC 0.93 for Ta tumors vs 0.99 for T1 and T2-4 tumors, 
supplementary table 5). Further, on the grade specific univariate and multivariate 
analyses all markers performed better in high than in low grade tumors. The model 
including age, mutation and methylation markers also had the highest predictive 
capacity for high grade tumors (AUC 1.00 vs 0.93). 
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Table 3. Effect on sensitivity, specificity, false-positive and false-negative findings, positive and 
negative predictive values, and cystoscopy reduction (fig. 2)
Cutoff 0.1917196
% Sensitivity 93.2
% Specificity 85.6
No. false-pos/1,000 tests†
5% 136
10% 129
No. false-neg/1,000 tests†
5% 3
10% 6
% Pos predictive value†
5% 25.7
10% 42.2
% Neg predictive value†
5% 99.6
10% 99.2
% Cystoscopy decrease†
5% 81.7
10% 77.7
* Based on van Kessel et al.19
† Calculated for estimated 5% or 10% prevalence of bladder cancer in patients referred for hematuria.
DISCUSSION
Patients with hematuria represent an important burden in urology clinics (20%) and no 
definite consensus exists despite the existence of many different guidelines to analyze 
the cause of hematuria.1,4,6-9 Mostly, cystoscopy is recommended. However, only 3% 
to 28% of patients with hematuria will be diagnosed with BC depending on other risk 
factors.2
In this study we were able to establish that the combination of mutation and methylation 
markers is a robust tool to select patients with hematuria for cystoscopy workup. The 
optimal prediction model, which comprised 3 methylation assays, 3 mutation markers 
and patient age, resulted in 93.2% sensitivity and 85.6% specificity. Previously, we have 
found good reproducibility of the interpretation of the methylation assays (R2 = 0.99 for 
OTX1 and R2 = 0.98 for ONECUT2).23 Also, the reproducibility of the mutation analyses was 
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robust. In an earlier study we noted that the FGFR3 mutation analysis could be repeated 
at 2 independent laboratories in 2 countries with a 100% agreement in a total of 81 
samples.12 Implementing this assay for all patients with hematuria could potentially 
lead to a 77.7% to 81.7% reduction in cystoscopies in the primary diagnostic workup, 
although we acknowledge that some cystoscopies may still be necessary for alternative 
diagnosis. Further, since the assay takes several days to complete, the application of this 
assay in acute hematuria cases will not be feasible. 
The assay can be performed in any molecular pathology laboratory. The minimum DNA 
input for the proposed assay combination is approximately 50ng (i.e. the amount of 
DNA present in 8,000 cells). Total material costs do not exceed US$23 per patient. Labor 
costs would depend on the volume of patients that could be analyzed simultaneously. 
In contrast, negative cystoscopies would lead to an extra cost of US$627 per patient.10 
Further, we have previously reported that the sensitivity of cystoscopy increases when 
the urologist is aware of a positive urine test.24 In this regard, it is also relevant to mention 
that the sensitivity (68% to 84%) and the specificity (31% to 93%) of standard white light 
cystoscopy are not perfect, although that method is the gold standard.25 
Some urinary biomarker tests are FDA (Food and Drug Administration) approved, of 
which one is the NMP22® BladderChek® Test.26 In 2014 the prospective evaluation of 
the accuracy of the test in a cohort of patients referred for hematuria evaluation was 
published.27 This study included 381 patients, of whom 6% were diagnosed with bladder 
cancer. This proportion is comparable to the 5% expected prevalence that we used to 
calculate the NPV in the current study and it more closely resembles a natural cohort of 
patients than our case enriched cohort. The predictive accuracy of the test was 80.2%. In 
our study we achieved 96% predictive accuracy. In this study the exclusion criteria were 
urinary tract infections, urinary retention or stone disease, kidney failure, ureteral stents, 
nephrostomy tubes, bowel interposition or recent genito-urinary instrumentation. In 
contrast, in our study the only exclusion criterion was a prior history of BC.27 
Interestingly, we detected FGFR3 and TERT mutations in 4 patients who were diagnosed 
with nonmalignant hematuria. In 2 patients with a TERT mutation and in 1 with a FGFR3 
mutation no bladder tumor was diagnosed after updated follow-up (follow-ups was 1, 
3.5 and 4 years, respectively). In the remaining patient with a TERT mutation carcinoma 
in situ of the bladder was diagnosed 18 months after the primary diagnostic workup.
A limitation of our study is that information on microscopic vs macroscopic hematuria 
and cytology was not available. Since the Swedish guidelines recommend cystoscopy 
only in patients with macroscopic hematuria, these samples can be considered 
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macroscopic.9 Analysis of the Swedish cohort showed no major difference in overall 
performance of the optimal model (AUC 0.96, 95% CI 0.92-1.00) compared to the total 
cohort. Further, in this case enriched series 94 patients (47%) were diagnosed with BC, a 
proportion that is much higher than would be expected in a urology clinic population of 
patients presenting with hematuria. Therefore, a multicenter, prospective validation of 
the study results is currently being performed. In that study we will also collect data on 
the type of hematuria and cytology. In conclusion, we validated a urine assay based on 
the methylation markers OTX1, ONECUT2 and TWIST1 combined with mutation markers 
and patient age to predict the presence of BC in patients presenting with hematuria.
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Supplementary table 1. Sequences of the primers and probes and size of the generated 
amplicons in the methylation analysis for different CpGs in the OTX1, ONECUT2 and TWIST1 
genes
OTX1
Forward primer 5'-TTTTGAGAGGTATAGAGAGGGGTAGT-3'
Reverse primer 5'-CCCCTAACAAACCCAAATCTC-3'
Amplicon size 172 bp
Probe 2 5’-TTTTTTTTTTTTTTTTTTTTTATTTGTGGTTTTTTAGGTT-3’
ONECUT2
Forward primer 5'-GGGGTTTTTTGTTTTTTGTATTTTT-3'
Reverse primer 5'-TCATTTTCAAACTTAAACTTAATCACC-3'
Amplicon size 206 bp
Probe 1 5’-TTTTTTTTTTTTTGTTTGGGYGGTTGGGTT-3’
Probe 4 5’-TTTTTTTTTTTTTTTTTTTTTTTTTTTGTGYGTATATATTGTTATTTG-3’
TWIST1
Forward primer 5’-GTTAGGGTTCGGGGGCGTTGTT-3’
Reverse primer 5’-CCGTCGCCTTCCTCCGACGAA-3’
Amplicon size 77 bp
Probe 5’-/FAM/CGGCGGGGAAGGAAATCGTTTC/BHQ1/-3’
TWIST1 Neutral
Forward primer 5’-GTGGAAGGAAATTTAGTTTATGGGAAAGGT-3’
Reverse primer 5’-CCACAAAATCTCTCCCTTAAATTAACATTACC-3’
Amplicon size 113 bp
Probe 5’-/ROXN/TAGAGTTAGAGGGGGGTAG/BHQ2/-3’
Supplementary table 2. Cutoffs used for dichotomization of the methylation markers based 
on van Kessel et al.19
Methylation markers Cutoff 
OTX1 probe 2 6.5444
ONECUT2 probe 1 6.9711
ONECUT2 probe 4 7.3936
TWIST1 0.1318
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Supplementary table 3. Sociodemographic, tumor and urine characteristics of patients 
presenting with hematuria (n=200) included in the study
BC (n=97) Nonmalignant (n=103) P-value
Patient characteristics
Age Mean (range) 71 (38-110) 62 (50-82) <0.01
N (%) N (%)
Gender Male 80 (83) 101 (98) <0.01
Female 17 (18) 2 (2)
Tumor characteristics
Clinical Stage Ta 52 (54)
T1 28 (29)
T2-4 8 (8)
Tx† 9 (9)
Grade G1 25 (26)
G2 24 (25)
G3 38 (39)
Gx† 10 (10)
Urine characteristics
DNA yield (ng/ml) DNA concentration 26.1 (1.17-110) 16.7 (1.29-104) 0.02
Positive test
Mutation analyses FGFR3 33 / 95 1 / 99 <0.01
TERT 70 / 96 3 / 99 <0.01
HRAS 2 / 90 0 / 98 0.23
Mutation combined 68 / 88 3 / 98 <0.01
Methylation TWIST1 77 / 87 43 / 98 <0.01
OTX1 74 / 91 44 / 96 <0.01
ONECUT2 70 / 94 6 / 98 <0.01
Methylation combined 77 / 81 65 / 92 <0.01
† Tx and Gx; stage and/or grade not specified
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Supplementary table 4. Results per sample for each marker and composite model given 
the following algorithm: -10.156+0.110*Age+4.241*Mutation+0.905*Methylation, which is 
Intercept+βAge+βMutation+βMethylation. Blanks represent missing values.
Study ID Case Age Mutation† Methylation*
Combined model 
result
Classified as case 
by model
1 1 60 1 3 0,96769 1
2 1 89 1
3 1 79 1 2 0,98988 1
4 1 70 0 1 0,1747 2
5 1 81 1 3 0,99669 1
6 1 82 1 3 0,99704 1
7 1 83 1 2 0,99346 1
8 1 78 1 3 0,99541 1
9 1 80 1 3 0,99631 1
10 1 75 1 2 0,98438 1
11 1 50 1 2 0,80128 1
12 1 77 1 3 0,99488 1
13 1 69 0 3 0,53703 1
14 1 69 1 3 0,98774 1
15 1 81 1 3 0,99669 1
16 1 80 1 2 0,99093 1
17 1 75 0
18 1 67 1 3 0,98477 1
19 1 56 1 3 0,95072 1
20 1 71 1 3 0,99014 1
21 1 1 1
22 1 80 0 0 0,20448 1
23 1 73 1 3 0,99207 1
24 0 82 0
25 1 1 3
26 1 82 1 2 0,9927 1
27 1 0 3
28 1 86 0 3 0,88265 1
29 1 74 1 3 0,99289 1
30 1 76 1 3 0,99428 1
31 1 82 1 2 0,9927 1
32 1 84 0 3 0,85788 1
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Study ID Case Age Mutation† Methylation*
Combined model 
result
Classified as case 
by model
33 1 81 1 3 0,99669 1
34 1 3
35 1 62 1 3 0,9739 1
36 1 78 1 3 0,99541 1
37 1 77
38 0 75 1 1 0,96224 1
39 1 67 1 3 0,98477 1
40 1 60 1 3 0,96769 1
41 1 81 1 3 0,99669 1
42 1 50 0 0 0,0094 0
43 1 81 1
44 1 71 1 3 0,99014 1
45 1 83 0 2 0,68619 1
46 1 69 3
47 1 62 1 3 0,9739 1
48 1 84 1 3 0,99762 1
49 1 70 1 3 0,989 1
50 1 66 1 3 0,98303 1
51 1 83 1 3 0,99734 1
52 1 65 1 3 0,9811 1
53 1 52 0 3 0,15174 0
54 1 56 0 1 0,04343 0
55 1 53 1 3 0,93275 1
56 1 70 1 2 0,97324 1
57 1 81 1 3 0,99669 1
58 1 81 1 3 0,99669 1
59 1 78 2
60 1 110 0 1 0,94511 1
61 1 81 0 1 0,41507 1
62 1 1 3
63 1 89 0 0 0,40882 1
64 1 68 1 3 0,98634 1
65 1 81 1 2 0,99186 1
66 1 61 0 3 0,3249 1
67 1 73 1 3 0,99207 1
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Study ID Case Age Mutation† Methylation*
Combined model 
result
Classified as case 
by model
68 0 1 1
69 1 77 0 1 0,31369 1
70 0 0
71 1 61 1 3 0,97096 1
72 1 78 2
73 1 57 1 1 0,77878 1
74 1 79 1
75 1 82 1 3 0,99704 1
76 1 62 1 2 0,93784 1
77 1 61 1 3 0,97096 1
78 1 38 1 2 0,51869 1
79 1 57 1 2 0,89698 1
80 1 56 1 3 0,95072 1
81 1 65 1 3 0,9811 1
82 1 77 1 3 0,99488 1
83 1 86 1 1 0,98843 1
84 1 76 1 3 0,99428 1
85 1 72 1 3 0,99116 1
86 1 66 1
87 1 69 1
88 1 54 1
89 1 58 1
90 1 1
91 1 59 1 3 0,96407 1
92 1 82 1 3 0,99704 1
93 1 74 0 0 0,1173 0
94 1 51 0
95 1 76 0 2 0,50316 1
96 1 77 1 3 0,99488 1
97 1 53
98 1 48
99 1 57
100 1 74
101 1 72 0
102 0 58
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Study ID Case Age Mutation† Methylation*
Combined model 
result
Classified as case 
by model
103 0 50 0 2 0,05487 0
104 0 57 0 1 0,04824 0
105 0 62 0 0 0,0343 0
106 0 67 0 1 0,1321 0
107 0 58 0 1 0,05354 0
108 0 53 0 1 0,03161 0
109 0 69 0 1 0,15941 0
110 0 55 0
111 0 52 0
112 0 58 0 1 0,05354 0
113 0 54 0 1 0,03516 0
114 0 55 0 1 0,03909 0
115 0 70 0 2 0,34363 0
116 0 55 0 1 0,03909 0
117 0 59
118 0 58
119 0 57 0 1 0,04824 0
120 0 59 0 1 0,0594 0
121 0 57 0 2 0,11138 0
122 0 57 0 1 0,04824 0
123 0 54 0 2 0,08267 0
124 0 57 0 1 0,04824 0
125 0 68 0 2 0,29586 1
126 0 58 0 2 0,12274 0
127 0 57 0 2 0,11138 0
128 0 56 0 1 0,04343 0
129 0 56 0 2 0,10096 0
130 0 56 0 0 0,01803 0
131 0 57 0 0 0,02008 0
132 0 54 0 0 0,01452 0
133 0 57 0 0 0,02008 0
134 0 54 0 0 0,01452 0
135 0 0 2
136 0 53 0 1 0,03161 0
137 0 57 0 2 0,11138 0
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Study ID Case Age Mutation† Methylation*
Combined model 
result
Classified as case 
by model
138 0 55 0 2 0,0914 0
139 0 58 0 2 0,12274 0
140 0 56 0
141 0 60 0 0 0,02771 0
142 0 56 0 1 0,04343 0
143 0 59 0 2 0,13508 0
144 0 58 0 1 0,05354 0
145 0 55 0 1 0,03909 0
146 0 54 0 2 0,08267 0
147 0 58 0 2 0,12274 0
148 0 55 0 1 0,03909 0
149 0 57 0 1 0,04824 0
150 0 60 0 1 0,06585 0
151 0 59 0 1 0,0594 0
152 0 62 0 1 0,08074 0
153 0 64 0 1 0,09864 0
154 0 60 0 1 0,06585 0
155 0 61 0 0 0,03083 0
156 0 61 0 0 0,03083 0
157 0 60 0 0 0,02771 0
158 0 54 0 1 0,03516 0
159 0 64 0 0 0,04237 0
160 0 61 0 0 0,03083 0
161 0 66 0 0 0,05225 0
162 0 60 1 1 0,8304 1
163 0 65 0 1 0,10886 0
164 0 62 0 1 0,08074 0
165 0 63 0 1 0,08929 0
166 0 64 0 0 0,04237 0
167 0 66 0 0 0,05225 0
168 0 65 0 1 0,10886 0
169 0 60
170 0 67
171 0 67 0 0 0,05797 0
172 0 66 0 1 0,11999 0
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Study ID Case Age Mutation† Methylation*
Combined model 
result
Classified as case 
by model
173 0 68 0 0 0,06428 0
174 0 69 0 0 0,07122 0
175 0 71 0 2 0,36884 1
176 0 70 0 1 0,1747 0
177 0 71 0 0 0,08721 0
178 0 75 0 1 0,26838 1
179 0 54 0 1 0,03516 0
180 0 74 0 0 0,1173 0
181 0 71 0 3 0,59105 1
182 0 72 0 1 0,20871 1
183 0 69 0 0 0,07122 0
184 0 73 0 1 0,22745 1
185 0 71 0 0 0,08721 0
186 0 72 0 2 0,39479 1
187 0 69 0 0 0,07122 0
188 0 74 0 1 0,24735 1
189 0 69 0
190 0 55 0 1 0,03909 0
191 0 74 0 0 0,1173 0
192 0 70 0 1 0,1747 0
193 0 72 0 0 0,09637 0
194 0 73 0 3 0,64296 1
195 0 55 0 1 0,03909 0
196 0 67 0 0 0,05797 0
197 0 65 0 1 0,10886 0
198 0 75 0 2 0,47569 1
199 0 69 0 1 0,15941 0
200 0 53 0 0 0,01303 0
†Mutation: any mutation present in either FGFR3, TERT and/or HRAS = 1, no mutations present = 0
*Methylation: one gene methylated = 1, two genes methylated = 2, three genes methylated = 3
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Supplementary table 5. Univariate and multivariable stage-specific analysis for Ta tumors (a) 
or T1 and T2-4 tumors (b) and grade specific analysis for low grade (G1+G2) tumors (c) or high 
grade (G3) tumors (d).
a) Ta tumors (n=52)
Variable OR 95% CI P-value AUC 95% CI
Age 2.20 1.06-1.15 <0.01 0.72 0.61-0.82
Gender 12.02 2.53-57.23 <0.01 0.59 0.49-0.69
Mutation combined 75.51 20.19-282.46 <0.01 0.84 0.75-0.92
Methylation combined 5.48 3.12-9.64 <0.01 0.85 0.77-0.93
Ta tumors, methylation and mutation
Mutation combined 26.23 6.07-113.32 <0.01 0.87 0.79-0.96
Methylation combined 2.52 1.27-4.99 <0.01
Ta tumors, optimal model
Age 1.11 1.04-1.19 <0.01 0.93 0.87-1.00
Mutation combined 48.86 7.39-323.05 <0.01
Methylation combined 2.14 1.04-4.42 0.04
b) T1 and T2-4 tumors (n=36)
Variable OR 95% CI P-value AUC 95% CI
Age 1.15 1.08-1.21 <0.01 0.78 0.69-0.87
Gender 8.15 1.51-44.08 0.02 0.56 0.45-0.67
Mutation combined 245.42 52.04-1157.28 <0.01 0.93 0.86-0.99
Methylation combined 28.35 8.03-100.09 <0.01 0.96 0.92-1.00
T1 and T2-4 tumors, methylation and mutation
Mutation combined 140.93 10.15-1957.03 <0.01 0.98 0.95-1.00
Methylation combined 20.53 3.65-115.50 <0.01
T1 and T2-4 tumors, optimal model
Age 1.12 0.94-1.32 0.20 0.99 0.98-1.00
Mutation combined 101.02 7.03-1450.91 <0.01
Methylation combined 13.85 2.56-74.91 <0.01
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Supplementary table 5. Univariate and multivariable stage-specific analysis for Ta tumors (a) 
or T1 and T2-4 tumors (b) and grade specific analysis for low grade (G1+G2) tumors (c) or high 
grade (G3) tumors (d).
c) Low-grade tumors (n=49)
Variable OR 95% CI P-value AUC 95% CI
Age 1.09 1.04-1.14 <0.01 0.68 0.57-0.79
Gender 14.62 3.10-69.02 <0.01 0.60 0.50-0.70
Mutation combined 83.49 21.80-319.67 <0.01 0.85 0.76-0.93
Methylation combined 5.72 3.20-10.24 <0.01 0.86 0.77-0.94
Low-grade tumors, methylation and mutation
Mutation combined 30.61 6.83-137.06 <0.01 0.88 0.79-0.97
Methylation combined 2.51 1.23-5.16 0.01
Low-grade tumors, optimal model
Age 1.10 1.01-1.18 0.02 0.93 0.86-1.00
Mutation combined 40.75 6.62-250.81 <0.01
Methylation combined 2.30 1.10-4.83 0.03
d) High-grade tumors (n=38)
Variable OR 95% CI P-value AUC 95% CI
Age 1.17 1.10-1.23 <0.01 0.81 0.72-0.90
Gender 7.65 1.42-41.31 0.02 0.56 0.44-0.67
Mutation combined 168.89 39.91-714.71 <0.01 0.91 0.83-0.98
Methylation combined 28.15 8.20-96.71 <0.01 0.96 0.92-0.99
High-grade tumors, methylation and mutation
Mutation combined 144.45 9.44-2210.06 <0.01 0.98 0.96-1.00
Methylation combined 29.57 5.09-171.75 <0.01
High-grade tumors, optimal model
Age 1.36 0.95-1.96 0.09 1.00 0.995-1.00
Mutation combined 23867.81 0.134-….. 0.10
Methylation combined 235.20 0.28-
201420.91
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ABSTRACT
Background: Microscopic hematuria is reason for referral to the urology clinic. Only 
2-5% of these patients are diagnosed with a urothelial carcinoma. Still the vast majority 
of all hematuria patients undergo cystoscopic evaluation to rule out bladder tumor 
presence. Hence, a non-invasive diagnostic test to rule in (micro)hematuria patients for 
cystoscopy is an unmet clinical need. In addition, a urothelial carcinoma diagnosis in 
women may be delayed as they are often treated for cystitis first, before they are referred 
to the urology clinic. An accurate rule in assay could reduce this diagnostic delay.
Objective: To assess the accuracy to detect bladder cancer of a previously developed 
molecular assay in a large prospective cohort of patients referred for  hematuria.
Design, Setting and Participants: We prospectively included 1003 patients referred 
to the urology clinic for hematuria whom received a cystoscopy. Mutation status of the 
FGFR3, TERT and HRAS genes and methylation of the OTX1, ONECUT2 and TWIST1 genes 
was determined. 
Outcome Measurements and Statistical Analysis: The predictive capacity of the urine 
assay, potential confounders and the association between potential predictor variables 
and the detection of bladder cancer were determined via logistic regression analyses.
Results: Of all patients, 59% were male and 41% female, 55% presented with macroscopic 
hematuria compared to 45% with microscopic hematuria. A total of 115 patients was 
diagnosed with urothelial cancer. The assay resulted in an AUC of 0.95 and a sensitivity 
of 93%, a specificity of 81% and a NPV of 99%. All 4 upper tract tumors were identified.
Conclusion: In patients referred for hematuria the urine assay was able to predict the 
absence of bladder cancer, especially in the microhematuria patient population with 
very high accuracy. This assay seems ready to be implemented clinically  to select 
patients for diagnostic cystoscopy.
Patient Summary: Microscopic hematuria is of frequent occurrence, however in only a 
small percentage a malignancy will be the cause. This urine assay detected all 12 high 
risk tumors in microscopic hematuria patients. Therefore, we conclude that the urine 
assay proved accurate in this group and can be used to select microhematuria patients 
for diagnostic cystoscopy. The urine assay could potentially reduce the diagnostic delay 
of bladder cancer in female patients presenting with hematuria.
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Take home message: Clinical implementation of this assay will result in a reduction 
of cystoscopies and a subsequent reduction of patient burden and costs. Primary care 
use of the assay could potentially reduce the diagnostic delay in female patients with 
hematuria.
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INTRODUCTION
Hematuria is a frequent finding in daily clinical practice; in a health screening study 
among 80.000 individuals the presence of microscopic hematuria ranged from 2.4% - 
31.1%.1, 2 Persistent microscopic or macroscopic hematuria is a reason for referral to the 
urology clinic. Hence, 20% of all visits to the urologist are because of hematuria.3 The 
cause of hematuria can either be renal (malignant or benign masses, nephropathies 
or pyelonephritis) or urological (stones, cystitis, strictures, benign prostatic hyperplasia, 
urological malignancies or trauma). Global consensus on how to evaluate hematuria 
patients is lacking. Most of the clinical guidelines advise a diagnostic cystoscopy in all 
hematuria patients, irrespective of the type of hematuria.4-7 For example, the AUA and 
the Canadian guidelines recommend cystoscopy in combination with imaging  in all 
patients with risk factors (age, smoking history). The prevalence of a bladder tumor is 
10-28% in macroscopic hematuria patients and only 2-5% in microscopic hematuria 
patients.7 This implies that 70-90% of patients has a different, mostly benign, cause 
of hematuria. Cystoscopy could be abandoned in these benign or idiopathic patients. 
Moreover, cystoscopy is not 100% sensitive and cannot detect upper urinary tract 
tumors.8 In addition, cystoscopy is a costly and invasive diagnostic procedure, often 
causing discomfort and pain.9 Hence, there is a clear clinical need for a noninvasive 
diagnostic test to improve selection of hematuria patients for diagnostic cystoscopy 
and thereby reducing costs, overtesting and patient burden.10, 11 A screening method 
to rule out patients for cystoscopy would be particularly valuable in the microscopic 
hematuria patient population.1, 2 Moreover, a cystitis is often thought to be the cause of 
microhematuria in women, leading to treatment with antibiotics, prior to referral to the 
urology clinic. Hence, a bladder cancer diagnosis in female patients may be erroneously 
delayed.12 A urine assay that can accurately select patients for imminent urological 
evaluation because of the high suspicion of bladder cancer, could improve current 
referral policy at the level of the general practitioner. 
Previously, we developed a non-invasive urine assay that was found to accurately detect 
bladder cancer in two case enriched series of patients presenting with hematuria.13 This 
assay included methylation of the OTX1, ONECUT2 and TWIST1 genes and mutation of 
the FGFR3, TERT and HRAS genes, and showed a 93% sensitivity and 86% specificity for 
the detection of bladder cancer.14 The aim of the present study was to prospectively 
validate this assay and evaluate its efficiency to select patients presenting with 
hematuria for cystoscopy, especially for the microhematuria population, and to present 
a simple assay to general practicioners to facilitate earlier detection of bladder cancer 
in women. Therefore, we collected voided urine samples before diagnostic cystoscopy 
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of more than 1000 patients presenting with hematuria in six Dutch hospitals. We show 
that in this prospective, non-case enriched cohort the assay is even more efficient when 
adding the micro- or gross hematuria status to our prediction model. 
MATERIALS AND METHODS
Patient selection and data collection
We aimed to prospectively include at least 1000 patients referred to the urologist for 
evaluation of macroscopic or microscopic hematuria in six hospitals in The Netherlands. 
After written informed consent, patients provided a voided urine sample prior to 
cystoscopy. Patients younger than 18 years of age and/or with a prior history of 
bladder cancer were excluded from the study. Urine was collected in an 80ml container, 
containing a preservation tablet (Sedi-tectTM, Global Scientific inc.) and was stored at 
4°C. This study was approved by the institutional review board of Erasmus MC (MEC-
2015-274) and additionally approved in all participating centers. 
Sample processing
Samples were collected once a week from all participating centers and processed at the 
Erasmus MC Pathology laboratory. First, urine dipstick analysis was done on all urine 
samples. Samples were then spun down at 2,500 rpm for 10 minutes. Urine supernatant 
was discarded; the cell pellet was re-suspended in 900μl PBS and transferred to a 1.5ml 
Eppendorf vial. The Eppendorf vials were centrifuged once more at 6,000 rpm for 5 
minutes. Excess fluids were removed and the cell pellets were stored at -20°C until DNA 
isolation.
Molecular analyses
DNA was isolated using the Puregene DNA Isolation kit (Fischer Scientific) and aliquoted 
for two separate analyses (mutation and methylation analyses). Hotspot mutation 
analyses for FGFR3, TERT and HRAS were done at the Erasmus MC Pathology laboratory 
in Rotterdam, The Netherlands, via single-nucleotide extension reaction (Snapshot). See 
supplementary table 1 for primer and probe sequences. Probes were designed to cover 
the 5 most frequent mutations in FGFR3, the 2 most frequent mutations in TERT and the 
two most frequent mutations in HRAS. For FGFR3 these were; R248C and S249C (exon7); 
G327C, Y375C and A393E (exon 10). For TERT these comprised of; C228T/A, C242T 
and C250T, and for HRAS these included; G12C/S, S12D/V, G13C/R, Q61K and Q61L/R. 
Methylation analyses for OTX1, ONECUT2 and TWIST1 were done at the MDxHealth 
laboratory in Irvine, California, using methylation-specific PCR (MSP) analyses. 
88
Part I: Diagnosis
Mutation analyses (Erasmus MC Pathology laboratory) and methylation analyses 
(MDxHealth laboratory) were performed blinded from each other. The clinical data was 
also collected without knowledge of the results of the urine assay.
Statistical analysis
Patient and urine characteristics were compared between benign and malignant, 
by the Mann Whitney-U-test and the Fisher’s exact test. Methylation and mutation 
markers were dichotomized using the same cutoff values based on previous work.15, 
16 The association between outcome and potential predictor variables was determined 
by univariate and multivariate logistic regression analysis. The previously published 
optimal multivariable logistic regression model and its cutoff were used for prospective 
validation.14 The predictive capacity of the model was illustrated by the Area Under the 
Receiver Operating Characteristic (ROC) Curve (AUC). Further, recursive partitioning 
was applied to obtain a decision rule model, applicable for clinical practice. Statistical 
analyses were performed using IBM SPSS Statistics for Windows, Version 22.0, R 
statistical software (R Foundation for Statistical Computing, Vienna, Austria) and WEKA 
– University of Waikato software.
RESULTS
Inclusion and patient characteristics
Voided urine samples of 1092 patients were prospectively collected. Inclusion criteria 
were not met by 89 patients. For 118 patients, mutation/methylation status could not 
be determined for one or more of the biomarkers, resulting in 885 patients included in 
the final analyses (supplementary figure 1). A total of 115 patients was diagnosed with 
histopathologically confirmed urothelial cancer. Of the 885 patients included, 525 (59%) 
were male and 360 (41%) were female. Urothelial carcinoma was significantly more 
present in male patients (91 vs 24, p<0.01). Macroscopic hematuria was present in 485 
patients (55%), microscopic hematuria in 400 patients (45%) and urothelial carcinoma 
was significantly more present in macroscopic hematuria patients (101 vs 14, p<0.01). 
See table 1 for the patient, urine and tumor characteristics of the study population.
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Table 1. Patient, urine and tumor characteristics
   
Urothelial carcinoma 
(n=115)
Non-malignant 
(n=770)
Patient characteristics 
Age Median (range) 70 (39-96) 64 (19-76)
N (%) N (%)
Gender Male 91 (79.1)) 434 (56.4)
Female 24 (20.9) 336 (43.6)
Smoking Current 37 (32.2) 190 (24.7)
Former 45 (39.1) 156 (20.3)
Never 19 (16.5) 256 (33.2)
Unknown 14 (12.2) 168 (21.8)
Urine characteristics
Volume (ml) Median (range) 40 (5-80) 40 (2-100)
DNA concentration (ng/ml) Mean (range) 19.3 (0.33-120) 14.2 (0.33-400)
N (%) N (%)
Type of hematuria Microscopic 14 (12.2) 386 (50.1)
Macroscopic 101 (87.8) 384 (49.9)
Cytology Not done 79 (68.8) 512 (66.5)
No abnormalities 13 (11.3) 212 (27.5)
Suspect 3 (2.6) 5 (0.6)
Low Grade 2 (1.7) 1 (0.1)
High grade 13 (11.3) 2 (0.3)
Atypic 2 (1.7) 13 (1.7)
No diagnosis possible 2 (1.7) 16 (2.1)
Unknown 1 (0.9) 9 (1.2)
Tumor characteristics 
Localization Bladder 111 (96.5)  
  Upper Urothelial Tract 4 (3.5)  
Clinical stage Ta 61 (53.0)  
  T1 32 (27.8)  
  At least T2 12 (10.5)  
  Tis 10 (8.7)  
Grade G1 33 (28.7)  
  G2 24 (20.9)  
  G3 48 (41.7)  
  Gx 10 (8.7)  
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Urothelial carcinoma 
(n=115)
Non-malignant 
(n=770)
Concomitant CIS Yes 15 (13.0)  
  No 86 (74.8)  
  Unknown 14 (12.2)  
Validation and refit
Previously, we developed a prediction model in a case enriched discovery cohort, which 
was subsequently validated in an external case enriched cohort (93% sensitivity and 
86% specificity). This optimal multivariate prediction model contained the variables age, 
mutation combined and methylation combined.13, 14 Applying this prediction model 
and its predefined cutoff to the present prospectively collected cohort for external 
validation, resulted in a sensitivity of 88%, a specificity of 80%, a negative predictive 
value (NPV) of 98% and a predictive capacity of 0.92 (95% CI: 0.89-0.96), as presented by 
the AUC. In summary, this model proved robust in this independent cohort. Next, the 
model was refitted on the current cohort by running a multivariate logistic regression 
analysis, including the same three variables as in the previous model. This refit led to a 
prediction model with a similar predictive capacity (optimism corrected AUC: 0.93).
Optimization of the prediction model
Univariate logistic regression analysis also identified type of hematuria and gender as 
possible predictor variables in this dataset. Consequently, the prediction model was 
optimized by adding these to the multivariate logistic regression model. This so called full 
model (age, mutation combined, methylation combined, gender and type of hematuria) 
was compared with the refit of the previous model (age, mutation combined and 
methylation combined) in this cohort and showed a significantly improved goodness-
of-fit (Likelihood Ratio Test (LRT): P=0.0005) with a higher predictive capacity (optimism 
corrected AUC: 0.95). Results depicted in table 2. Hereafter, we compared this improved 
full model with a reduced model, from which age and gender were left out. This reduced 
model (mutation combined, methylation combined and type of hematuria) showed the 
same predictive capacity (optimism corrected AUC: 0.95) and no significant difference 
in goodness-of-fit (LRT: p=0.5686). The reduced model was then considered to be the 
optimal regression model as it showed the same performance as the full model, whilst 
containing only 3 predictor variables instead of 5. Figure 1 shows the ROC curve of this 
optimal prediction model with possible cutoffs and their corresponding sensitivity/
specificity. Using the 0.049 cutoff results in a 93% sensitivity, a 81% specificity and a 
99% NPV for the detection of bladder cancer in this cohort.
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Table 2. Logistic regression analyses validating and optimizing the multivariable prediction 
model. The optimal prediction model contains the type of hematuria, mutation combined and 
methylation combined variables.
External Validation
Variables Coefficients (β) AUC 95% CI
Validation of the previously developed logistic regression model in this prospective cohort
Intercept -10.156 0.9246 0.8925 - 0.9567
Age 0.110  
Mutation combined (binary) 4.241 Cutoff: 0.1917196 Sensitivity 88%
Methylation combined 0.905   Specificity 80%
Univariate analysis
Variables Coefficients (β) AUC 95% CI
Association between predictor variables and urothelial carcinoma
Type of Hematuria 7.252 <0.0001 0.6898 0.6550 - 0.7246
Gender 2.935 <0.0001 0.6140 0.5726 - 0.6550
Multivariate analysis
Variables Coefficients (β) AUC 95% CI
Refit variables of previous model 
Age 1.022 0.0861 0.9320 0.8999 - 0.9642 0.9311
Mutation combined (binary) 65.326 <0.0001  
Methylation combined 2.091 <0.0001      
Full model containing all predictor variables
Age 1.014 0.3022 0.9492 0.9249 - 0.9735 0.9461
Mutation combined (binary) 58.174 <0.0001  
Methylation combined 2.058 <0.0001  
Type of Hematuria 4.921 0.0003  
Gender 0.898 0.7749      
Optimal model (without age and gender)
Mutation combined (binary) 56.746 <0.0001 0.9479 0.9229 - 0.9729 0.9473
Methylation combined 2.145 <0.0001 Cutoff: 0.04902711 Sensitivity 93%
Type of Hematuria 5.072 0.0002     Specificity 81%
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Specificity
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AUC: 0.95
Figure 1. Receiver Operating Characteristic (ROC) curve of the optimal multivariable prediction 
model with 3 different cutoff values and their corresponding sensitivity/specificity. The 0.049 
cutoff results in a 93% sensitivity, 81% specificity. AUC is the Area under the ROC curve 
expressing the predictive capacity of the optimal prediction model.
Generation of a decision model
To facilitate use of the model in the clinic, we used recursive partitioning analysis (‘PART’ 
classifier in WEKA software) for a clinically applicable decision rule model (figure 2). 
Decision rules were constructed after 10-fold cross-validation and a cost matrix was 
set to 25 on the false negatives (i.e. false negatives were considered 25 times worse 
than false positives) to maximize sensitivity. The variables included in the analysis were 
the same as included in the optimal logistic regression model (mutation combined, 
methylation combined and type of hematuria), all contributing to the performance of 
the clinical decision model. Applying the constructed decision rule model to this cohort 
resulted in exactly the same sensitivity, specificity and NPV (93%, 81% and 99%) as when 
the optimal logistic regression model was applied.
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Patients presenting with 
Hematuria (N=885)  
Presence of any
Mutation? 
Positive test (N=99) 
Tumor present in 86  
Presence of 3 
Methylations? 
Presenting with 
Microhematuria? 
Negative test (N=379) 
Tumor present in 2 
Absence of any 
Methylation? 
YES 
YES 
YES 
NO 
YES 
NO 
NO 
NO 
Positive test (N=26) 
Tumor present in 8  
Negative test (N=255) 
Tumor present in 6 
Positive test (N=126) 
Tumor present in 13  
Figure 2. The constructed decision rule model. When applied to the study population leading 
to a 93% sensitivity, 81% specificity and 99% NPV. 107 of the 115 urothelial cancer cases had a 
positive test result when following the decision rule model.
DISCUSSION
Bladder cancer is a serious public health problem necessitating long term follow-up or 
cystectomy. One prominent symptom of bladder cancer is hematuria and most patients 
presenting with hematuria will undergo a cystoscopy and/or CT-scan to rule out the 
presence of a bladder tumor. However, by far the majority of patients presenting with 
hematuria does not have bladder cancer.7 Consequently, a sensitive urine test to select 
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patients for cystoscopy could greatly reduce the percentage of cystoscopies. The purpose 
of this multicenter prospective cohort study was to provide evidence that a diagnostic 
urine assay based on methylation and mutation can identify patients with bladder 
cancer in an unselected cohort of 885 hematuria subjects with sufficient accuracy. 
Here we show that the assay, combined with type of hematuria (either macroscopic 
or microscopic) identifies the 111 bladder cancer cases as well as the 4 upper urinary 
tract urothelial tumors, that are not visible by cystoscopy, with a sensitivity of 93%, a 
specificity of 81% and a NPV of 99%. These results suggest that a reduction of 71% of 
cystoscopies is possible by replacing cystoscopy with the urine test.
It could be argued that patients presenting with macroscopic hematuria are not the 
ideal target for a urine assay since cystoscopy is mostly done as soon as possible, which 
may leave insufficient time for a urine assay that takes 2-4 days.17 Cystoscopies are 
thereby often necessary for alternative diagnosis in macrohematuria patients. In this 
study, we show that macroscopic and microscopic hematuria are equally distributed in 
our patient population. Only a small proportion of patients with microscopic hematuria 
will ultimately be diagnosed with urothelial cancer (14/400, 3.5% in this cohort), while 
in current clinical practice a cystoscopy for urologic evaluation is performed on all. The 
urine assay detected all 12 high risk tumors, but missed 2 low risk (TaG1) urothelial 
cancer cases in the microscopic hematuria group. For these reasons, we conclude that 
the urine assay proved to be clinically useful in the microscopic hematuria group and 
can be introduced in the clinic to rule in microscopic hematuria patients for diagnostic 
cystoscopy. Implementation of this assay will result in a reduction of cystoscopies and 
thus a reduction of patient burden and costs. In addition, when the urine test becomes 
available for primary care, this could reduce the diagnostic delay in female patients 
presenting with hematuria. Moreover, we have previously reported an increase in the 
sensitivity of a cystoscopy when the urologist is aware of a positive urine test.18 This 
could even further increase sensitivity when the urine test is used to rule in hematuria 
patients for cystoscopy.
A limitation of our study was that for 118 patients, mutation/methylation status 
could not be determined for 1 or more of the biomarker genes. In 27 patients, both 
the mutation and the methylation status could not be determined at all. A probable 
cause for these unknown assay results is a too small yield of DNA isolated from the urine 
samples. Indeed, the DNA concentration was significantly lower for the 118 patients 
that did not show an assay result for 1 or more biomarker genes, compared to the 885 
patients that did show a result in all 6 genes (p<0.01). The DNA concentration was also 
significantly lower for 27/118 patients, from which both the mutation/methylation 
status could not be determined, when compared to the 91/118 patients that either did 
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show a methylation or a mutation result (p<0.01). In clinical setting, this limitation can 
be solved by requesting an additional urine sample from these patients to increase the 
DNA yield, as shown in previous research.19 In addition, the urine DNA concentration 
was significantly higher in urothelial cancer patients (p<0.01), which suggests that the 
probability of tumor presence is smaller in patients with a low DNA concentration. 
In conclusion, we proved that a diagnostic urine assay based on methylation and 
mutation markers is able to identify patients with urothelial carcinoma in this prospective 
cohort of 885 hematuria subjects with sufficient accuracy. The assay is clinically useful, 
especially in the microhematuria patient population, and can be implemented in the 
clinic to rule in patients for diagnostic cystoscopy. 
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Supplementary table 1. Sequences of the primers and probes in the analysis for FGFR3, TERT 
and HRAS genes
Primer sequence 
HRAS
HRAS exon1 Fw 5’-CAGGAGACCCTGTAGGAGG-3’
HRAS exon1 Rev 5’-TCGTCCACAAAATGGTTCTG-3’
HRAS exon2 Fw 5’-GGAGACGTGCCTGTTGGA-3’
HRAS exon2 Rev 5’-GGTGGATGTCCTCAAAAGAC-3’
TERT
hTERT Fw 3 5’-AGCGCTGCCTGAAACTCG-3’
hTERT Rev 1 5’-CCCTTCACCTTCCAGCTC-3’
FGFR3
FGFR3 RI Fw 5’-AGT GGC GGT GGT GGT GAG GGA G-3’
FGFR3 RI Rev2 5’-GCA CCG CCG TCT GGT TGG -3’
FGFR3 RII Fw 5’-CAA CGC CCA TGT CTT TGC AG-3’
FGFR3 RII Rev2 5’-AGGCGGCAGAGCGTCACAG-3’
Probe sequence 
HRAS
HRAS pos.34 5’-TTTTTTTTTTTTTTTTTCTGGTGGTGGTGGGCGCC-3’
HRAS pos.182 5’-TTTTTTTTTTTTTTTTTTGCATGGCGCTGTACTCCTCC-3’
HRAS pos.35 5’-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCGCACTCTTGCCCACACCG-3’
HRAS pos.181 5’-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCATCCTGGATACC
GCCGGC-3’
HRAS pos.37 5’-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCAGC
GCACTCTTGCCCACAC-3’
TERT
hTERT 1295228 Fw (37) 5’-TTTTTTTTTTTTTTTTTTTTGGCTGGGAGGGCCCGGA-3’
hTERT 1295242 Fw (44) 5’-TTTTTTTTTTTTTTTTTTTTTTTTTTTGGAGGGGGCTGGGCCGG-3’
hTERT 1295250 Fw 5’-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCTGGGCCGGGGACCCGG-3’
FGFR3
FGFR3-SNP R248C 5’-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCGTCATCTGCCCC
CACAGAG-3’
FGFR3_S249C 55BP 5’-T36 TCT GCC CCC ACA GAG CGC T-3’
FGFR3-SNP G372C 5’-T29 GGT GGA GGC TGA CGA GGC G-3’
Y375C-63BP Fw 5’-T43 ACG AGG CGG GCA GTG TGT-3’
FGFR3-SNP A393E 5’-T34 CCT GTT CAT CCT GGT GGT GG-3’
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ABSTRACT 
Purpose: The European Association of Urology (EAU) guidelines for non-muscle-invasive 
bladder cancer (NMIBC) recommend risk stratification based on clinicopathological 
parameters. Our aim was to investigate the added value of biomarkers to improve risk 
stratification of NMIBC. 
Experimental design: We prospectively included 1,239 patients in follow-up for 
NMIBC in six European countries. Fresh-frozen tumor samples were analyzed for GATA2, 
TBX2, TBX3 and ZIC4 methylation and FGFR3, TERT, PIK3CA and RAS mutation status. 
Cox regression analyses identified markers that were significantly associated with 
progression to muscle-invasive disease. The progression incidence rate (PIR=rate of 
progression per 100 patient-years) was calculated for subgroups. 
Results: In our cohort, 276 patients had a low, 273 an intermediate and 555 a high risk 
of tumor progression based on the EAU NMIBC guideline. Fifty-seven patients (4.6%) 
progressed to muscle-invasive disease. The limited number of progressors in this large 
cohort compared to older studies is likely due to improved treatment in the last two 
decades. Overall, wild type FGFR3 and methylation of GATA2 and TBX3 were significantly 
associated with progression (HR 0.34, 2.53 and 2.64, respectively). The PIR for EAU 
high-risk patients was 4.25. On the basis of FGFR3 mutation status and methylation of 
GATA2 this cohort could be reclassified into a good class (PIR=0.86, 26.2% of patients), a 
moderate class (PIR=4.32, 49.7%) and a poor class (PIR=7.66, 24.0%). 
Conclusions: We conclude that the addition of selected biomarkers to the EAU risk 
stratification, increases its accuracy and identifies a subset of NMIBC patients with a very 
high risk of progression. 
Translational relevance: The EAU guideline for non-muscle-invasive bladder cancer 
(NMIBC) recommends risk stratification based on clinicopathological parameters only. 
This large prospective international study shows that the addition of FGFR3 mutation 
status and GATA2 methylation status to this risk stratification reclassifies EAU high-risk 
patients in good, moderate or poor progression risk subsets. Based on this biomarker 
subclassification of EAU high-risk patients, these patients could be allocated to 
different treatment strategies. Patients at very high risk of progression could receive 
more intensive surveillance and additional treatments or may even be considered 
for early cystectomy. We conclude that addition of selected biomarkers to the EAU 
risk stratification increases its accuracy and that the use of these progression markers 
has potential for implementation in the EAU NMIBC guidelines. Further validation is 
however recommended.
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INTRODUCTION
Patients with non-muscle-invasive bladder cancer (NMIBC) have a recurrence rate of 
approximately 70% and in up to 15% of cases, the tumor progresses to muscle-invasive 
bladder cancer (MIBC) 1-3. Hence, patients with NMIBC need to be monitored frequently 
for many years. This contributes to the fact that the management of patients accounts 
for 3% of all cancer costs in the EU (€ 143 billion in 2012) 4. 
The European Association of Urology (EAU) has developed widely adopted guidelines 
for the treatment and follow-up of NMIBC patients. In these guidelines, patients are 
stratified into low-, intermediate- and high-risk groups based on clinicopathological 
characteristics 5. These guidelines are based on  European Organisation for Research 
and Treatment of Cancer (EORTC) nomograms 1. Patients included in this large study 
were recruited between 1979 and 1989. Treatment and follow-up differed from current 
practice. For instance, BCG was not FDA approved until 1990 and the mandatory 
retransurethral resection (TUR) for high-risk tumors was not standard practice in the 
1980s. Over the past decades, these items have changed NMIBC management, and 
insight on the molecular architecture of bladder tumors has dramatically increased. 
The EAU risk stratification does not include molecular markers, and it is important 
and challenging to determine whether the molecular knowledge can improve the 
management of NMIBC patients, particularly those at high risk of progression.
Previous work showed that activating point mutations in the FGFR3 gene were 
associated with a lower chance of progression of pTa and pT1 tumors 6-8. Methylation 
markers for progression of NMIBC (GATA2, TBX2, TBX3 and ZIC4) were identified and 
validated in two small patient series 9. Further validation of the four genes was done 
by Beukers and colleagues on 192 formalin-fixed paraffin-embedded (FFPE) bladder 
cancer samples enriched  for progressing cases 10. In this large international prospective 
study of NMIBC (FP7: UROMOL), we aimed to evaluate the added value of these markers 
to the well-established risk stratification of the EAU NMIBC guidelines 5. 
MATERIALS AND METHODS
Patient selection and data collection
A total of 1,239 patients in follow-up for NMIBC (urothelial carcinoma) were prospectively 
included in hospitals in Denmark (n=581), Germany (n=386), Serbia (n=77), Spain (n=75), 
Sweden (n=84), and the Netherlands (n=36) (table 1). Inclusion criteria were patients 
diagnosed with NMIBC and not previously diagnosed with MIBC. Of these primary and 
106
Part II: Prognosis
recurrent patients, 884 were in follow-up for stage pTa disease, 310 for pT1 disease and 
45 for pTis. Only one tumor per patient was included in this study. Because treatment 
and follow-up regimens were based on the original pathology reports, we used these 
for staging and grading. Fresh-frozen tumor tissue was collected. Sections with at least 
50% tumor cells were selected for DNA isolation. Clinicopathological parameters were 
entered in an online database. There was no attempt to modify current clinical practice 
at the participating centers; follow-up took place according to the national guidelines. 
The study was approved by the Central Denmark Region Committees on Biomedical 
Research Ethics (#1994/2920); the ethics committee of the University Hospital Erlangen 
(Erlangen, Germany; #3755); the ethics committee of the technical University of Munich 
(Munich, Germany; #2792/10); Medical Ethics Committee of Erasmus MC (Rotterdam, 
The Netherlands; MEC#168.922/1998/55); the Uppsala Region Committee on Biomedical 
Research Ethics (#2008/252); the Ethical Committee of Faculty of Medicine, University of 
Belgrade (Belgrade, Serbia; #440/VI-7); the Ethics Committee (CEIC) of Institut Municipal 
d’Assistència Sanitària/Hospital del Mar (Barcelona, Spain; 2008/3296/I); the ethics 
committee of the University Hospital Jena (Jena, Germany; #4774-4/16). Patients either 
gave their written informed consent, or samples were used according to “The Code for 
Proper Secondary Use of Human Tissues in the Netherlands” (http://www.federa.org/). 
The study was conducted according to the principles of the Declaration of Helsinki.  In 
all centers standardized procedures were applied for sampling, freezing and shipment 
of the samples 11.
Molecular analyses
DNA was isolated using Puregene DNA Isolation kit (Thermo Fischer Scientific). 
Methylation of the GATA2, TBX2, TBX3 and ZIC4 genes was determined as described 
by Kandimalla and colleagues 9. In short, DNA was converted with bisulfite (EZ-DNA 
Methylation Gold 30TM, Zymo Research Corp, Orange, CA, USA). The converted DNA 
samples were amplified in a bisulfite specific PCR. Primer and probe details can be 
found in supplementary table 1. After completion, the samples were treated with an 
Exonuclease I (EXOI)/Shrimp Alkaline Phosphatase (SAP) mixture in order to remove 
excess primers and dNTPs. Next, a single-nucleotide probe extension SNaPshot analysis 
was performed. Then, the sample was placed in an automatic sequencer (ABI PRISM 
3130 XL Genetic Analyzer, Applied Biosystems). SNaPshot data was analyzed by use of 
GeneMarker version 2.4 (SoftGenetics). Point mutations in the FGFR3, PIK3CA, TERT and 
RAS oncogenes were likewise determined using a probe extension SNaPshot analysis 
following PCR of selected regions 12, 13.
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Table 1. Patient and tumor characteristics of all included patients (N=1,239).
Patient characteristics
Age Mean (range) 70 (21-96)
n (%)
Gender Male 961 (77.6)
Female 278 (22.4)
Smoking Never 154 (12.4)
Former 390 (30.8)
Current 312 (25.2)
Unknown 383 (30.9)
Country of inclusion Denmark 581 (46.9)
Germany 386 (31.2)
Netherlands 36 (2.9)
Serbia 77 (6.2)
Spain 75 (6.1)
Sweden 84 (6.8)
Ever diagnosed with CIS Yes 191 (15.4)
No 1048 (84.6)
Intravesical instillation Yes 464 (37.4)
(BCG/MMC/Chemo ever) No 774 (62.5)
Unknown 1 (0.1)
Tumor characteristics
Tumor type Primary 583 (47.1)
Recurrent 656 (52.9)
Stage pTa 884 (71.3)
pT1 310 (25.0)
pTis 45 (3.6)
Grade† Low grade 849 (68.5)
High grade 353 (28.5)
PUNLMP 12 (1.0)
Unknown 25 (2.0)
Multiplicity Solitary 879 (70.9)
Multiple 344 (27.8)
Unknown 16 (1.3)
Tumor Size <3cm 663 (53.5)
≥3cm 162 (13.1)
Unknown 414 (33.4)
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Tumor characteristics
EAU risk category Low 276 (22.3)
Intermediate 273 (22.0)
High 555 (44.8)
Unknown 135 (10.9)
Prior recurrence rate <1/year 157 (12.4)
>1/year 86 (6.8)
Unknown 1028 (82.9)
Outcome
Progression to T2 Yes 57 (4.6)
No 1182 (95.4)
Months of follow up Median (range) 27.0 (0-81)
Positive test
Mutation analyses FGFR3 424 / 762 (55.6)
TERT 571 / 770 (74.2)
PIK3CA 171 / 778 (22.0)
RAS 58 / 774 (7.5)
Methylation dichotomized GATA2 241 / 792 (30.4)
TBX2 447 / 792 (56.4)
TBX3 273 / 792 (34.5)
ZIC4 242 / 792 (30.6)
† Low grade included ‘low grade’, ‘grade 1’ and ‘grade 2’; high grade included ‘high grade’, ‘grade 3’ and ‘grade 4’.
Statistical analysis
Analyses were performed retrospectively on the data that was collected in real time.  Each 
methylation marker was dichotomized as hypomethylated versus hypermethylated. 
The ROC curve was used to set a cutoff for each methylation marker by determining 
the optimum between sensitivity and specificity of the methylation ratio for predicting 
progression to MIBC. Progression-free survival (PFS) curves were estimated using 
the Kaplan-Meier method, followed by log-rank analysis to determine the difference 
between both groups. Progressive disease is defined as progression to stage T2 or 
higher stage disease, development of nodal or distant metastases or death of disease. 
Patients that died of other cause prior to progression were censored at time of death. 
Univariate and multivariable Cox regression analyses were performed to test the 
prognostic relevance of the different variables. Harrell c-statistic was defined to measure 
the predictive capacity. The progression incidence rate (PIR) was used to determine the 
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impact of a new risk stratification. The PIR is the number of progressors divided by the 
amount of person-years in that risk group, times 100 and can be interpreted as the 
rate of progression per 100 person-years of follow-up and is cumulative (14). Statistical 
analyses where performed by use of IBM SPSS Statistics 21 (IBM Corp.). Two-sided 
P values lesser than 0.05 were considered significant. 
RESULTS
Patient and tumor characteristics 
Over 47% of patients were included with a primary tumor and 37.4% received any type 
of intravesical instillation (table 1). Age and gender distribution was in accordance 
to the literature 2. Numbers of tumors with methylation or mutations in the analyzed 
genes are depicted in table 1. The determined cutoffs, sensitivities and specificities 
for all methylation markers are listed in supplementary table 2. Distribution of clinical 
characteristics per country are depicted in supplementary table 3.
Relation of potential predictor variables to progression of NMIBC
According to the EAU risk stratification 276 NMIBC patients had a low-risk, 273 an 
intermediate-risk and 555 patients had a high-risk tumor (table 1)5. Progression to 
muscle-invasive disease was seen in one (0.4%) of low-risk tumors, eight (2.9%) of 
intermediate-risk tumors and 45 (8.1%) of high-risk patients, the remaining nine 
progressions occurred in patients of an unknown EAU risk category. In all included 
patients, univariate Cox regression analysis identified a significantly higher hazard ratio 
of progression for increasing age (HR 1.04, p=0.004) and EAU risk category (HR 5.92, 
p<0.001) (table 2a).
Many of the clinical parameters included in the EAU risk category were significantly 
correlated to progression (Carcinoma in situ (CIS), stage, grade and tumor size). Of the 
biomarkers, FGFR3 mutations were associated with a lower hazard ratio for progression 
(HR 0.34, p=0.002) and methylation of GATA2 and TBX3 with a significantly higher 
hazard ratio (HR 2.53, p=0.003 and HR 2.64, p=0.002, respectively). All other potential 
biomarkers; mutation status of TERT, PIK3CA, RAS, and methylation status of TBX2 and 
ZIC4, were not significantly associated with progression. Overall, c-statistics were 
highest for EAU risk category (0.70), grade (0.70), stage (0.69), FGFR3 mutation status 
(0.66) and methylation of GATA2 (0.62) (table 2a). PFS was significantly poorer in patients 
with higher EAU risk categorization, FGFR3 wild-type and GATA2 and TBX3 methylated 
tumors (supplementary figure 5). 
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Table 2a. Univariate Cox regression analysis of potential predictor variables and time to 
progression in all patients (N=1,239).
Variable n* HR (95% CI) P c-statistic
Age 1,034 1.04 (1.01-1.07) 0.004 0.58
Gender 1,038 0.79 (0.40-1.56) 0.489 0.51
Smoking (ever) 794 1.13 (0.51-2.54) 0.760 0.52
Intravesical instill. 1,037 0.62 (0.36-1.07) 0.084 0.59
Primary / recurrent 1,038 1.12 (0.67-1.89) 0.664 0.51
Ever CIS 1,038 2.23 (1.25-3.97) 0.007 0.57
Stage 1,038 1.73 (1.31-2.29) <0.001 0.69
Grade 1,020 4.80 (2.81-8.18) <0.001 0.70
Tumor Size 742 2.12 (1.14-3.94) 0.018 0.56
Multiplicity 1,025 1.59 (0.94-2.70) 0.086 0.53
EAU risk category (low + interm. = reference) 946 5.92 (2.89-12.11) <0.001 0.70
Mutation markers
FGFR3 659 0.34 (0.17-0.68) 0.002 0.66
TERT 667 2.23 (0.87-5.73) 0.095 0.55
PIK3CA 676 1.21 (0.59-2.49) 0.605 0.49
RAS 671 0.44 (0.06-3.20) 0.416 0.51
 Methylation markers
GATA2 688 2.53 (1.36-4.71) 0.003 0.62
TBX2 688 1.90 (0.96-3.73) 0.064 0.56
TBX3 688 2.64 (1.41-4.92) 0.002 0.59
ZIC4 688 1.50 (0.79-2.81) 0.213 0.54
*n, number of patients included in that specific univariate analysis
The combination of EAU risk category, FGFR3 mutation status, GATA2 and TBX3 
methylation status resulted in an overall predictive capacity of 76% as calculated by the 
Harrell c-statistic (table 2b) and this was 0.72 for the biomarker combination without 
EAU risk category. 
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Table 2b. Multivariable Cox regression analysis of potential biomarker predictor variables and 
time to progression in all patients (patients with missing values were excluded).
Variables in model HR (95% CI) P
Complete 
model P c-statistic
Biomarkers + EAU category (n=614)
EAU category (low + interm. = reference) 3.08 (1.31-7.23) 0.010 <0.001 0.76
FGFR3 mutation 0.57 (0.28-1.20) 0.139
GATA2 methylation 1.90 (0.98-3.66) 0.057
TBX3 methylation 1.68 (0.84-3.34) 0.141
Biomarkers (n=659)
FGFR3 mutation 0.43 (0.21-0.87) 0.019 <0.001 0.72
GATA2 methylation 2.23 (1.16-4.31) 0.016
TBX3 methylation 1.85 (0.94-3.65) 0.076
Potential predictor variables for progression of high risk NMIBC
Because progression to MIBC was most prominent in the EAU high-risk group and a 
more personalized risk stratification for this group is of most benefit for patients, we 
next focused on this group. In this subgroup, age was again significantly associated with 
progression, even though the HR was low (HR 1.04, p=0.021) (table 3a). Furthermore, 
grade and hypermethylation of GATA2 resulted in a significantly higher hazard ratio 
for progression (HR 2.28, p=0.018 and HR 2.04, p=0.046, respectively). In contrast, 
intravesical instillations and FGFR3 mutations were associated with a lower hazard 
ratio of progression to MIBC (HR 0.35, p=0.002 and HR 0.31, p=0.010). The c-statistic 
was moderate for both biomarkers (FGFR3 0.63 and GATA2 0.58) (table 3a). PFS was 
significantly poorer in patients that did not receive intravesical instillation. In addition, 
higher grade, GATA2 hypermethylation or FGFR3 wild type were associated with a 
higher risk of progression (see supplementary figure 6).
Multivariable analysis showed that combining both FGFR3 mutation status and GATA2 
methylation status resulted in an overall significant model (p=0.005), with a predictive 
capacity of 67% (table 3b). The PFS curves diverged significantly, p<0.01 (figure 1: 
good class “hypomethylated GATA2 and mutated FGFR3”, moderate class “either 
hypermethylated GATA2 and mutated FGFR3” or “hypomethylated GATA2 and wild-type 
FGFR3” and poor class “hypermethylated GATA2 and wild-type FGFR3”). Supplementary 
figures 7 and 8 show further comparisons of EAU low-risk versus EAU high-risk good 
class patients and a comparison to overall high-risk EAU patients. Table 4 illustrates the 
distribution of characteristics of the subclassified patients.
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Table 3a. Univariate Cox regression analysis of potential predictor variables and time to 
progression in patients with high-risk tumors according to the EAU guidelines (n=555).
Variable n* HR (95% CI) P c-statistic
Age 465 1.04 (1.01-1.07) 0.021 0.57
Gender 467 1.00 (0.50-2.02) 0.999 0.51
Smoking (ever) 366 0.72 (0.30-1.73) 0.460 0.50
Intravesical instill. 467 0.35 (0.18-0.68) 0.002 0.64
Primary / Recurrent 467 1.22 (0.67-2.19) 0.518 0.53
Ever CIS 467 1.00 (0.54-1.84) 0.997 0.50
Stage 467 1.10 (0.76-1.59) 0.629 0.57
Grade 453 2.28 (1.15-4.52) 0.018 0.61
Tumor Size 283 1.28 (0.64-2.56) 0.483 0.52
Multiplicity 455 1.28 (0.70-2.36) 0.423 0.52
Mutation markers
FGFR3 321 0.31 (0.13-0.75) 0.010 0.63
TERT 322 2.16 (0.75-6.20) 0.151 0.55
PIK3CA 328 1.04 (0.43-2.53) 0.933 0.50
RAS 323 0.49 (0.07-3.63) 0.494 0.52
Methylation markers
GATA2 333 2.04 (1.01-4.10) 0.046 0.58
TBX2 333 1.36 (0.65-2.82) 0.413 0.52
TBX3 333 1.71 (0.86-3.43) 0.129 0.55
ZIC4 333 1.43 (0.70-2.89) 0.325 0.54
*n, number of patients included in that specific univariate analysis
Table 3b. Two multivariable Cox regression analysis of potential predictor variables and time 
to progression in patients with high-risk tumors according to the EAU guidelines (patients with 
missing values were excluded).
Variables in model HR (95% CI) P Complete model P c-statistic
Markers only (n=321)
FGFR3 mutation 0.33 (0.13-0.80) 0.014 0.005 0.67
GATA2 methylation 1.88 (0.91-3.89) 0.087
Biomarker predictor variables + grade (n=312)
Grade 1.60 (0.64-4.01) 0.318 0.010 0.69
FGFR3 mutation 0.40 (0.15-1.06) 0.064
GATA2 methylation 1.83 (0.86-3.86) 0.116
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Events
Good 95 77 64 38 10 2 2 
Moderate 180 115 86 52 21 12 15 
Poor 87 58 42 26 10 1 13
60483624120
1,0
0,8
0,6
0,4
0,2
0,0
 Poor
 Moderate
 Good
p<0.01
Figure 1. PFS curve in patients with EAU high-risk tumors of a combination of FGFR3 and 
GATA2 status. Dotted line, good status (hypomethylated GATA2 and mutated FGFR3); dashed 
line, moderate status (either hypermethylated GATA2 and mutated FGFR3 or hypomethylated 
GATA2 and wild-type FGFR3); or solid line, poor status (hypermethylated GATA2 and wild-type 
FGFR3). Progressive disease is defined as progression to stage T2 or higher stage disease. P 
value is based on log-rank test.
Addition of biomarkers improves EAU high-risk stratification precision
In order to compare the EAU high-risk group to the subclassified risk groups, the PIRs 
per risk group were calculated. In figure 2 and supplementary table 4, the PIRs for all 
risk groups are shown. The original EAU high-risk group had an PIR of 4.25. Using a 
combination of GATA2 methylation status and FGFR3 mutation status, 26.2% of the EAU 
high-risk patients could be subclassified in a good class (PIR 0.86). This is a 4.8 times 
lower progression risk than the original EAU high-risk stratification. In contrast, 24.0% 
of the original EAU high-risk patients would be subclassified as having a very high 
risk for progression, with an PIR of 7.66 (figure 2, supplementary table 4). Overall, the 
proportion of high-grade tumors and the proportion of patients ever diagnosed with 
CIS increased over the increasing risk groups (table 4). Progression to muscle-invasive 
disease was seen in 2.1% of the good class patients, increasing to 14.9% in the poor class 
patients (table 4). Based on this biomarker subclassification of EAU high-risk patients, 
these patients could be allocated to different management strategies (figure 2).
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Table 4. Patient and tumor characteristics of all reclassified patients based on a combination 
of FGFR3 mutation status and GATA2 methylation status (n=362).  Only high-risk patients with 
known marker results and known time of follow-up were included.
EAU risk group High risk (n=362)
Newly suggested risk groups Good (n=95) Moderate (n=180) Poor (n=87)
Patient characteristics
Age Mean (range) 69 (47-90) 68 (37-96) 72(51-93)
n (%) n (%) n (%)
Gender Male 69 (72.6) 139 (77.2) 72 (82.8)
Female 26 (27.4) 41 (22.8) 15 (17.2)
Intravesical instill. Yes 36 (37.9) 82 (45.6) 45 (51.7)
No 59 (62.1) 98 (54.4) 42 (48.3)
Tumor characteristics
Tumor type Primary 59 (62.1) 87 (48.3) 51 (58.6)
Recurrent 36 (37.9) 93 (51.7) 36 (41.4)
Stage pTa 29 (30.5) 65 (36.1) 34 (39.1)
pT1 62 (65.3) 104 (57.8) 49 (56.3)
pTis 4 (4.2) 11 (6.1) 4 (4.6)
Grade Low grade 59 (62.1) 60 (33.3) 14 (17.5)
High grade 34 (35.8) 111 (61.7) 73 (83.9)
Unknown 2 (2.1) 9 (5.0) -
Ever CIS Yes 13 (13.7) 64 (35.6) 32 (36.8)
No 82 (86.3) 116 (64.4) 55 (63.2)
Follow-up
Progression to T2 Yes 2 (2.1) 15 (8.3) 13 (14.9)
No 93 (97.9) 165 (91.7) 74 (85.1)
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GATA2 Methylated 
FGFR3 Wild Type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GATA2 Methylated 
FGFR3 Mutated 
or  
GATA2 Unmethylated 
FGFR3 Wild Type 
 
 
 
 
 
 
 
 
 
 
 
 
 
GATA2 Unmethylated 
FGFR3 Mutated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High risk 
PIR = 4.25 
Good 
PIR = 0.86 
Moderate 
PIR = 4.32 
Poor 
PIR = 7.66 
Single instillation of 
chemotherapy, 
consider BCG or 
chemotherapy 
instillations for 1 year 
Full-dose BCG  
maintenance therapy 
Consider radical 
cystectomy, intensive 
surveillance 
26.2% 
49.7% 
24.0% 
p=0.02 
p<0.01 
p=0.15 
Figure 2. Reclassification of EAU high-risk group patients identifying a group with very low 
and very high risk, suggesting that treatment for these patients should be changed. The PIRs 
are depicted in the box of each risk group. The PIR is the number of progressors divided by 
the amount of person-years in that risk group, times 100, and can be interpreted as the rate of 
progression per 100 person-years. The percentages at each arrow indicate the proportion of 
reclassified patients that were originally classified in the EAU high-risk group. P values are based 
on log-rank test.
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DISCUSSION
Currently, the EAU risk groups are used to stratify NMIBC patients for treatment and 
follow-up. Scoring according to this system is based on the clinicopathological 
parameters: tumor size, multiplicity, primary tumor, stage, grade, and CIS 5. In particular, 
grading has been shown to be subject to interobserver variation and not all variables 
are always taken into account 15. Furthermore the recommendation of the recent WHO 
classification (2016) to grade bladder cancer in two categories only (low and high grade) 
eliminates the importance of distinguishing Grade 2 from Grade 3 tumors for estimating 
progression in NMIBC 16. Robust biomarkers that can improve risk assessment are 
therefore needed. 
The purpose of this international prospective study was to investigate the previously 
discovered and validated methylation of GATA2, TBX2, TBX3 and ZIC4 as well as the 
hotspot mutations in the FGFR3, PIK3CA, RAS and TERT genes for the risk of progression of 
NMIBC 9, 10. We investigated whether these biomarkers are of added value to the EAU risk 
groups for the stratification of NMIBC patients for the treatment and follow-up protocol. 
Here, we confirm that methylation of GATA2 and mutation of FGFR3 was associated 
with progression. Furthermore, a combination of GATA2 and FGFR3 status stratified 
EAU high-risk patients into three classes with different progression risks. The rate of 
progression per 100 patient-years (PIR) was calculated and compared among EAU high-
risk plus biomarker subgroups. These data demonstrated that adding the FGFR3 and 
GATA2 biomarkers resulted in an improved prediction model. For instance, in the 24.0% 
of EAU high-risk patients was found to have an PIR of 7.66, which is 1.8 times higher 
than the entire high-risk group and almost 9 times higher than patients with the lowest 
risk of progression (26.2% of high-risk patients, who were subclassified in a good class). 
This finding suggests that these patients should receive more intensive surveillance and 
additional treatments or should even be considered for early cystectomy. Thus, we show 
that by adding the biomarkers, stratification of high-risk patients can be improved. 
The value of this cohort is, its large sample size; its prospective nature; its multi-
institutional and multinational character. From a statistical point of view, the low 
number of progressing patients (4.6% overall), is a limitation. However, the patients in 
this cohort were recruited between 2008 and 2013 and their progression risk is that 
of NMIBC patients in a 21st century urology clinic. In the large retrospective study by 
Sylvester and colleagues which formed the basis for the EAU risk group stratification, 11% 
of patients progressed to MIBC 1. The latter patients were recruited between the years 
1979 and 1989. Obviously, treatment and follow-up in those years differed considerably 
from current practice. In fact, the low numbers of patients with progression in our study 
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is most probably the result of improved treatment and surveillance protocols, e.g. MMC 
and BCG instillations, improved quality of endoscopic instruments and re-TUR in pT1 
cases.
There is robust literature on the favorable disease course of NMIBC patients having FGFR3 
mutant tumors 6, 7, 17, 18. In addition, van Rhijn and colleagues described the importance 
of FGFR3 mutation status in pT1 tumors;  FGFR3 mutations occurred in 28% of pT1 
tumors and multivariable analysis showed a hazard ratio of 2.2 for nonprogression in 
the multivariable analysis (p = 0.05)19. Although we found a higher mutation frequency 
in pT1 tumors (45%), we confirmed the favorable outcome of FGFR3 mutant tumors. 
Recently, a progression score based on expression of 12 genes was shown to add 
prognostic information beyond the EORTC risk score described by Sylvester and 
colleagues 1, 20. This 12-gene signature was developed on a subset of the patient cohort 
in the current study. Univariate Cox regression analysis of the 12 gene score resulted in 
an HR of 2.39 (p<0.001) for the continuous and HR 5.08 (p<0.001) for the dichotomized 
risk score. Moreover, the 12-gene progression score was also able to predict PFS within 
the EORTC high risk patients (p=0.035 or p=0.041, depending on the cutoff used) 20. In 
this study, using FGFR3 and GATA2 we were able to identify three groups with different 
progression risks within the EAU high risk patients (figure 1, p<0.01). Based on these 
data, we conclude that both gene expression profiling and FGFR3+GATA2 analysis can 
be very useful to further differentiate risk groups in the EAU highest risk category.  Both 
type of assays can be performed in a molecular pathology laboratory. 
In this study, DNA was isolated from fresh-frozen tissue; therefore, we had to redetermine 
cutoffs for the methylation markers. Still, for clinical implementation an FFPE-based 
analyses is more suitable. That the assays perform well also on FFPE tissue was already 
shown in  the study by Beukers and colleagues 10. The biomarker assays that we used 
are not very expensive (€20 material cost/sample), however, a cost-effectiveness 
analysis of the proposed stratification should be conducted. Finally, given the number 
of progressing patients in the EAU high-risk group, it would be wise to further validate 
the combination of FGFR3 mutations and GATA2 methylation in a case-enriched series.
CONCLUSION
Addition of FGFR3 mutation status and GATA2 methylation status to the EAU risk 
stratification, increases its accuracy and, moreover, identifies a subset of NMIBC patients 
with a very high yearly risk of progression. In these very high risk patients intensive 
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surveillance is warranted and early cystectomy should be considered. We conclude 
that the use of these progression markers has potential for implementation in the EAU 
NMIBC guidelines. Further validation in high-risk NMIBC patients is recommended.
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Supplementary table 1. Sequences of the primers and probes used in the methylation 
analyses for the different CpGs in the GATA2, TBX2, TBX3 and ZIC4 genes. All sequences are 
noted from 5’ to 3’.
GATA2
Forward primer GYGGTTTGATAATTGGTAAAT
Reverse primer AACAAACAAAATTCRAAAACC
Amplicon size 131 bp
Probe (T20)† ACAAACAAATTATACCTAAC
TBX2
Forward primer GYGAGTTAGYGGTTTGGATA
Reverse primer CCTTACCRCCACCACCAAC
Amplicon size 113 bp
Probe (T45)† GTTGATGGATATTGTAGT
TBX3
Forward primer TTTGTTAATGGTTTGTAAATTT
Reverse primer AAGAAAAATTCRCACCTTCCC
Amplicon size 128 bp
Probe (T13)† AATTTTGGGATTAAAAG
ZIC4
Forward primer TTTTTATTTTTTGAGGGTAAATATTTAGTA
Reverse primer ATCTCCAAAAAACCTCTAAAACAAC
Amplicon size 127 bp
Probe (T11)† AAATTTTGTTTAAATTTTT
† T20, T45, T13 and T11 represent poly-T tails of 20, 45, 13 and 11 T’s, respectively. These tails are added to distinguish the 
different probes in order to allow a multiplex sequence run.
Supplementary table 2. Cutoffs for dichotomization of the methylation marker results 
were chosen based on the desired sensitivity-specificity trade-off for progression to MIBC as 
visualized by the receiver-operating characteristic curve (ROC curve); the point on the curve 
closest to the upper left corner. 
Methylation markers
Gene Cutoff Sensitivity Specificity
GATA2 47.4982 56.3 63.0
TBX2 7.7190 65.6 39.7
TBX3 14.0013 53.1 58.3
ZIC4 46.8911 40.6 67.9
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Supplementary figure 5. Progression-free survival curves in all patients for (A) EAU risk 
category, (B) FGFR3, (C) GATA2 and (D) TBX3. Progressive disease is defined as progression to 
stage T2 or higher stage disease. P values (log-rank test) are indicated in each figure. 
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Supplementary figure 6. Progression-free survival curves in EAU high risk patients for (A) 
Intravesical instillations, (B) Grade, (C) FGFR3 and (D) GATA2. Progressive disease is defined as 
progression to stage T2 or higher stage disease. P values (log-rank test) are indicated in each 
figure. 
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Supplementary figure 7. Progression-free survival curve in patients with all EAU low-risk 
tumors and EAU high-risk patients with a good class tumor (good class: hypomethylated GATA2 
and mutated FGFR3). Progressive disease is defined as progression to stage T2 or higher stage 
disease. 
Supplementary figure 8. Progression-free survival curve in patients with EAU high-risk tumors 
of a combination of FGFR3 and GATA2 status. Blue: good status (hypomethylated GATA2 and 
mutated FGFR3), green; moderate status (either hypermethylated GATA2 and mutated FGFR3 or 
hypomethylated GATA2 and wild-type FGFR3) or red: poor status (hypermethylated GATA2 and 
wild-type FGFR3) compared to a progression free survival curve in all EAU high-risk patients. 
Progressive disease is defined as progression to stage T2 or higher stage disease.
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ABSTRACT
Background: Platinum-based pre-operative chemotherapy (POC) for muscle-invasive 
bladder cancer (MIBC) increases the complete pathological response rate at cystectomy 
and improves overall survival. However, 60% of MIBC patients still has muscle-invasive 
disease at cystectomy despite POC. Therefore, accurate prediction of response to POC is 
an important clinical need. We hypothesized that an elevated neutrophil-to-lymphocyte 
ratio (NLR) corresponds with adverse outcome in patients undergoing POC and radical 
cystectomy.
Objective: To explore the correlation between the NLR and outcome in MIBC patients 
treated by POC and radical cystectomy. 
Methods: In 123 MIBC patients (urothelial carcinoma) who were treated by platinum-
based POC and radical cystectomy, the derived NLR (dNLR) was retrospectively 
calculated by dividing the neutrophil count by the difference between leukocytes and 
neutrophil counts, prior to the start of chemotherapy. The correlation of the dNLR with 
pathological response at cystectomy and survival was analyzed by logistic regression 
analysis or the Kaplan-Meier method.
Results: The complete pathological response (ypT0N0Mx) rate was 28.5%, 8.9% 
obtained a partial response (ypTa/T1/TisN0Mx), and 62.6% were non-responders (stage 
≥ ypT2 and/or N+). An elevated dNLR (>2.21) correlated with non-response to POC (OR 
2.70, 95% confidence interval: 1.15–6.38, p = 0.02) but this effect was nullified when 
corrected for clinically node-positive disease and clinical T stage. Patients with an 
elevated dNLR had shorter progression-free and overall survival albeit non-significant 
(p = 0.42, and p = 0.45, respectively).
Conclusions: An elevated dNLR corresponded with poor outcome in terms of survival 
and non-response to POC in MIBC patients undergoing radical surgery. However, after 
correction for well-known prognostic factors, such as positive lymph node status 
at diagnostic imaging and clinical T stage, the correlation for the dNLR was nullified. 
Therefore, we conclude that the dNLR is insufficient to predict response to POC in this 
heterogeneous patient population.
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INTRODUCTION 
The standard curative treatment for patients with non-metastatic MIBC is radical 
cystectomy, which can be preceded by pre-operative chemotherapy (POC): neoadjuvant 
chemotherapy (NAC) for clinical stage T2-T4aN0 or induction chemotherapy in case of 
N+disease1. The prognosis of MIBC is poor; the 5-year survival rate for stage pT2 UC is 
around 62% but it drops to a mere 5.5% for stage pT42. 
Cisplatin-based chemotherapy is the current standard neoadjuvant regimen for MIBC3. 
A large multicenter randomized trial showed that a neoadjuvant regimen of cisplatin, 
methotrexate and vinblastine (CMV) gave a reduction in the risk of death (HR: 0.84) and 
an absolute increase in 10-year survival from 30% to 36% in MIBC patients4. In addition, 
another randomized trial showed that patients who received NAC of methotrexate, 
vinblastine, doxorubicin and cisplatin (MVAC) prior to radical cystectomy had a longer 
median overall survival than patients who underwent radical cystectomy alone (77 
and 46 months respectively, p = 0.06)5. Despite level I evidence, controversies on the 
use of NAC in MIBC remain because the survival benefit is small, patients who do not 
respond to NAC are exposed to treatment-related toxicity5-7. On the contrary, the 25% of 
patients who do have a complete pathological response (no residual tumor) at radical 
cystectomy after NAC, have excellent outcomes (5-year survival rate of 80%)8,9. Therefore, 
an accurate marker that can predict response to POC in MIBC is clearly needed. Recently, 
genetic aberrations, such as oncogenic mutations and gene expression profiling 
have been reported to correspond with response to NAC10-13. Additionally, evidence 
is emerging on the causal relationship between inflammation and cancer. As part of 
the tumor microenvironment, neutrophils and lymphocytes both play prominent 
regulatory roles in tumor progression. The neutrophil-to-lymphocyte ratio (NLR) is a 
marker of systemic inflammatory response that reflects the balance of the inflammatory 
system and immune system. Several studies reported that the presence of neutrophils 
in tumor stroma is associated with a poor prognosis, while lymphocyte infiltration 
surrounding a tumor is associated with an improved prognosis14. Therefore, the NLR 
could be of prognostic value and an elevated NLR in the peripheral blood has proven 
to be an independent predictor of adverse outcome in several malignancies including 
colon, prostate and genito-urinary tract cancers14-17. Because of the important clinical 
need to accurately predict who will benefit from POC and who will not, the aim of this 
study was to assess the correlation between the NLR and the outcome of MIBC patients 
undergoing POC and radical cystectomy.
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MATERIALS AND METHODS
Patient selection
The medical records from patients diagnosed with histologically proven non-metastatic 
MIBC (pure or predominant urothelial carcinoma) undergoing POC and radical 
cystectomy between 1990 and 2014 were retrospectively reviewed. A total of 283 
patients was eligible for the study. Patients (n = 148) without documented neutrophil 
or leukocyte count at start of POC were excluded, as were patients who did not receive 
cisplatin- or carboplatin-based chemotherapy (n = 4), and patients who had completed 
insufficient cycles of POC (<3 cycles) (n = 8). Finally, 123 patients were eligible for 
analysis. These patients originated from three different hospitals in the Netherlands 
(Erasmus Medical Center, Antoni van Leeuwenhoek Hospital, Sint Franciscus Gasthuis).
Data collection and definitions
Clinicopathological parameters were collected retrospectively (Tables 1 and 2). The 
pathological response at cystectomy was classified as: i) complete response (CR, 
ypT0N0Mx); ii) partial response (PR, ypTa/T1/TisN0Mx); iii) non-response (NR, stage 
≥ypT2 and/or N+). In the Netherlands, white blood cell and neutrophil counts are 
routinely measured in clinical practice, but this is less frequent for the lymphocyte count. 
Therefore, instead of the NLR, the derived NLR (dNLR) was calculated. Since peripheral 
white blood cells count consists almost exclusively of neutrophils and lymphocytes, the 
dNLR can be calculated by dividing the absolute neutrophil count by the difference 
between leukocytes and neutrophil counts16. The dNLR has been demonstrated to 
provide similar prognostic value as the NLR18. Baseline hemoglobin (HB), creatinine, 
Glomerular Filtration Rate (GFR) and dNLR before start of POC treatment were collected. 
Progression-free survival (PFS) was defined as time from POC initiation to date of cancer 
progression. Overall survival (OS) was defined as time from POC initiation to death from 
any cause. Patients were examined every three months and underwent a CT-scan of the 
thorax and abdomen every six months for the first two years after radical cystectomy. 
Lymphadenopathy at diagnostic imaging was defined as a lymph node with a short axis 
diameter of >10 mm in dimension on CT scan. Patients who were alive with or without 
disease and patients who were lost to follow up at the last follow-up date were censored.
Statistical analysis
Statistical analyses were performed using SPSS version 21 for Windows (IBM Corp. 
Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp) 
and R statistical software (R Foundation for Statistical Computing, Vienna, Austria). 
Clinicopathological characteristics were compared between patients having a CR and 
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the NR group, using the Mann Whitney-U-test and the Fisher’s exact test. The dNLR 
was dichotomized by choosing a cutoff based on the optimal sensitivity-specificity 
trade-off as visualized by the receiver operating characteristic (ROC), being the point 
on the curve which is situated closest to the upper left corner. The association of the 
dNLR and other predictor variables with POC response was evaluated by univariable 
and multivariable logistic regression analysis. The multivariable models were formed 
using backward elimination at the 5% level. To determine if there was a difference 
between the pathological response outcomes at cystectomy, uni- and multivariable 
analyses were performed with CR versus NR as an endpoint and CR plus PR versus 
NR as an endpoint. Input variables were selected based on their performance in the 
univariable analysis or their potential confounding effect. The predictive accuracy of 
the model was determined by the area under the curve (AUC) and c-statistic. Internal 
validation was done using the bootstrapping method with 1000 bootstrap samples. 
Based on the multivariable models, a POC treatment decision-making model was 
formed. A cutoff was determined based on the optimal sensitivity-specificity trade off 
of whether a positive advice concerning POC treatment should be given to patients or 
a negative advice. Survival curves were estimated using the Kaplan–Meier method and 
the difference between these curves was assessed by the log-rank test. P values<0.05 
were considered statistically significant.
RESULTS
Baseline characteristics
The baseline characteristics of the individual response groups are depicted in table 1. 
The mean age of the 123 patients was 61 years of whom 91 (74%) patients were male. 
Of all patients, 87 (70.7%) had received 3 or 4 cycles of a cisplatin-based POC regimen 
(Gemcitabine/Cisplatin, Methotrexate/Vinblastine/Adriamycin/Cisplatin (MVAC), dose 
dense MVAC, Cisplatin/Methotrexate/Vinblastine (CMV) or Cisplatin/Paclitaxel), whereas 
36 (29.3%) had received a carboplatin-based POC regimen (Gemcitabine/Carboplatin). 
Median time from diagnostic TUR (dTUR) to surgery was five months and median time 
from start of POC to surgery was three months, which both did not significantly differ 
between complete or non-responders (p = 0.30 and p = 0.67), respectively (Table 1).
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Table 1. Baseline characteristics of patients originating from three different Dutch hospitals 
(Erasmus Medical Center, Antoni van Leeuwenhoek Hospital, Sint Franciscus Gasthuis) who 
underwent POC and radical cystectomy for MIBC (N = 123). Patients are categorized by response 
to POC.
Variables CR (n=35) PR (n=11) NR (n=77)
P-value 
CR vs NR
Age, years (median, range) 58 (45-77) 57 (34-75) 63 (35-76) 0.76
Gender
   Male
   Female
27 (77.1%)
8 (22.9%)
7 (63.6%)
4 (36.4%)
57 (74%)
20 (26%)
0.82
Smoking status
   Never
   Former
   Current
   Unknown
5 (14.3%)
9 (25.7%)
9 (25.7%)
12 (34.4%)
-
1 (9.1%)
3 (27.3%)
7 (63.6%)
10 (13.0%)
18 (23.4%)
12 (15.6%)
37 (48.1%)
0.74
Charlson Comorbidity Index
   3
   4
   5
   6
   7
   Unknown
1 (2.9%)
4 (11.4%)
4 (11.4%)
2 (5.7%)
-
24 (68.6%)
1 (9.1%)
2 (18.2%)
-
2 (18.2%)
-
6 (54.5%)
-
7 (9.1%)
6 (7.8%)
4 (5.2%)
2 (2.6%)
58 (75.3%)
0.72
Karnofsky Performance Score
   70
   80
   90
   100
   Unknown
-
-
8 (22.9%)
3 (8.6%)
24 (68.6%)
1 (9.1%)
-
2 (18.2%)
2 (18.2%)
6 (54.5%)
1 (1.3%)
5 (6.5%)
8 (10.4%)
5 (6.5%)
58 (75.3%)
0.20
Tumor presentation   
   Primary 
   Recurrence
   Unknown
23 (65.7%)
9 (25.7%)
3 (8.6%)
10 (90.9%)
1  (9.1%)
-
58 (75.3%)
13 (16.9%)
6  (7.8%)
0.30
Clinical tumor stage
   T1
   T2
   T3
   T4
   Unknown 
3 (8.6%)
8 (22.9%)
17 (48.6%)
7 (20%)
-
-
3 (27.3%)
6 (54.5%)
2 (18.2%)
-
1 (1.3%)
16 (20.8%)
31 (40.3%)
28 (36.4%)
1 (1.3%)
0.11
Extravesical extension at diagnostic imaging
   Positive
   Negative
   Unknown
10 (28.6%)
17 (48.6%)
8 (22.9%)
2 (18.2%)
7 (63.6%)
2 (18.2%)
33 (42.9%)
29 (37.7%)
15 (19.5%)
0.18
Lymphadenopathy at diagnostic imaging
  Positive
  Negative
  Unknown
8 (22.9%)
19 (54.3%)
8 (22.9%)
4 (36.4%)
5 (45.5%)
2 (18.2%)
40 (51.9%)
25 (32.5%)
12 (15.6%)
<0.01
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Variables CR (n=35) PR (n=11) NR (n=77)
P-value 
CR vs NR
Hydronephrosis at diagnostic imaging
   Positive
   Negative
   Unknown
9 (25.7%)
18 (51.4%)
8 (22.9%)
5 (45.5%)
4 (36.4%)
2 (18.2%)
32 (41.6%)
32 (41.6%)
12 (16.9%)
0.17
Hemoglobin level, mmol/L (median, range) 8.3 (5.5-10.3) 8.6 (7.3-9.5) 8.0 (5.5-10.0) 0.12
Creatinine level , μmol/L (median, range) 75 (56-209) 76 (65-122) 92 (46-186) 0.28
Glomerular Filtration Rate (GFR), ml/min 
(median, range)
87 (35-115) 80 (53-90) 72 (44-124) 0.56
POC regimen
   Cisplatin based
   Carboplatin based
26 (74.3%)
9 (25.7%)
10 (90.9%)
1 (9.1%)
51 (66.2%)
26 (33.8%)
0.51
Recurrence after cystectomy
   Yes
   No
7 (20%)
28 (80%)
2 (18.2%)
9 (81.8%)
48 (62.3%)
29 (37.7%)
<0.01
Last follow up status
   Alive, no evidence of disease
   Alive, with recurrent disease
   Dead of non-disease
   Dead of disease
   Lost to follow up
25 (71.4%)
3 (8.6%)
3 (8.6%)
3 (8.6%)
1 (2.9%)
8 (72.7%)
-
1 (9.1%)
2 (18.2%)
-
22 (28.6%)
6 (7.8%)
5 (6.5%)
39 (50.6%)
5 (6.5%)
<0.01
Time from dTUR to surgery, months (median, 
range)
5.0 (3-8) 5.0 (4-6) 5.0 (2-19) 0.30
Time from POC to surgery, months (median, 
range)
3.0 (2-4) 3.0 (2-5) 3.0 (1-9) 0.67
CR, complete response; NR, non-response; PR, partial response; POC, pre-operative chemotherapy 
Complete pathological response was seen in 35 (28.5%) patients, 11 (8.9%) showed a 
partial response and 77 (62.6%) were classified as non-responders. In the NR group, 
positive lymphadenopathy prior to cystectomy was more frequent (p = 0.01), recurrence 
after cystectomy occurred more frequently (p < 0.01) and the median PFS and the OS 
were significantly shorter than in the CR group (33 vs 12 months, p < 0.01 and 33 vs 17 
months, p < 0.01). The other clinicopathological parameters did not significantly differ 
between the two groups.
The median dNLR of all patients was 2.10 at baseline. Based on the ROC curve, the 
optimal cutoff value for the dNLR was determined at 2.21 (51.1% sensitivity and 71.4% 
specificity for predicting NR).
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Pre-operative chemotherapeutic response at cystectomy
In the univariable analysis, an elevated dNLR corresponded with NR to POC in the CR vs 
NR analysis (OR 2.70, 95%-CI: 1.15–6.38, p = 0.02), but not in the CR+PR vs NR analysis (OR 
1.98, 95%-CI: 0.92–4.26, p = 0.08) (Table 2). Extravesical extension and lymphadenopathy 
on diagnostic imaging before cystectomy significantly correlated with a higher non-
response rate to POC in CR+PR vs NR analysis (OR 2.37, 95%-CI: 0.99–5.66, p = 0.05 and 
OR 3.30, 95%-CI: 1.38–7.87, p = 0.01, respectively) (table 2). To analyze the correlation 
between the dNLR and response to NAC and not POC, clinically node-positive patients 
were excluded from the analysis. In this NAC-only cohort (n = 49), none of the proposed 
predictor variables significantly correlated with NR. Also, the correspondence between 
dNLR and non-response was no longer statistically significant (OR 1.70 p = 0.31 in CR vs 
NR and OR 1.62 p = 0.33 in CR+PR vs NR).
In the multivariable analysis for both CR vs NR as for CR+PR vs NR, dNLR was removed 
from the model by backward elimination (table 3). The optimal multivariable model A 
for CR vs NR included lymphadenopathy and clinical T stage. The optimal multivariable 
model B for CR+PR vs NR included lymphadenopathy and extravesical extension at 
diagnostic imaging (table 3). The predictive capacity, represented by the AUC of the 
optimal model A for CR vs NR was 0.75 (96% CI 0.64–0.86, c-statistic 0.75) with an 
optimism-corrected AUC of 0.72 and 0.71 (95% CI 0.60–0.82, c-statistic 0.70) with an 
optimism-corrected AUC of 0.68 for CR+PR vs NR; model B. The type of POC was also 
removed by back-ward selection. However, because carboplatin-based POC is not 
the regimen of choice in MIBC the analyses were repeated excluding all patients who 
received carboplatin-based chemotherapy, leading to similar results (AUC model A: 0.79 
(95% CI 0.67–0.90) and AUC model B: 0.73 (95% CI 0.60–0.86)).
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Table 3. Multivariable logistic regression analyses assessing the association between predictive 
variables and the response to POC at cystectomy.
Multivariable model A
CR (n= 35) vs. NR (n=77) OR (95% CI) P-value AUC (95% CI)
Optimism-
corrected AUC
Step 1
dNLR, dichotomized 2.08 (0.69-6.33) 0.20 0.78 (0.68-0.88)
Hemoglobin at baseline 0.91 (0.54-1.56) 0.74
Lymphadenopathy 5.21 (1.69-16.11) <0.01
Hydronephrosis 0.97 (0.29-3.24) 0.96
Clinical T stage (T1 reference)
T2
T3
T4
-
7.17 (0.47-109.83)
9.39 (0.63-139.95)
23.24 (1.34-404.12)
-
0.16
0.10
0.03
POC regimen 0.75 (0.23-2.40) 0.63
Final step 
Lymphadenopathy 5.49 (1.85-16.33) <0.01 0.75 (0.64-0.86) 0.72
Clinical T stage (T1 reference)
T2
T3
T4
-
7.97 (0.56-114.00)
11.11 (0.82-150.25)
30.30 (1.94-473.87)
-
0.13
0.07
0.02
Multivariable model B
CR (n=35) + PR (n=11) vs. NR (n=77) OR (95% CI) P-value AUC (95% CI)
Optimism-
corrected AUC
Step 1
dNLR, dichotomized 1.17 (0.43-3.17) 0.76 0.75 (0.65-0.85)
Hemoglobin at baseline 0.81 (0.49-1.34) 0.41
Lymphadenopathy 4.09 (1.53-10.93) <0.01
Extravesical extension 2.21 (0.71-6.87) 0.17
Clinical T stage (T1 reference)
T2
T3
T4
-
5.93 (0.41-86.07)
4.12 (0.30-56.27)
6.08 (0.39-95.83)
-
0.19
0.29
0.20
POC regimen 0.65 (0.23-1.88) 0.43
Final step
Lymphadenopathy 3.81 (1.52-9.57) <0.01 0.71 (0.60-0.82) 0.68
Extravesical extension 2.89 (1.14-7.31) 0.03
CR, complete response; NR, non-response;  OR, odds ratio; AUC, area under the Receiver Operating Characteristic curve; 
dNLR, derived neutrophil-to-lymphocyte ratio
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Progression-free and overall survival
An elevated dNLR (>2.21) corresponded with an absolute shorter PFS and OS, although 
not significantly (median 15 vs 21 months, p = 0.42 and median 21 vs 24 months, p = 
0.45, respectively) (fig. 1a and 1b). In the NAC-only cohort, the same trend was observed 
(median 26 vs 35 months, p = 0.28 and median 29 vs 35 months, p = 0.29, respectively) 
(fig. 2a and 2b). The corresponding Kaplan-Meier curves indicated that in the first 12 
months after start of POC, both the PFS and OS rates of patients with low dNLR and 
high dNLR barely differed. However, after 12 months the survival rate lines diverged. 
To investigate if there were any significant differences, we compared all patients with 
a PFS and OS shorter than 12 months with patients with a PFS and OS of 12 months 
and longer. The group with a PFS <12 months had significantly higher clinical T stage, 
more frequent extravesical extension and lymphadenopathy on diagnostic imaging 
before cystectomy, less frequent cisplatin-based POC, and more often recurrence after 
cystectomy. There were also significantly more non-responders in both the shorter PFS 
and OS group (supplementary table 1 and 2). In the group with OS <12 months there 
was, besides more non-responders, also significantly more frequent lymphadenopathy 
at diagnostic imaging before cystectomy and a lower baseline hemoglobin count. 
The distribution of the type of POC regimen and clinical T stage was not significantly 
different between OS groups (supplementary table 2).
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Figure 1. The progression-free survival (a) and overall survival (b) according to the dNLR. An 
elevated dNLR corresponded with an absolute shorter PFS (median 21 versus 15 months, 
p=0.42) or OS (median 24 versus 21 months, p=0.45), albeit not significantly.
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Figure 2. The progression-free survival (a) and overall survival (b) according to the dNLR , 
excluding node-positive patients. An elevated dNLR corresponded with an absolute shorter 
PFS (median 35 versus 26 months, p=0.28) or OS (median 35 versus 29 months, p=0.29), albeit 
not significantly.
141
dNLR and outcome in MIBC patients treated by chemotherapy and radical surgery
6
DISCUSSION
There is an important clinical need for a marker that correlates with the response and 
eventual benefit by to the use of POC in patients with MIBC. Here, we show that an 
elevated NLR corresponded with non-response to POC at radical cystectomy. However, 
this correlation was nullified when corrected for positive lymph node status at diagnostic 
imaging and clinical T stage. Further, patients who had an elevated dNLR had a trend 
towards a shorter PFS and OS. This did not reach statistical significance, possibly due 
to the limited sample size. An elevated dNLR, did not show a statistically significant 
association with non-response, nor with prognosis, in a NAC-only cohort, possibly due 
to the limited sample size of this subgroup analysis. Our findings suggest that pre-
chemotherapy dNLR, which is an easily available clinical marker, is insufficient to guide 
treatment decisions on POC in MIBC. 
Although several studies have shown a relationship between NLR and adverse outcome 
in solid malignancies including MIBC15-17, the literature on the association with response 
to NAC is scarce. Seah et al. could not find an association between pre-treatment NLR 
and the pathological response to NAC in MIBC patients (OR = 0.69, 95%-CI: 0.36–1.32, 
p = 0.26)7. Their definition of pathological response to NAC, however, differed from the 
definition we used; these authors defined a pathological response as T0/Tis, N0 disease 
together with down staging from T2/T4 to T1 and in N status (from N-positive to N0), 
whereas in our study a complete response to POC was defined as ypT0N0M0. More 
importantly, the sample size (26 patients) in the study by Seah et al. was too small to 
allow meaningful conclusions.
In esophageal cancer, the pre-treatment NLR was previously reported to be a significant 
predictive marker of pathologic response to NAC (p < 0.01)19. In metastatic advanced 
gastric cancer, as well, a low pre-treatment NLR was associated with a significantly 
higher chemotherapeutic disease control rate (90.0% vs. 80.4%; p = 0.03) and longer 
PFS and OS (186 vs. 146 days, p < 0.01 and 414 vs. 280 days, p < 0.01) 20. 
Research of the tumor microenvironment has been intensive in recent years. The 
inflammatory microenvironment has been found to be an essential component of 
tumors21. The NLR is a marker of systemic inflammatory response that indicates the 
balance of the inflammatory system and immune system respectively14. The exact 
mechanisms underlying the prognostic implications of the NLR are unknown. However, 
it is known that cancer cells can induce neutrophils to form a microenvironment that 
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is beneficial to the malignant cells22. An elevated NLR is usually caused by neutrophilia 
together with lymphopenia and indicates a tumor-promoting environment15. This could 
explain why an elevated NLR is associated with an unfavorable outcome.
Our study has some limitations. First, this study has a retrospective design and a relatively 
small sample size. Data about factors that could influence the neutrophil and lymphocyte 
blood counts (e.g. medication) was not available for the majority of patients. Further, 
our cohort is a mixture of patients receiving neoadjuvant chemotherapy and induction 
chemotherapy. The presence of positive lymph nodes at time of start of chemotherapy 
and the clinical T stage had a major influence on non-response prediction. Our NAC-only 
cohort was probably too small to draw any significant conclusions on the predictive 
capability of the dNLR on therapy response. We believe this study again proves the 
difficulty of doing retrospective studies in such heterogeneous patient cohorts. Lastly, 
although the NLR might have potential as a prognostic biomarker, the use of the NLR as 
such a biomarker may be difficult to examine. Patients with a higher NLR had a worse 
outcome after cystectomy, but would perhaps have done even worse without POC. The 
results of this study should be re-examined in a large prospective cohort of patients with 
MIBC receiving POC before radical cystectomy. In addition, other molecular predictive 
markers like ERBB2 and ERCC2 mutation status may be combined with the dNLR and 
could potentially enhance the overall predictive capacity10,11.
POC bears substantial short- and long-term toxicity, and hospital admission is necessary 
to administer cisplatin, making it a costly treatment as well. Therefore, an accurate 
prediction of the response to POC may improve patient selection and thus reduce 
patient burden by avoiding unnecessary treatment and reducing costs. The dNLR is an 
easily available biomarker at virtually no extra expense. However, the predictive and 
prognostic value of the dNLR seem insufficient in MIBC patients undergoing POC and 
radical cystectomy and should therefore not be used to guide treatment decisions.
CONCLUSIONS
Accurate prediction of the response to POC in MIBC may improve patient selection and 
thus reduce patient burden by avoiding unnecessary treatment and reduce cost. In the 
present study, we found that an elevated dNLR (>2.21) corresponded with poor outcome 
in terms of non-response to POC and shorter PFS and OS. However, this correlation was 
nullified when corrected for positive lymph node status and clinical T stage. Therefore, 
we conclude that the dNLR is insufficient to predict the response to POC in patients with 
MIBC undergoing radical cystectomy.
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Supplementary table 1. Univariable analysis of different potential predictor variables for 
patients with progression-free survival (PFS) of < 12 months or> 12 months. 
Variables PFS <12 (n=45) PFS >12 (n=69) P-value 
Age, years (median, range) 64 (41-76) 58 (34-77) 0.04
Gender
   Male
   Female
34 (70.8%)
14 (29.2%)
55 (75.3%)
18 (24.7%)
0.67
Non-Responder
   Yes  
   No
40 (83.3%)
8 (16.7%)
35 (47.9%)
38 (52.1%)
<0.01
Smoking status
   Never
   Former
   Current
   Unknown
4 (8.3%)
10 (20.8%)
7 (14.6%)
27 (56.3%)
11 (15.1%)
16 (21.9%)
17 (23.3%)
29 (39.7%)
0.87
Charlson Comorbidity Index
   3
   4
   5
   6
   7
   Unknown
-
2 (4.2%)
4 (8.3%)
4 (8.3%)
2 (4.2%)
36 (75.0%)
2 (2.7%)
10 (13.7%)
6 (8.2%)
3 (4.1%)
-
52 (71.2%)
0.10
Karnofsky Performance Score
   70
   80
   90
   100
   Unknown
1 (2.1%)
3 (6.3%)
7 (14.6%)
1 (2.1%)
36 (75.0%)
1 (1.4%)
2 (2.7%)
11 (15.1%)
7 (9.6%)
52 (71.2%)
0.34
Tumor presentation   
   Primary 
   Recurrence
   Unknown
33 (68.8%)
9 (18.8%)
6(12.5%)
57 (78.1%)
13 (17.8%)
3 (4.1%)
0.81
Clinical tumor stage
   T1
   T2
   T3
   T4
   Unknown 
-
12 (25.0%)
14 (29.2%)
21 (43.8%)
1 (2.1%)
4 (5.5%)
14 (19.2%)
40 (54.8%)
15 (20.5%)
-
<0.01
Extravesical extension at diagnostic imaging
   Positive
   Negative
   Unknown
23 (47.9%)
14 (29.2%)
11 (22.9%)
21 (28.8%)
38 (52.1%)
14 (19.2%)
0.01
Lymphadenopathy at diagnostic imaging
  Positive
  Negative
  Unknown
26 (54.2%)
12 (25.0%)
10 (20.8%)
26 (35.6%)
35 (47.9%)
12 (16.4%)
0.01
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Variables PFS <12 (n=45) PFS >12 (n=69) P-value 
Hydronephrosis at diagnostic imaging
   Positive
   Negative
   Unknown
20 (41.7%)
19 (39.6%)
9 (18.8%)
26 (35.6%)
33 (45.2%)
14 (19.2%)
0.54
Hemoglobin level, mmol/L (median, range) 8.0 (5.5-9.5) 8.3 (5.5-10.3) 0.15
Creatinine level , μmol/L (median, range) 86 (53-209) 80 (46-202) 0.30
Glomerular Filtration Rate (GFR), ml/min (median, range) 74.5 (48-109) 76.5 (35-124) 0.65
POC regimen
   Cisplatin based
   Carboplatin based
28 (58.3%)
20 (41.7%)
57 (78.1%)
16 (21.9%)
0.03
Recurrence after cystectomy
   Yes
   No   
37 (77.1%)
11 (22.9%)
20 (27.4%)
53 (72.6%)
<0.01
Last follow up status
   Alive, no evidence of disease
   Alive, with recurrent disease
   Dead of non-disease
   Dead of disease
   Lost to follow up
3 (6.3%)
5 (10.4%)
6 (12.5%)
30 (62.5%)
4 (8.3%)
50 (68.5%)
4 (5.5%)
3 (4.1%)
14 (19.2%)
2 (2.7%)
<0.01
Time to surgery, months (median, range) 5 (3-10) 5 (2-19) 0.75
Time from POC to surgery, months (median, range) 3 (1-6) 3 (2-9) 0.28
CR, complete response; NR, non-response; PR, partial response; POC, pre-operative chemotherapy 
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Supplementary table 2. Univariable analysis of different potential predictor variables for 
patients with an overall survival (OS) of < 12 months vs > 12 months. 
Variables OS <12 (n=29) OS >12 (n=94) P-value 
Age, years (median, range) 63 (41-73) 60 (34-77) 0.44
Gender
   Male
   Female
20 (69.0%)
9 (31.0%)
71 (75.5%)
23 (24.5%)
0.48
Non-Responder
   Yes 
   No
25 (86.2%)
4 (13.8%)
52 (55.3%)
42 (44.7%)
<0.01
Smoking status
   Never
   Former
   Current
   Unknown
3 (10.3%)
7 (24.1%)
4 (13.8%)
15 (51.7%)
12 (12.8%)
21 (22.3%)
20 (21.3%)
41 (43.6%)
0.93
Charlson Comorbidity Index
   3
   4
   5
   6
   7
   Unknown
-
1 (3.4%)
2 (6.9%)
3 (10.3%)
1 (3.4%)
22 (75.9)
2 (2.1%)
12 (12.8%)
8 (8.5%)
5 (5.3%)
1 (1.1%)
66 (70.2%)
0.31
Karnofsky Performance Score
   70
   80
   90
   100
   Unknown
-
2 (6.9%)
4 (13.8%)
1 (3.4%)
22 (75.9%)
2 (2.1%)
3 (3.2%)
14 (14.9%)
9 (9.6%)
66 (70.2%)
0.54
Tumor presentation   
   Primary 
   Recurrence
   Unknown
21 (72.4%)
5 (17.2%)
3 (10.3%)
70 (74.5%)
18 (19.1%)
6 (6.4%)
1.00
Clinical tumor stage
   T1
   T2
   T3
   T4
   Unknown 
-
9 (31.0%)
8 (27.6%)
12 (41.4%
-
4 (4.3%)
18 (19.1%)
46 48.9%)
25 (26.6%)
1 (1.1%)
0.09
Extravesical extension at diagnostic imaging
   Positive
   Negative
   Unknown
11 (37.9%)
11 (37.9%)
7 (24.1%)
34 (36.2)
42 (44.7%)
18 (19.1%)
0.81
Lymphadenopathy at diagnostic imaging
  Positive
  Negative
  Unknown
20 (69.0%)
3 (10.3%)
6 (20.7%)
32 (34.0%)
46 (48.9%)
16 (17.0%)
<0.01
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Variables OS <12 (n=29) OS >12 (n=94) P-value 
Hydronephrosis at diagnostic imaging
   Positive
   Negative
   Unknown
11 (37.9%)
13 (44.8%)
5 (17.2%)
35 (37.2%)
41 (43.6%)
18 (19.1%)
1.00
Hemoglobin level, mmol/L (median, range) 7.7 (5.5-9.5) 8.3 (5.5-10.3) 0.03
Creatinine level , μmol/L (median, range) 79 (53-138) 82 (46-209) 0.78
Glomerular Filtration Rate (GFR), ml/min (median, range) 74.5 (48-109) 78 (35-124) 0.68
POC regimen
   Cisplatin based
   Carboplatin based
19 (65.5%)
10 (34.5%
68 (72.3%)
26 (27.7%)
0.49
Recurrence after cystectomy
   Yes
   No
11 (37.9%)
18 (62.1%)
39 (41.5%)
55 (58.5%)
0.06
Last follow up status
   Alive, no evidence of disease
   Alive, with recurrent disease
   Dead of non-disease
   Dead of disease
   Lost to follow up
2 (6.9%)
-
6 (20.7%)
18 (62.1%)
3 (10.3%)
53 (56.4%)
9 (9.6%)
3 (3.2%)
26 (27.7%)
3 (3.2%)
<0.01
Time to surgery, months (median, range) 5 (3-7) 5 (2-19) 0.40
Time from POC to surgery, months (median, range) 3 (1-5) 3 (2-9) 0.68
CR, complete response; NR, non-response; PR, partial response; POC, pre-operative chemotherapy 
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ABSTRACT
Background: Neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer 
(MIBC) provides a small but significant survival benefit. Nevertheless, controversies on 
applying NAC remain because the limited benefit must be weight against chemotherapy-
related toxicity and the delay of definitive local treatment. Therefore, there is a clear 
clinical need for tools to guide treatment decisions on NAC in MIBC. Here, we aimed 
to validate a previously reported 20-gene expression signature that predicted lymph 
node-positive disease at radical cystectomy in clinically node-negative MIBC patients, 
which would be a justification for upfront chemotherapy.
Methods: We studied diagnostic transurethral resection of bladder tumors (dTURBT) 
of 150 MIBC patients (urothelial carcinoma) who were subsequently treated by radical 
cystectomy and pelvic lymph node dissection. RNA was isolated and the expression 
level of the 20 genes was determined on a qRT-PCR platform. Normalized Ct values 
were used to calculate a risk score to predict the presence of node-positive disease. 
The Cancer Genome Atlas (TCGA) RNA expression data was analyzed to subsequently 
validate the results.
Results: In a univariate regression analysis, none of the 20 genes significantly correlated 
with node-positive disease. The area under the curve of the risk score calculated by the 
20-gene expression signature was 0.54 (95% Confidence Interval: 0.44-0.65) versus 
0.67 for the model published by Smith et al. Node-negative patients had a significantly 
lower tumor grade at TURBT (p = 0.03), a lower pT stage (p<0.01) and less frequent 
lymphovascular invasion (13% versus 38%, p<0.01) at radical cystectomy than node-
positive patients. In addition, in the TCGA data, none of the 20 genes was differentially 
expressed in node-negative versus node-positive patients.
Conclusions: We conclude that a 20-gene expression signature developed for nodal 
staging of MIBC at radical cystectomy could not be validated on a qRT-PCR platform in a 
large cohort of dTURBT specimens.
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INTRODUCTION
Muscle-invasive bladder cancer (MIBC) comprises 20-25% of all newly diagnosed 
bladder cancers (urothelial carcinoma). Curative treatment options are few and survival 
is highly dependent on radical surgery and accompanying lymph node status. Patients 
having node-positive disease at radical cystectomy have a poor outcome. A large study 
on recurrence after cystectomy showed that around 80% of the cases with pathological 
node-positive disease (pN1-3) recurred versus only 20% of pathological node-negative 
organ-confined disease1. To eradicate micro metastases and thereby reducing the risk 
of node-positive disease at radical cystectomy, radical surgery can be preceded by 
cisplatin-based neoadjuvant chemotherapy (NAC). A clinical trial meta-analysis showed 
that about eight out of 100 patients with node-positive disease could benefit from 
upfront chemotherapy2. However, controversies on the use of NAC in MIBC remain 
because the survival benefit is small. A neoadjuvant regimen of cisplatin, methotrexate 
and vinblastine was shown to give a reduction in the risk of death (HR: 0.84) and an 
absolute increase in 10-year overall survival from 30% to 36% in a large multicenter 
randomized trial3. On the contrary, patients who do not respond to NAC experience 
a delay in time to curative surgery while being exposed to treatment-related toxicity. 
The limited survival benefit and the accompanying toxicities render many physicians 
reluctant to apply NAC for non-metastatic MIBC. As a result, the use of NAC in MIBC 
greatly varies across centers. Therefore, there is a clear clinical need for tools to guide 
treatment decisions on NAC in MIBC.
In other tumor types, several commercially available gene expression assays are used in 
clinical practice. In prostate cancer, Prolaris® and OncotypeDx Prostate® can be used for 
clinical decision making on surveillance of primary prostate cancer and Decipher® for 
clinical decisions on adjuvant therapy in surgically treated patients4-6. In breast cancer, 
assays such as OncotypeDx® and MammaPrint® have been clinically implemented7. In 
bladder cancer, a 12-gene expression signature to predict the outcome in non-muscle 
invasive bladder cancer was developed on a microarray platform and transferred to a 
qRT-PCR assay8. Although this 12-gene signature is still in need of further validation, 
it does suggest a potential role for gene expression assays in bladder cancer. Further, 
a 20-gene expression signature was developed to predict the presence of lymph 
node metastases at radical cystectomy in clinically node-negative MIBC patients. This 
signature might have the potential to be used to select patients for NAC9. Smith et 
al identified differentially expressed genes by microarray on 32 pairs of fresh frozen 
(FF) and formalin-fixed paraffin embedded (FFPE) tissues from three different cohorts 
of cystectomy specimens. Since NAC is administered before radical cystectomy, the 
selection for NAC would have to take place before cystectomy, i.e. after diagnostic 
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trans-urethral resection of the primary bladder tumor (dTURBT). Further, to clinically 
implement such a signature a less complex laboratory assay on paraffin-embedded 
tissue samples is mandatory. Therefore, we aimed to validate this 20-gene expression 
signature on a qRT-PCR platform in a large cohort of 150 FFPE dTURBT specimens of 
MIBC patients who subsequently underwent radical cystectomy and pelvic lymph node 
dissection.
MATERIALS AND METHODS
Patient selection and data collection
This study was approved by the Erasmus MC institutional review board (MEC-2014-641), 
samples were collected and analyzed according to the code of conduct for responsible 
use of left over materials10. As part of standard procedure, all patients were informed and 
offered an option to opt out. Patients that opted out, by written or verbal notification, 
were excluded from the study. In total, 201 patients who were diagnosed with MIBC 
(urothelial carcinoma) and who were treated by radical cystectomy and pelvic lymph 
node dissection were retrospectively collected for the present study. None of the 
patients had received NAC. In seven patients, the FFPE blocks of the dTURBT could 
not be retrieved. Of the remaining 194 patients, 30 patients were excluded because 
the tumor area did not fulfill the minimum demand of at least 70% tumor cells or the 
RNA quality was insufficient to complete the analyses. Another 14 patients had to be 
excluded because the lymph node status at time of cystectomy could not be retrieved 
from the pathology reports. Therefore, 150 patients were included in the qRT-PCR 
analyses. Based on reliability criteria (see RNA expression data analysis) another 11 
patients were excluded from the statistical analysis leaving 139 patients for the final 
analyses (fig 1).
RNA expression data
The 20 genes included in the assay were: TOX3, SLC11A2, FAM36A/COX20, LIMCH1, 
RAB15, AVL9, PCMTD2, PTHLH, DPP4, PCDHGA10, MT1E, MAP4K4, SLC16A1, BST2, MMP14, 
IFI27, NCLN, HLA G, RRBP1 and ICAM1. The Taqman assays were chosen based on the 
Affimetrix probes used by Smith et al9 and were selected by best coverage and exon 
spanning. First, the qRT-PCR of the 20 genes was optimized using cell line RNA (TCCSUP) 
and pooled FFPE derived tumor RNA by dilution series and calibration lines per gene. 
Then, all FFPE tumor samples (H&E slides) were centrally reviewed to select areas that 
contained at least 70% tumor cells. Of these tumor cell areas, a 2.2-mm core biopsy 
was taken (Beecher Instruments®, Silver Spring, MD, USA). The core was deparaffinized 
155
Gene expression to predict nodal disease in bladder cancer is clinically not applicable
7
and RNA was isolated by High Pure FFPE RNA Micro Kit (Roche Applied Science®, 
Mannheim, Germany) according to the manufacturer's protocol. The RNA concentration 
was measured using the Qubit RNA Assay (Invitrogen, Ltd, Paisley UK). Next, total RNA 
was reverse transcribed and cDNA was synthesized using a pool of 22 Gene Expression 
Taqman assays (20 genes + 2 housekeeping genes). The assay was done in two 
replicates for all samples. Then, 2 μl of the cDNA was pre-amplified using Pooled Gene 
Expression TaqMan assays and TaqMan PreAmp Master Mix (Applied Biosystems, Foster 
City, USA). Amplification was done in 15 cycles of 15 seconds at 95°C and 4 minutes at 
60°C each. Pre-amplification was then followed by denaturation of 10 minutes at 99.9°C. 
Quantitative qRT-PCR was done in duplicate using the 7500 FAST Real Time PCR System 
(Applied Biosystems, Foster City, USA) including the preAmp cDNA, TaqMan Universal 
Master MIX II and single Gene Expression TaqMan assays (both Applied Bio-systems, 
Foster City, USA). For normalization purposes, the housekeeping genes HPRT, ACTB and 
a plate control (T24 bladder cancer cell line RNA) was also included in the assay11. Two 
patient samples were run per plate, see for the plate design supplementary fig. 1. The 
qRT-PCR was done under the following conditions: 10 minutes at 95°C, 40 cycles of 
15 seconds at 95°C and 1 minute at 60°C. The threshold for determining the Ct value 
was set at 0.05. Since the amplification efficiency of the different assays was good, the 
comparative delta Ct method was used to quantify the gene expression levels.
ϮϬϭƉĂƚŝĞŶƚƐŚĂǀŝŶŐĐdϮͲdϰĂEϬDϬŵƵƐĐůĞͲŝŶǀĂƐŝǀĞhŽĨƚŚĞ
ďůĂĚĚĞƌŝĚĞŶƚŝĨŝĞĚ
ϭϭƐĂŵƉůĞƐŵĂƌŬĞĚƵŶƌĞůŝĂďůĞďĂƐĞĚŽŶƋZdͲWZƌĞƐƵůƚƐ
ϳĚdhZdƐĂŵƉůĞƐŶŽƚƌĞƚƌŝĞǀĂďůĞĨƌŽŵĂƌĐŚŝǀĞƐ
ϯϬ>ĞƐƐƚŚĂŶϳϬйƚƵŵŽƌĐĞůůƐŝŶƚŚĞĚdhZdƐƉĞĐŝŵĞŶ
ϭϰ>EƐƚĂƚƵƐƵŶŬŶŽǁŶ
ϭϱϬƉĂƚŝĞŶƚƐĞůŝŐŝďůĞĨŽƌŝŶĐůƵƐŝŽŶ
ϭϯϵƉĂƚŝĞŶƚƐŝŶĐůƵĚĞĚŝŶĨŝŶĂůĂŶĂůǇƐŝƐ
Figure 1. Flowchart of the selection of patients for the present study. UC: Urothelial Carcinoma, 
dTURBT: diagnostic transurethral resection of a bladder tumor, LN: lymph node. 
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RNA expression data analysis
The qPCR data were analyzed and visualized using the R/Bioconductor package HtqPCR 
version 1.26.012. Sample data were split according to the qPCR plate design. A qPCR 
value was set to its replicated Ct value if the qPCR result was undetermined. However, 
if both replicated Ct values were undetermined both Ct values were set to 35 and were 
marked as undetermined. The qPCR data were set as unreliable if the Ct value was 
outside a confidence interval of 95% within each transcript. Samples were discarded 
if the housekeeping genes ACTB and HPRT had two or more data points that were 
undetermined or unreliable.
Correlation plots were generated using the Pearson's product-moment correlation 
coefficient values (r) and the subsequent hierarchical clustering was employed through 
complete linkage using the 1-r distances. Since ACTB expression analysis was the highest 
expressed gene and had the least missing values, all assays were normalized over the 
average ACTB Ct value resulting in a ΔCt value. Overall, the gene expression analysis was 
robust within each patient as depicted by the plots of the duplicate samples per patient 
(Supplementary fig. 2).
For each patient a risk score was calculated using the normalized Ct values based 
on the formula: the average ΔCt value of the genes downregulated in lymph node-
positive (LN+) tumors minus the average ΔCt value of the genes upregulated in LN+ 
tumors according to Smith et al9. This formula was previously performed for validating 
microarray data using qPCR data8. Subsequently, using the risk score a logistic regression 
analysis was performed to predict the LN status. The area under the Receiver Operating 
Characteristic (ROC) curve was calculated and compared to the Area Under the Curve 
(AUC) reported by Smith et al9.
The Cancer Genome Atlas (TCGA) clinical data and mRNA expression data was 
downloaded with CGDSR R package version 1.2.5 (https://github.com/cBioPortal/
cgdsr)13. The lymph node-positive group was indicated by N1-3 and the lymph node-
negative group by N0. The beeswarms were plotted with the R package beeswarm 
version 0.2.3 (https://github.com/aroneklund/beeswarm) and the Mann Whitney-U-
test was applied to compare lymph node-positive with lymph node-negative patients. 
Statistical analyses were performed using SPSS for Windows (IBM Corp. Released 2012. 
IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp) and R statistical 
software version 3.3.1 (R Core Team, 2016), which was also used for plotting the data.
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RESULTS
Patient and tumor characteristics
The clinical and histopathological characteristics of the 139 included patients are 
described in table 1. The mean age was 64 years and 111 (80%) patients were male. 
None of the patient characteristics significantly differed between node-positive and 
node-negative patients. Node-negative patients had a significantly lower tumor grade 
at TURBT (p = 0.03), a significantly lower pT stage disease at radical cystectomy (p<0.01) 
and less frequent lymphovascular invasion at radical cystectomy than node-positive 
patients (13% versus 38%, p<0.01).
The median RNA yield was similar for both node-negative and node-positive patients: 
606 ng/μL (range 32-5360) versus 428 ng/μL (range 44-3000), p = 0.81.
20-gene expression signature validation
After normalization, the mean expression level differences per gene for node-positive 
versus node-negative patients were plotted in a bar plot (fig 2). The overall risk score per 
patient was calculated and a ROC curve was used to visualize the discriminatory value 
of the overall risk score. The predictive capacity of this risk score was minimal with an 
AUC of 0.54 (95% Confidence Interval (CI): 0.44-0.65, fig 3). Of the 20 genes included in 
the model, normalized BST2 and IF127 ΔCt values were the best performing individual 
predictors resulting in an odds ratio of 1.10 (95% CI: 0.96-1.25) and 1.11 (95% CI: 0.95-
1.30) respectively (table 2). Multivariate analysis of the ΔCt values of these two genes 
combined resulted in an AUC of 0.59 (95% CI: 0.49-0.69).
Beeswarm plots of the different genes showed the distribution of ΔCt values for node-
positive and node-negative samples per gene (BST2 and IF127 are shown in fig 4, 
whereas all genes are shown in supplementary fig. 3). Distribution of the ΔCt values in 
these plots showed major overlap in all genes with some outliers. Mean and median 
results of the ΔCt values showed similar trends in most genes (node-positive versus 
node-negative) with some exceptions (e.g. TOX3, median expression level higher in 
node-positive versus node-negative, mean expression level lower in node-positive 
versus node-negative).
158
Part II: Prognosis
Table 1. Patient and tumor characteristics of all included patients with lymph node-negative 
or lymph node-positive disease (n=139). The P-value indicates the (non)significant differences 
between both groups.
LN negative (n=91) LN positive (n=48) P-value
Patient characteristics
Age Mean (range) 65 (32-83) 63 (37-81) 0.12
N (%) N (%)
Gender Male 74 (81) 37 (77) 0.35
Female 17 (19) 11 (23)
Smoking Current 40 (44) 12 (25) 0.15
Former 13 (14) 11 (23)
Never 12 (13) 7 (15)
Unknown 26 (29) 18 (38)
dTURBT  characteristics
Clinical Stage T2 91 (100) 47 (98) 0.35
T3 - 1 (2)
Grade (WHO 1973) G2 8 (9) 2 (4) 0.03
G3 74 (81) 46 (96)
Gx† 9 (10) -
Concomitant CIS Yes 16 (18) 14 (29) 0.49
No 63 (70) 33 (69)
Unknown 3 (3) 1 (2)
Cystectomy characteristics
Pathological Stage T0 11 (12) 1 (2) <0.01
Tis 2 (2) -
T1 4 (4) -
T2 20 (22) 7 (15)
T3 21 (23) 17 (35)
T4 8 (9) 6 (13)
Tx† 25 (28) 17 (35)
Grade (WHO 1973) G2 6 (7) 1 (2) 0.70
G3 47 (52) 29 (60)
Gx† 38 (42) 18 (38)
Concomitant CIS Yes 22 (24) 11 (23) 1.00
No 11 (12) 5 (10)
Unknown 58 (64) 32 (67)
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LN negative (n=91) LN positive (n=48) P-value
LVI Yes 12 (13) 18 (38) <0.01
No 14 (15) 2 (4)
Unknown 65 (72) 28 (58)
Total LN dissected Mean (range) 16 (2-40) 15 (2-33) 0.94
Total LN positive Mean (range) - 2 (1-14) <0.01
Sample characteristics
RNA yield (ng/μl) Median (range) 606 (32-5360) 428 (44-3000) 0.81
LN: lymph nodes, CIS: carcinoma-in-situ, LVI: lymphovascular invasion, †: stage and/or grade not specified
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Figure 2. Risk score calculation, a barplot showing the mean ΔCt values per gene in node-
negative versus node-positive patients. Gene names colored red indicate higher expression in 
node-positive patients and gene names colored green indicate lower gene expression in node-
positive patients according to Smith et al9.
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ROC AUC 0.54
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Figure 3. Model performance represented by the ROC curve. The predictive capacity of the 
20-gene expression signature is represented by a ROC curve with an AUC of 0.54 (95% CI: 0.44-
0.65).
161
Gene expression to predict nodal disease in bladder cancer is clinically not applicable
7
Fi
gu
re
 4
. B
ee
sw
ar
m
 p
lo
ts
 fo
r B
ST
2 
an
d 
IF
27
 sh
ow
in
g 
th
e 
di
st
rib
ut
io
n 
of
 Δ
Ct
 v
al
ue
s f
or
 n
od
e-
ne
ga
tiv
e 
ve
rs
us
 n
od
e-
po
si
tiv
e 
pa
tie
nt
 sa
m
pl
es
. T
he
 
bo
x 
in
di
ca
te
s t
he
 u
pp
er
 a
nd
 lo
w
er
 q
ua
rt
ile
s o
f d
is
tr
ib
ut
io
n.
 T
he
 so
lid
 li
ne
 in
di
ca
te
s t
he
 m
ed
ia
n 
an
d 
th
e 
do
tt
ed
 li
ne
 in
di
ca
te
s t
he
 m
ea
n 
Δ
Ct
 v
al
ue
162
Part II: Prognosis
Table 2. Univariate regression analysis of the Ct values of the 20 single genes predicting node-
positive disease at radical cystectomy (n = 139).
Gene OR (95% CI) P-value 
TOX3 0.98 (0.92-1.05) 0.57
SLC11A2 0.98 (0.76-1.28) 0.90
FAM36A 1.02 (0.87-1.18) 0.85
LIMCH1 1.05 (0.94-1.16) 0.40
RAB15 1.00 (0.88-1.13) 0.96
AVL9 0.99 (0.91-1.09) 0.90
PCMTD2 1.00 (0.91-1.11) 0.96
PTHLH 0.99 (0.87-1.13) 0.90
DPP4 0.99 (0.91-1.08) 0.81
PCDHGA10 1.01 (0.92-1.11) 0.78
MT1E 1.03 (0.95-1.13) 0.47
MAP4K4 0.97 (0.82-1.14) 0.70
SLC16A1 1.03 (0.95-1.12) 0.50
BST2 1.10 (0.96-1.25) 0.19
MMP14 0.99 (0.89-1.09) 0.80
IFI27 1.11 (0.95-1.30) 0.19
NCLN 0.96 (0.76-1.22) 0.74
HLA_G 1.01 (0.94-1.10) 0.73
RRBP1 0.99 (0.80-1.22) 0.93
ICAM1 1.05 (0.94-1.17) 0.42
Pearson correlation analysis showed significant positive correlation in a cluster of 
eight genes (fig 5). Of these eight genes, five were determined as upregulated (AVL9, 
PCMTD2, FAM36A, LIMCH1, RAB15) in node-positive disease and three were determined 
as downregulated (NCLN, MAP4K4, MMP14) in node-positive disease by Smith et al9
20-gene expression signature and validation in TCGA
The TCGA gene expression data by RNA sequencing from 408 chemo-naïve cystectomy 
specimens is publicly available12 and was used as an additional external validation 
cohort. All 20 genes from the 20-gene expression signature and necessary clinical data 
were available for 365 MIBC samples. Beeswarm plots of the 20 genes of interest showed 
a similar overlap in data points (Supplementary fig. 4). Gene expression levels did not 
differ significantly between node-positive and node-negative patients for any of the 
genes (Mann Whitney-U-test, range p-values 0.07-0.93, Supplementary fig. 4). Pearson 
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correlation analysis did not convincingly substantiate the positive correlations in the 
eight genes found in our data (except LIMCH1 and RAB15). It did show some correlation 
between a number of other genes (e.g. ICAM, DPP4. TOX3) (Supplementary fig. 5).
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Figure 5. Pearsons’product moment correlation coefficient matrix showing a cluster of eight 
highly positively correlated genes (AVL9, PCMTD2, FAM36A, LIMCH1, RAB15, NCLN, MAP4K4, 
MMP14) (r = 0.66-0.96)
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Technical evaluation
Since there were no major differences in patient and tumor characteristics between 
node-negative and node-positive patients, we checked the data for possible technical 
confounders that might have influenced the gene expression levels. We hypothesized 
that the originating hospital might have influenced the RNA quantity and quality of the 
samples, for instance by differences in fixation protocols. Since most samples originated 
from Erasmus MC (35%), we repeated the ROC analysis for Erasmus MC archival material 
only (n = 37 node-negative and n = 11 node-positive) as an attempt to rule out this 
bias. The predictive capacity was marginally poorer in this more homogeneous but 
significantly smaller sample set (AUC 0.52, 95% CI: 0.31-0.72).
DISCUSSION
Curative treatment options for MIBC are few and survival is highly dependent on radical 
surgery and lymph node status. The presence of micrometastasis in lymph nodes could 
be an additional argument to justify the administration of NAC before radical surgery. 
There is a clear clinical need to have tools that could aid in the decision whether or not 
to give NAC. In the present study, we aimed to validate a 20-gene expression signature, 
which previously was shown to predict the presence of lymph node metastases at 
cystectomy in clinically node-negative MIBC patients9.
Since the dTURBT represents the starting point for treatment decisions in MIBC patients, 
we used RNA isolated from a large cohort of dTURBT and not radical cystectomy 
specimens. In addition, we aimed to validate the 20-gene expression signature using 
qRT-PCR, which is an easier to use technology than microarray analysis and is being used 
in many pathology laboratories around the world. Our data showed robust performance 
of the qRT-PCR per-formed: 1) the dilution series and calibration plots in the optimization 
of the qRT-PCR showed a good quality in the FFPE-derived RNA samples; 2) the gene 
plots of the duplicate samples per patient also showed a near optimal result as robust 
measurements in the RT-qPCR. Nevertheless, we were unable to validate the predictive 
capacity of the previously published 20-gene expression signature. Smith et al who 
obtained the 20-gene expression signature and accompanying cut-offs by optimization 
in two independent training cohorts of archival FFPE cystectomy specimens and one 
additional test cohort of 185 cystectomy specimens described an AUC of 0.67 (95% CI: 
0.60-0.75)9. In contrast, our expression model only reached an AUC of 0.54 (95% CI: 0.44-
0.65). In addition, analysis of the TCGA expression data in 365 MIBC patients also did 
not show a difference between node-positive and node-negative patients based on the 
suggested 20 genes.
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Recently, Seiler et al published a study that attempted to design another gene expression 
signature to predict the presence of lymph node metastases at time of cystectomy14. 
Seiler et al used RNA isolated from cystectomy specimens for a whole transcriptome 
approach in order to include also non-coding transcripts. This approach resulted in a 51 
K-nearest neighbor classifier (KNN51). Of the 51 genes included in this signature, none 
overlapped with the 20 genes from the 20-gene expression signature of Smith et al9,14. 
However, Seiler et al did attempt to validate the 20-gene expression signature. The 20-
gene expression signature had an AUC of 0.46 and a non-significant OR of 1.39 versus an 
AUC of 0.82 and an OR of 2.65 (p<0.01) for the KNN51 model14. A number of important 
differences should be noted between the study of Seiler et al and our study. The platform 
used by Seiler et al was whole transcriptome expression analysis, a laborious technique 
that is not widely available for standard diagnostic procedures in contrast to the qRT-
PCR technology we used. Further, Seiler et al like Smith et al used radical cystectomy 
for their analysis and not dTURBT specimens we used. As the authors stated in their 
conclusions, the KNN51 expression signature should also first be validated on dTURBT 
specimens before implementation in clinical practice is possible.
In general, the discordance between the study by Smith et al and our current study 
does not undermine the value of the primary study, given the different methodologies. 
However, we believe it does illustrate the practical limitations and the difficulties related 
to translation into the clinical setting. Several other hypotheses could be raised for the 
lack of validation of the predictive gene expression model in our study. In general, MIBC 
is known to be a heterogeneous cancer in terms of biological behavior. Even in similar 
histological subtypes, the biological profile of the tumor may differ greatly. Recent 
publications identified the presence of very distinct molecular subtypes in MIBC having 
different phenotypes and accompanying biological behavior15,16. These molecular 
subtypes might be differently distributed among the different datasets that were used 
to develop and validate the 20-gene expression signature. Secondly, the punches taken 
from the dTURBT samples might not have portrayed the overall tumor expression levels 
due to intra-tumor heterogeneity. Also, the punch taken from the FFPE TURBT material 
could have been contaminated by normal cells. We cannot fully exclude this possibility, 
even though we carefully selected areas of at least 70% tumor cells and we punched 
centrally in the tumor sections. Thirdly, from a statistical point of view, robustness of 
the predictive model would increase if gene expression could be defined as either `on' 
or `off'. The subtle differences in higher or lower expression of certain genes in node-
positive versus node-negative samples probably led to part of the frailty of the model. 
Lastly, correlation between different genes in this expression signature could suggest 
a biological interaction, such as cross-communicating pathways. Even though we 
could not confirm this finding in the TCGA data and this data was not available for the 
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model presented by Smith et al. Multi-collinearity between different components of a 
predictive model risks overestimation of the predictive capacity of a model and should 
therefore be corrected for in the development process.
The present study showed the difficulty of validating gene expression data, not only in 
an independent patient cohort but also on a different platform. In line with the whole 
transcriptome approach by Seiler et al on 199 patients and the RNA sequencing data 
of 365 patients of TCGA, we were unable to validate the 20-gene signature on a qRT-
PCR platform in 139 MIBC patients who underwent dTURBT. We therefore conclude that 
a previously developed 20-gene expression signature that predicted the presence of 
lymph node metastases at pelvic lymph node dissection and radical cystectomy in MIBC 
patients who were clinically node-negative is clinically not applicable and cannot serve 
as a tool to guide treatment decisions on NAC in MIBC patients.
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1 2 3 4 5 6 7 8 9 10 11 12 sample
A SLC11A2 COX20 TOX3 LIMCH1 RAB15 AVL9 PCMTD2 PTHLH DPP4 PCDHGA10 MT1E MAP4K4 1a
B SLC16A1 BST2 MMP14 IFI27 NCLN HLA-G RRBP1 ICAM1 ACTB HPRT 1a
C SLC11A2 COX20 TOX3 LIMCH1 RAB15 AVL9 PCMTD2 PTHLH DPP4 PCDHGA10 MT1E MAP4K4 1b
D SLC16A1 BST2 MMP14 IFI27 NCLN HLA-G RRBP1 ICAM1 ACTB HPRT T24 HPRT nt HPRT 1b
E SLC11A2 COX20 TOX3 LIMCH1 RAB15 AVL9 PCMTD2 PTHLH DPP4 PCDHGA10 MT1E MAP4K4 2a
F SLC16A1 BST2 MMP14 IFI27 NCLN HLA-G RRBP1 ICAM1 ACTB HPRT 2a
G SLC11A2 COX20 TOX3 LIMCH1 RAB15 AVL9 PCMTD2 PTHLH DPP4 PCDHGA10 MT1E MAP4K4 2b
H SLC16A1 BST2 MMP14 IFI27 NCLN HLA-G RRBP1 ICAM1 ACTB HPRT T24 HPRT T24 HPRT 2b
Supplementary figure 1. Plate-design of the qRT-PCR assay validating the 20-gene expression 
signature. Two patients were run per plate in duplicate. For normalization purposes the 
housekeeping genes HPRT, ACTB and a plate control (T24 bladder cancer cell line RNA) was also 
included in the assay.
170
Part II: Prognosis
Supplementary figure 2. Plots of the Ct values for the 20 genes and household genes of the 
duplicate samples per patient. Can be retrieved online at: http://journals.plos.org/plosone/
Supplementary figure 3. Beeswarm plots of the 20 different genes and 2 household genes, 
which show the distribution of ΔCt values for node-positive and node-negative samples per 
gene (n=139). The box indicates the upper and lower quartiles of distribution, with the solid 
line indicating the median and the dotted line indicating the mean ΔCt value. Can be retrieved 
online at: http://journals.plos.org/plosone/
Supplementary figure 4. Beeswarm plots based on TCGA data (n=365) of the distribution of 
ΔCt values for the 20 different genes in node-positive and node-negative samples per gene. 
The box indicates the upper and lower quartiles of distribution, with the solid line indicating 
the median and the dotted line indicating the mean ΔCt value. Can be retrieved online at: http://
journals.plos.org/plosone/
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Supplementary figure 5. Pearson’s product moment correlation coefficient matrix based on 
the TCGA RNA expression data of the 20 genes of interest (n=408).
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ABSTRACT 
Survival of patients with muscle-invasive bladder cancer is poor and new therapies are 
needed. Currently, none of the targeted agents that are approved for cancer therapy 
have been approved for the treatment of bladder cancer and the few clinical trials that 
have been performed had limited success, often owing to a lack of efficacy and toxic 
effects. However, many other novel targeted agents have been investigated in animal 
models of bladder cancer. EGFR, FGFR3, VEGF, mTOR, STAT3, the androgen receptor and 
CD24 are molecular targets that could be efficiently inhibited, resulting in reduced tumor 
growth, and that have been investigated in multiple independent studies. Several other 
targets, e.g. COX-2, IL, Bcl-xL, Livin and Choline kinase α,  have also been observed to 
inhibit tumor growth, but these findings have not been replicated to date. Limitations 
of several studies include the use of cell lines with mutations downstream of the target, 
providing resistance to the tested therapy. Furthermore, certain technologies, such as 
interfering RNAs, although effective in vitro, are not yet ready for clinical applications. 
Further preclinical research is needed to discover and evaluate other possible targets, 
but several validated targets are now available to be studied in clinical trials. 
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INTRODUCTION
Bladder tumors can be classified as either non-muscle-invasive bladder cancer (NMIBC) 
or muscle-invasive bladder cancer (MIBC). At diagnosis, 75% of patients will present with 
NMIBC (stage Ta, Tis or T1) and 25% will present with MIBC (stage ≥T2).1,2 In patients with 
NMIBC, although the 5-year survival is over 90%, the recurrence rate is high (>50%), which 
necessitates costly long-term surveillance with invasive cystoscopies.1,3-5  By contrast, 
MIBC has a poor outcome: the 5-year overall survival after radical cystectomy and lymph 
node dissection ranges from 49% for T3-4N0 stage disease to 66% for T2N0 staged 
disease.6  In patients with MIBC, cisplatin-based neoadjuvant chemotherapy preceding 
radical surgery results in an overall long-term survival benefit of 6%.7 However, overall, 
no improvement in the survival of patients with MIBC has been accomplished over the 
past 20 years.8,9 The high incidence and recurrence rate, together with the poor survival, 
make bladder cancer a serious public health problem.10 Therefore, a clear clinical need 
for new effective therapies in both NMIBC and MIBC exists. 
In the 1990s, targeted molecular therapy was introduced as a novel treatment strategy 
in oncology.11 These therapies aim to interfere with cellular processes that are essential 
to cancer cell survival at the molecular level — for example, by blocking proteins 
involved in tumor cell proliferation or tumor cell metabolism, or by delivering toxic 
compounds to tumor cells. A number of targeted therapies are now well established 
for the treatment of different cancers: imatinib in leukemia and gastrointestinal stromal 
tumors, cetuximab in colorectal cancer and bevacizumab in kidney cancer. However, 
none of the registered targeted therapies have been approved for the treatment of 
bladder cancer and the small number of clinical trials that have been performed showed 
disappointing effects.12 Patients included in these phase I and phase II clinical trials were 
mostly not selected based on their molecular tumor profile, which might explain the lack 
of treatment effect.12 In addition, resistance to therapy occurs quickly, probably owing 
to molecular heterogeneity of the tumor.13 This molecular heterogeneity contributes to 
the clonal evolution and selection of resistant subclones leading to therapy resistance.14 
Lastly, some trials investigating therapy with sunitinib or gefitinib were stopped early 
because of substantial toxic effects of treatment. 12,15,16 
This review provides a comprehensive overview of targeted therapies for bladder 
cancer that have been investigated in animal models, some of which have potential for 
clinical application. We provide insights into both the challenges and the promises of 
the preclinical development of the targeted agents, highlighting the most promising 
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studies (table 1), grouped by the mechanisms and pathways the investigated targets 
are involved in. Summaries of all studies included in this review are provided in the 
supplementary information.
OVERVIEW OF PRECLINICAL ANIMAL MODELS
In the development of novel targeted therapies, in  vitro and in  vivo studies precede 
clinical trials. Only few of the potential novel therapies will eventually be evaluated in 
clinical studies. In bladder cancer research, three types of animal models are typically 
used in in vivo research: syngeneic mouse or rat models, and heterotopic or orthotopic 
xenogeneic mouse or rat models (box 1).
Box 1 | Main types of animal models used in preclinical bladder cancer research
In vivo tumor models can be classified according to the genetic background of tumor and host and 
according to tumor location.
Genetic background
• Syngeneic model: the tumor arises from tissue of the host animal and has the same genetic 
background as the animal; examples include spontaneously developing cancers, BBN-induced 
tumors and mice that are genetically modified to develop tumors.
• Xenogeneic model: tissue or cells from another species are transplanted into the host animal
Tumor location
• Orthotopic model: the tumor develops in the same anatomical location as the source cell line or 
tissue, for example when bladder cancer cells are injected into the bladder wall.
• Heterotopic model: the tumor develops in a different anatomical location than the source cell line or 
tissue, for example when bladder cancer cells are subcutaneously injected into the flank, or results 
from metastasis.
Abbreviation: BBN, N-butyl-N-(4-hydroxybutyl) nitrosamine.
Syngeneic tumor models have the advantage of an intact tumor host environment 
including an active immune system.17  However, obvious drawbacks of these models 
exist, as mouse tumors are intrinsically different from human tumors. In addition, only 
few tumor types are available.17 Xenogeneic tumor models more closely resemble the 
tumors of bladder cancer patients; however, the stroma and vasculature is murine and 
the animals are immunodeficient to allow growth of human cancer cells.17 Furthermore, 
tumors grown from injected cell lines no longer resemble the tumor from which the 
cell line originated, owing to years of cultivation, passaging and expansion. Xenografts 
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that are derived from fresh patient material represent a possibility to achieve better 
resemblance of the true heterogeneous tumor architecture. In 2015, the first study 
describing a method to create patient-derived xenografts for bladder cancer studies 
was published.18
In studies published since 2009, the heterotopic and orthotopic animal models were 
generated using many different bladder cancer cell lines and several of these have 
been genotyped, revealing specific oncogenic mutations (table  2). These mutations 
are important to consider when choosing which tumor model to use in in vivo studies, 
particularly when the target of the tested agent is upstream of these mutations in the 
signaling pathway, as downstream mutations might activate the signaling cascade 
despite inhibition of the upstream target. However, for correct interpretation of the 
treatment effect, awareness of all potential mutations – downstream or upstream of the 
target – that could influence the study result is required. 
Furthermore, in 2013, a study showed that KU7 bladder cancer cells are actually HeLa 
cervical carcinoma cells, as the original KU7 cell line had been contaminated with HeLa 
cells at the source site at some point before 1984.19 Consequently, KU7 cells should be 
considered cervical cancer cells and not bladder cancer cells. In vivo studies using KU7 
animal models are listed in supplementary table  1, but owing to their nonurological 
origin they are not being discussed in this review.
RECEPTOR TYROSINE KINASES
Since 2009, many in vivo studies have investigated agents targeted at receptor tyrosine 
kinases (RTKs). An overview of these studies is given in supplementary table 2. RTKs, 
such as the epidermal growth factor receptor (EGFR), the fibroblast growth factor 
receptors (FGFRs) and the vascular endothelial growth factor receptors (VEGFRs), are 
essential for the communication between cells and their environment. Specific growth 
factors (for example, cytokines or hormones) bind to the extracellular domain of an RTK, 
thereby activating the intracellular kinase domain of the receptor. The activation results 
in the stimulation of downstream signaling cascades that affect cell proliferation and 
cell growth.20 The RTK–Ras–MAPK pathway and the RTK–PI3K–Akt pathway are among 
the most frequently affected signaling pathways in cancer (figure  1, figure  2).21,22 In 
bladder cancer, RTKs are often overexpressed or mutated, resulting in overstimulation 
of downstream signaling pathways. 
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EGFR
EGFR is overexpressed in many bladder tumors and EGFR overexpression correlates 
with a poor prognosis.23,24 Examples of agents targeting EGFR are gefitinib, a small-
molecule inhibitor used for the treatment of chemotherapy-refractory non-small-cell 
lung cancer, and cetuximab, an antibody used for the treatment of head and neck cancer 
and advanced colorectal cancer.25,26  The effect of inhibiting EGFR in bladder cancer was 
investigated in five mouse studies (figure 2).27-31 Cetuximab was used in three of these 
studies and researchers found that growth of MGH and T24 xenografts was inhibited 
by this antibody.27,30,31 In two studies, cetuximab was combined with photodynamic 
therapy, which enhanced the inhibitory effect in one study and was synergistic in the 
other.27,30 Similarly, combining afatinib (an inhibitor of EGFR and erbB-2) with cetuximab 
was more effective than cetuximab alone.31 Addition of bevacizumab (an antibody 
against VEGFA) to cetuximab and photodynamic therapy resulted in regression of 
tumor vessels.30
Caution must be taken in interpreting the results of four of these studies, which used 
T24 cells28,31 or MGH cells,27,30  as these cell lines carry activating mutations downstream 
of the treatment target.  Molecular profiling has shown that T24 cells have a mutation in 
HRAS, which activates the Ras-MAPK and P13K-Akt pathways downstream of EGFR.32,33 
One study in colorectal tumor samples demonstrated that activating mutations in 
another Ras protein (GTPase KRas, encoded by KRAS) render the tumor cells insensitive 
to cetuximab.34 In one of the two studies using T24 cells, the authors describe a 
cetuximab resistance mechanism but the influence of the HRAS mutation in this 
resistance mechanism remains unknown.31 In the other study using T24 cells, LRIG1 was 
introduced into these cells that were then used in a xenograft model.28 
The protein leucine-rich repeats and immunoglobulin-like domains protein 1, which is 
expressed from LRIG1, inhibits EGFR through direct interaction;28 however, its effect on 
the Ras–MAPK and PI3K–Akt pathways is most likely nullified by the presence of the 
HRAS mutation in T24 cells. In addition, the cell line MGH, which was used in the two 
studies by Bhuvaneswari and colleagues,27,30 has a mutation in AKT1; the corresponding 
protein PKB is an effector for the PI3K–Akt pathway.32,33 MGH cells also carry an FGFR3 
mutation that might activate the Ras–MAPK pathway, independently of EGFR.32,33 
Although a beneficial effect of targeting EGFR was observed, the effect could have been 
more convincing if a different cell line would had been used to establish the treated 
mouse xenografts. Furthermore, the observation that EGFR was downregulated does 
not imply that the downstream signaling pathways were also downregulated.27,30 By 
contrast, in the study of Rebouissou et al.,29 in which EGFR was inhibited by erlotinib, 
resulting in tumor growth inhibition or delayed tumor detection by ultrasonography, 
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the results are convincing.  The cell lines used (BFTC-905, JMSU1, KK47, L1207, UMUC6, 
VMCUB1) were selected using a 40-gene expression classifier, discriminating between 
high EGFR expression for a basal-like phenotype or low EGFR expression for non-basal-
like phenotype, and thoroughly examined for downstream mutations (table 1).29
Several EGFR-targeted therapies have been evaluated in clinical trials and a number 
of clinical trials are ongoing.12 For instance, erlotinib monotherapy was studied in the 
neoadjuvant setting in 20  patients with MIBC.35 The authors reported a pathologic 
response rate with downstaging to <T2 in 35% of patients. Gefitinib and cetuximab 
combined with chemotherapy were studied in the metastatic setting.36,37 Median 
overall survival times were 15.1 months and 14.3 months for gefitinib and cetuximab, 
respectively. Gefitinib was also studied as a single-agent second-line therapy in 
the metastatic setting: only one of 31 treated patients responded to treatment.38 
Nevertheless, we believe that treatments targeting the EGFR can still have a role as 
therapies for patients with bladder cancer in the future. The disappointing trial results 
and data from in vivo research clearly highlight the need to carefully select patients for 
therapy based on the molecular profile of their tumor. 
In addition, agents targeting erbB-2 are being investigated in phase II trials in patients 
with bladder cancer but most results are still pending. Examples include a number of 
trials in which trastuzumab or lapatinib are being combined with chemotherapy or 
given as single agents.39-44 Promising results are expected, particularly in the light of new 
data reported by The Cancer Genome Atlas (TCGA) Research Network21 and Groenendijk 
and co-workers. 45 The TCGA study found that ERBB2 was mutated or amplified in 9% 
of samples, demonstrating the importance of ERBB2 mutations in the pathogenesis of 
bladder cancer.21 Groenendijk et al.45 found that ERBB2 mutations were associated with 
a very good response to neoadjuvant chemotherapy: 24% of complete responders but 
none of the nonresponders had ERBB2 mutations.45
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Table 1. Promising in vivo research*
Target Pathway Tumor type (n) Intervention Study
EGFR Ras–MAPK Orthotopic (40)
Heterotopic (144; 
2 per mouse)
EGFR inhibitor (erlotinib) 29
FGFR-3 Ras–MAPK Heterotopic (NR) FGFR inhibitor (PD173074) 48
FGFR-3 Ras–MAPK Heterotopic (80) mAb against FGFR3 (R3Mab) 49
FGFR-3 Ras–MAPK Orthotopic (128) mAb against FGFR3(R3Mab) 50
FGFR-3 Ras–MAPK Heterotopic (72) FGFR inhibitor (PD173074) 51
FGFR-3 
EGFR
Ras–MAPK Experiment 1: 
Heterotopic (30)
Experiment 2: NR
Experiment 1: FGFR inhibitor (PD173074) and/or 
EGFR inhibitor (gefitinib)
Experiment 2: FGFR inhibitor (PD173074 and/or 
mAb against EGFR (cetuximab)
54
VEGFRs Ras–MAPK Metastatic (NR) Tyrosine kinase receptor inhibitor (sunitinib) 
and/or chemotherapy (epirubicin)
149
VEGF-A
VEGF-C
VEGFR-3
Ras–MAPK Heterotopic (22) siRNA against VEGF-A, or siRNAs against VEGF-C 
and VEGFR-3
59
VEGF-A
EphB4
Ras–MAPK Heterotopic (32) EphB4 inhibitor (sEphB4-HSA) and/or mAb 
against VEGF(bevacizumab)
150
mTOR PI3K–Akt Heterotopic (37) Knockdown of TP53 and PTEN and  mTOR 
inhibitor (rapamycin)
75
mTOR PI3K–Akt Heterotopic (40) mTOR inhibitor (rapamycin) and/or 
chemotherapy (cisplatin)
75
mTOR PI3K–Akt Heterotopic (40) mTOR inhibitor (rapamycin) and/or PI3K 
inhibitor (wortmannin)
76
STAT3 
mTOR
MAPK
Jak
PI3K–Akt
Ras-MAPK
Orthotopic (84) mTOR inhibitor (rapamycin) and/or MAPK 
inhibitor (UO126) and/or STAT3 inhibitor 
(S3I201)
78
STAT3
Survivin
Jak
Apoptosis
Heterotopic (35) siRNAs against STAT3, survivin or both STAT3 
and survivin
151
AR Jak
PI3K–Akt
Ras–MAPK
Heterotopic (18) siRNA against AR 94
AR Jak
PI3K–Akt
Ras–MAPK
Heterotopic (10) Androgen deprivation (surgical castration) 93
AR Jak
PI3K–MAPK
Ras–Akt
Heterotopic (18) siRNA against AR 95
CD24 
AR
Metastasis
Jak
PI3K–Akt
Ras–MAPK
Orthotopic (190)
Heterotopic (20)
CD24-knockout mice or androgen deprivation 
(surgical castration)
99
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Target Pathway Tumor type (n) Intervention Study
CD24 Metastasis Heterotopic (16)
Metastatic (44)
mAb against CD24 (ALB9) 96
CD24
HIF1α
Metastasis
Angiogenesis
Heterotopic (40)
Metastatic (32)
shRNA against CD24 or HIF1α 129
* Additional details can be found in the Supplementary Information online. Abbreviations: EGFR, epidermal growth factor 
receptor; FGFR, fibroblast growth factor receptor; EphB4, ephrin typeB receptor  4; mAb, monoclonal antibody; mTOR, 
mammalian target of rapamycin; STAT3, signal transducer and activator of transcription 3; MAPK, mitogen-activated 
protein kinase; AR, androgen receptor; CD24, Signal transducer CD24; HIF1α, hypoxia-inducible factor  1α; siRNA, small 
interfering RNA; VEGFRs, vascular endothelial growth factor receptors 
Figure 1. Cellular processes involved in cancer development. External stimuli, such as hormones 
and growth factors, stimulate receptors on the cellular membrane, leading to activation of 
downstream pathways. These pathways lead to activation of transcription factors and, thus, 
gene expression. RNA is either translated to functional proteins or can have regulatory functions 
on its own. In cancer cells, many processes eventually lead to increased cellular proliferation by 
amplifying cell growth, evading cell cycle arrest and evading apoptosis. Abbreviations: EGFR, 
epidermal growth factor receptor; FGFRs, fibroblast growth factor receptors; MAPK, mitogen-
activated protein kinases; TP53, cellular tumor antigen p53; VEGFRs, vascular endothelial 
growth factor receptors.
184
Part III: Therapy & Surveillance
FGFRs
In addition to EGFR overexpression, approximately two-thirds of all NMIBCs have 
activating FGFR3 mutations.46 In MIBC, <15% of tumors have FGFR3 mutations, although 
>40% of MIBCs overexpress FGFR3.47 Seven in  vivo studies reported the effects of 
targeting FGFR3.48-54 In most cases, the cell lines used either carried a mutant FGFR3 gene 
or a FGFR3 fusion gene, both leading to activation of downstream pathways. The FGFR-3 
was inhibited by the small-molecule inhibitor PD173074 in four studies,48,51,52,54 and by 
the monoclonal antibody R3Mab in two studies (Figure 2).49,50 One study evaluated the 
effect of the pan-FGFR inhibitor BGJ-398.53 
Five studies reported growth inhibition, reduced cell proliferation or both.48-51,54 
Induction of apoptosis — which demonstrates cytotoxic effects of the treatment —was 
only reported in one study.48 The MGH cell line used in the study by Lamont et al.52 has 
an AKT1 mutation, leading to activation of the PI3K pathway regardless of inhibition of 
the FGFR; nevertheless, the investigators did observe a cytostatic response by treatment 
with PD173074. The cell line UMUC3 used in the study by Cheng et  al.53 has a KRAS 
mutation and a deletion in the PTEN gene, resulting in constitutive activation of both 
Ras–MAPK and PI3K–Akt pathways. In this study, blockage of tumor cell extravasation 
was reported but not growth inhibition. In another study, inhibition of FGFR3 and EGFR 
was combined in a mouse model using RT112 cells, which have no known downstream 
mutations in Ras–MAPK and PI3K–Akt pathways.54 Combination therapy with the 
FGFR3 inhibitor PD173074 and cetuximab gave the best result regarding tumor growth 
inhibition, compared to treatment with either agent alone, and also led to sustained 
tumor growth control.54 Overall, these mouse studies provided compelling evidence 
that targeting FGFR3 in human bladder tumors is potentially effective (table 1).
In clinical trials, however, the strategy of targeting FGFR3 has not yielded the expected 
positive results. The small-molecule inhibitor dovitinib was investigated as a single-
agent, second-line treatment in patients with metastatic urothelial carcinoma.55 The 
results were disappointing and the study was terminated owing to a lack of beneficial 
treatment effects. In a phase  Ib study of dovitinib plus gemcitabine combined with 
cisplatin or carboplatin in patients with advanced solid tumors, which included two 
bladder cancer patients, no treatment effect was observed.56 Furthermore, combined 
treatment was poorly tolerated owing to myelosuppression. A phase II trial of dovitinib 
in patients with NMIBC who did not respond to BCG treatment is ongoing and reports 
of the results are pending.57
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Table 2. Bladder cancer cell lines and known oncogenic mutations and gene fusions relevant 
to this review32
Cell line [alternative name] Origin
Oncogenic mutations and 
gene fusions* In vivo studies‡
253J-BV [253JBV, 253J_B-V] Human Unknown 156
5637 Human ERBB2, TP53,RB1 77, 111, 150
AY-27 Rat Unknown 157-159
BFTC-905 [BFTC905] Human NRAS, TP53 29
BIU-87 Human Unknown 160, 161
BTT739 Human Unknown 59, 61, 91
EJ [MGH-U1] Human Unknown 92, 99, 131
HT-1197 [HT1197] Human NRAS, PIK3CA 162
HT-1376 [HT1376] Human TP53, RB1 162
J82 Human FGFR3, ERBB2, TP53 51, 163, 164
JMSU1 Human Unknown 29
KK47 Human Unknown 29
KU-19-19 [KU1919] Human NRAS, AKT1 89
KU-7 Human NA§ 165-174
L1207 Human Unknown 29
MB49 Mouse Unknown 174-177
MBT-2 [MBT2] Mouse Unknown 60, 121, 124, 125, 130, 149, 178
MGH [MGH-U3, MGHU3, RN] Human FGFR3, AKT1, CDKN2A 27, 30, 48, 52
RT112 [RT-112] Human TP53, FGFR3/TACC3 fusion 49, 50, 52, 54, 179, 180
RT4 [RT-4] Human RHOA 51, 74, 152, 181
SW780 [SW-780] Human FGFR3/BIAIAP2L1 fusion 51, 52, 120, 182
T24 [T-24] Human HRAS, TP53, 28, 31, 94, 95, 100, 113, 114, 128, 
151, 162, 177, 183-190
TSU-pr1 Human NA 143
UMUC1 [UM-UC-1] Human Unknown 50
UMUC3 [UM-UC-3] Human PTEN, KRAS,TP53 53, 75, 76, 88, 90, 93, 96, 99, 109, 
112, 126, 129, 152, 191, 192, 193
UMUC6 [UM-UC-6] Human FGFR3 29
UMUC14 [UM-UC-14] Human FGFR3 48-50, 82, 120
VMCUB1 [VM-CUB-1] Human TP53,ERBB2, PIK3CA CDKN2A 29
YTS-1 Human Unknown 144
* Only mutations registered in COSMIC databases are listed.32 ‡ Only studies in which the cell lines have been used to create 
xenografts are listed. § Cervical carcinoma cell line.  TSU-pr1 cells have been derived from T24 cells. Abbrevation: NA, not 
applicable.
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In summary, studies of the inhibition of RTKs in cell-line-derived animal models should 
be performed after molecular profiling of the chosen cell line to exclude the possibility 
of activating mutations downstream of the target RTK. In human bladder cancer 
tumors, mutations in the Ras family of genes are rare (for example, HRAS mutations 
exist in 5% of patients)21 and mutations in the PI3K–Akt pathway occur in approximately 
20% of bladder cancer tumors.21 For these subgroups of patients, tumor models 
harboring mutations in these pathways will be useful in therapy evaluation. However, 
RTK inhibition therapy will probably lack effectivity and therapies not involving these 
pathways could be beneficial for this patient category. 
The data reviewed here suggest that inhibition of RTKs after stratification of patients 
based on molecular analysis of the tumor does have potential in bladder cancer therapy 
for the majority of patients. In addition, combination of treatments might enhance 
treatment effects; however, some treatment combinations might also result in increased 
toxic effects.
VEGFRs and angiogenesis
As tumors become larger, hypoxia will occur unless the tumor is able to grow new 
blood vessels. Most tumors stimulate neoangiogenesis by secreting VEGF. VEGF binds 
to its cognate receptor on endothelial cells and stimulates the formation of new blood 
vessels.58
In one study, Feng and co-workers59 treated mice that had heterotopic mouse bladder 
carcinomas with intratumoral injections of synthetic small interfering RNAs (siRNAs) 
against Vegfa, Vegfc and Vegfr3. The siRNAs specifically inhibited synthesis of the 
corresponding proteins (VEGFA, VEGFC and VEGFR3, respectively). VEGFA and VEGFC 
are two types of ligands that can bind to VEGFRs. Interestingly, all mice in the control 
group and in the group that received siRNAs against Vegfc and Vegfr3 developed lung 
metastases but 37.5% of mice in the group treated with siRNA against Vegfa had no 
lung metastases. In addition, no animals in the group treated with siRNA against Vegfa 
had liver metastases compared with 50% and 25% of mice in the control group and the 
group receiving siRNAs against Vegfc and Vegfr3, respectively. These data suggest that 
inhibition of VEGF-A expression reduces the development of metastases. 
Three of the studies on angiogenesis inhibition used technologies that cannot yet be 
implemented in clinical practice (for example, viral vehicles).59-61 Two of these studies 
reported tumor growth inhibition 59,61, but one study did not find an effect on tumor 
growth.60 All three studies reported a combination of either reduced angiogenesis, 
reduction in lymphatic vessels or metastasis.59-61  
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Figure 2. Cellular pathways affected in bladder cancer and targeting therapies. Multiple small-
molecule inhibitors and antibodies against different receptors and pathways have been tested 
in preclinical and clinical studies. Agents targeting protein translation and cell metabolism 
affect the molecules at the end of signaling pathways and are not shown. Pathways and targets 
are located at various sites in and around the tumor cell (figure 1). The percentage of bladder 
cancer samples harboring mutations are shown for targets that have been screened by the 
TCGA.21 *Percentage depends on the RTK analyzed. ‡Percentage harboring a copy number 
variation. Abbreviations: ARF, tumor suppressor ARF; Akt, serine/threonine-protein kinases; 
B-raf, serine/threonine-protein kinase B-raf; BAX, apoptosis regulator BAX; E2F, transcription 
factors of the E2F family; MAPK, mitogen-activated protein kinases; MDM2, E3 ubiquitin-protein 
ligase Mdm2; MEK, dual specificity MAPK kinases 1 and 2; NF-κB, nuclear factor κB; p21, cyclin-
dependent kinase inhibitor 1; p53, cellular tumor antigen p53; RPS6, 40S ribosomal protein S6; 
RTK, receptor tyrosine kinase; STAT, signal transducer and activator of transcription 1 and 3; 
TCGA, The Cancer Genome Atlas Research Network; VEGF, vascular endothelial growth factor.
Many clinical trials of agents targeting VEGFs and VEGFRs in patients with bladder 
cancer have already been reported.12 Four studies investigated the use of bevacizumab 
(targeting VEGF-A) or sunitinib (targeting VEGFRs) combined with chemotherapy in 
the neoadjuvant setting (figure  2).62-65 Pathological response rates with downstaging 
to <T2 ranged from 22% to 53%. One study of sunitinib was terminated early owing to 
substantial toxic effects.65 Combining bevacizumab with chemotherapy has also been 
studied as adjuvant treatment in two studies.64,66 The reported median progression-free 
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survival was 6.5  months in one study47 and 8.2  months in the other study.66 In both 
studies, the aspired study goal of 50% improved progression-free survival was not 
met.64,66
Other studies have analyzed monotherapy of sunitinib, aflibercept (a fusion protein that 
binds VEGFs) or pazopanib (which targets VEGFRs) as second-line treatment strategies 
in phase II trials in patients with advanced urothelial cancer.67-70  Two studies reported no 
beneficial effect of aflibercept and pazopanib,68,69 and the other two studies reported a 
partial response in 7% and 17.1% of patients for sunitinib and pazopanib, respectively.67,70 
At present, three clinical trials investigating anti-VEGF therapies (bevacizumab, 
pazopanib and sunitinib) in patients with bladder cancer are ongoing.71-73 
Overall, VEGF-targeted therapies show promise for clinical application. However, 
sunitinib treatment resulted in high toxicity in clinical trials12,16 and a more selective 
VEGF inhibitor or antibody will be more likely to be well tolerated. Again, selection of 
patients based on the downstream mutations in their tumor will be necessary to achieve 
the highest benefits. 
SIGNAL TRANSDUCTION
Several studies have identified potential new targets for bladder cancer therapy in 
different signal transduction pathways. Signals coming from cell membrane receptors 
must be communicated to downstream effector molecules. This signal transduction 
occurs through kinases, such as MAP kinases and PI3 kinases, or GTPase activity, for 
example of Ras proteins (figure 1, figure 2). 
The signal transduction cascades offer many possible new therapeutic targets. As a 
consequence, inhibitors have not been generated for all potential targets. In cell culture 
and animal models, inhibition of a target by inhibiting translation of its mRNA by siRNAs 
usually gives the first insight into whether the target is suitable for further study.  An 
overview of in vivo studies in which targeting of signal transduction pathways has been 
investigated is provided in supplementary table 3.
The protein mTOR acts in the PI3K–Akt pathway and is targeted by rapamycin. Several 
rapamycin analogues, such as temsirolimus and everolimus, have been developed and 
are in use for the treatment of advanced renal cell carcinoma. In three studies that used 
heterotopic xenograft models and one study that used an orthotopic mouse model, 
mTOR was targeted via intraperitoneal injection of rapamycin (figure 2).74-76,78 All studies 
showed that rapamycin reduced tumor growth. In addition, Makhlin et al.75 showed that 
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the addition of cisplatin to rapamycin treatment resulted in increased median survival 
and a lower proliferation index (decreased expression of the proliferation marker Ki67) in 
comparison with rapamycin alone. Similarly, Zhou et al.78 demonstrated that combining 
rapamycin with inhibitors of MAPK and signal transducer and activator of transcription 3 
(STAT3) significantly prolonged survival in a bladder cancer model in transgenic mice in 
comparison with rapamycin alone. Seront et al.76 found that rapamycin was less effective 
in UMUC3 cells in comparison with UMUC14 cells (UMUC3 cells have a homozygous 
deletion of PTEN, whereas UMUC14 cells express wild-type PTEN). The researchers  also 
found that combining rapamycin with a PI3K inhibitor was required to inhibit UMUC3 
cell tumor growth.76 This finding, however, was not confirmed by Puzio-Kuter et al.74 in a 
mouse model of conditional knockout of PTEN and Makhlin et al.75 in a xenograft model 
using UMUC3 cells. In summary, in vivo studies investigating rapamycin treatment 
of bladder cancer have demonstrated that this inhibitor is promising, displaying 
effectiveness in human xenografted cell lines and models of mouse bladder cancer 
(table 1). 
Examples of phase II clinical trials targeting mTOR and the PI3K – Akt pathway in patients 
with bladder cancer include several trials that combined temsirolimus or everolimus 
with chemotherapy.79-81 The results of these studies are not yet available. Other trials 
have evaluated a single-agent strategy of temsirolimus or everolimus (figure 2).82-84 One 
study was terminated because of futility.83 Although most of the patients in these trials 
did not respond to the single-agent treatment, some patients had stable disease or 
partial response. For example, upon treatment with everolimus eight and two out of 
37 patients in one study82 and 12 and 2 out of 45 patients in another study84 had stable 
disease or partial response, respectively, indicating a beneficial effect in selected groups 
of patients. 
A single-agent strategy with the PI3K inhibitor BKM120 (also known as buparlisib) is 
being investigated in an ongoing trial but study results are still pending (figure  2).85 
BKM120 has previously shown partial responses in the treatment of patients with 
breast cancer.86 Furthermore, one trial evaluating the effect of everolimus in patients 
with NMIBC is currently underway86; however, the tumors of the patients enrolled in 
this trial have not been molecularly characterized. Hence, the eventual treatment effect 
might differ between patients depending on the molecular profile of their tumor, which 
could result in an underestimation of the overall treatment effect. If enough patients are 
included, stratified analysis based on the molecular tumor profile might indicate which 
patients benefit more (or less) than others. 
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Other targets in signal transduction cascades include transcription factors (for example, 
STAT3, NF-κB, zinc finger protein 224 and the androgen receptor [AR]) or proteins that 
regulate transcription (for example, histone deacetylases).78,88-97 Inhibition of these 
transcription factors resulted in tumor growth inhibition in all studies included in this 
review.78,88-94,96,97 
Testosterone and the AR might have a role in the increased incidence of bladder cancer 
in men compared with women.98 Hence, surgical castration was explored as therapy 
in two studies: Overdevest et al.99 observed a reduction in tumor growth in orthotopic 
and heterotopic xenografted mice using this approach, whereas Shiota et al.93 did not 
find a significant inhibition of tumor growth in their heterotopic xenograft model. 
In addition, two studies that investigated siRNAs targeting the AR in subcutaneous 
xenografts observed statistically significant tumor growth inhibition.94,95 Considering 
these findings, inhibition of the AR might be a possible therapeutic strategy for men 
with bladder cancer (table 1); however, none of the possible transcription factor targets 
have been evaluated in clinical studies yet.
CELL CYCLE PROTEINS AND APOPTOSIS
Cell division occurs after the cell has gone through the four cell cycle phases G1, S, G2 
and M (figure 1). Cell cycle checkpoint proteins, which regulate progression through the 
cell cycle, are often mutated or bypassed in malignant cells and are therefore considered 
potential targets for therapy. Studies that have investigated targeting cell cycle control 
and apoptosis pathways in vivo are listed in supplementary table 4. 
In the M  phase, the accurate formation of the mitotic spindle is controlled during a 
quality check. Aurora kinase A is a protein that is involved in mitotic spindle formation 
and function that was evaluated as a potential therapeutic target for bladder cancer 
by Zhou et al.99 (figure 2). The researchers found that aurora kinase A expression was 
increased in clinical bladder cancer tumor samples and that inhibition of aurora kinase A 
with the inhibitor MLN8237 (also known as alisertib) in T24 bladder cancer xenografts 
in mice resulted in suppressed tumor growth. A phase II clinical trial evaluating alisertib 
combined with paclitaxel in advanced bladder cancer was registered in 2014.100
The apoptosis pathway can become activated during the cell cycle, for example when 
DNA damage occurs. In addition, apoptosis can be induced by activation of the Ras-MAPK 
pathway and subsequent activation of the tumor suppressor TP53, which is encoded 
by TP53, a gene that is often mutated in cancer cells. Mutations that change an amino 
acid in the DNA-binding domain of p53 inhibit its function as a transcription factor and, 
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as a consequence, expression of the proapoptotic apoptosis regulator BAX. Deletions 
of the gene likewise lead to loss of function.101,102 In one study, CP31398, a compound 
that stabilizes the conformation of the DNA-binding domain of TP53 (figure  2), was 
administered to SV40T-transgenic mice.103 The SV40 large T protein binds and inhibits 
both p53 and the retinoblastoma-associated protein and thereby induces bladder 
cancer.104 Administration of CP31398 resulted in decreased tumor weight and inhibition 
of invasive tumor growth with an increase in apoptosis.73 In clinical trials, p53-targeted 
therapy is being evaluated using ALT801, a fusion protein of IL2 and a T-cell receptor 
domain.105 The efficacy of ALT801 is being investigated as a combination treatment with 
gemcitabine, with or without cisplatin, in patients with MIBC and NMIBC.106,107 Patient 
recruitment is currently ongoing. 
Bcl-xL (Bcl-2-like protein  1 expressed from BCL2L1) is an antiapoptotic protein of 
the Bcl2 family. One study investigated the clinicopathological significance of Bcl-
xL expression in patients with upper urinary tract urothelial carcinoma (figure  2).108 
Using a subcutaneous UMUC3 xenograft model in mice, the researchers evaluated the 
therapeutic effect of the V-ATPase inhibitor bafilomycin A1 against Bcl-xL and observed 
reduced tumor growth with signs of apoptosis (confirmed by terminal deoxynucleotidyl 
transferase dUTP nick end labelling (TUNEL) assay, which is used to detect DNA 
fragmentation caused by apoptosis). Another target in this category is livin, which 
belongs to the inhibitors of apoptosis proteins (IAP) family and was shown to predict 
disease relapse in bladder cancer.109 Inhibiting livin in an in vivo heterotopic xenograft 
model led to tumor inhibition and increased apoptosis.110. 
Targeting and inducing the apoptosis pathway is an especially interesting strategy 
in cancer treatment, as the occurrence of apoptosis shifts the treatment effect from 
cytostatic to cytotoxic. This shift could, in theory, lead to tumor regression rather 
than only reduced cell proliferation. However, most of the targeted therapies that 
are currently used clinically are cytostatic rather than cytotoxic. With the exception 
of the study investigating the p53 stabilizer CP31398,103 the number of animals used 
in experiments in this category of targets is small and none of the studies have been 
replicated to date.
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PROTEIN SYNTHESIS AND CELL METABOLISM
Protein synthesis
During the G1 phase of the cell cycle, many proteins that are required for subsequent cell 
division are being synthesized (translation). As the step of protein translation is essential 
to cell proliferation, the participating proteins are potential targets for anticancer agents. 
Supplementary table 4 provides an overview of the relevant in vivo studies.
Eukaryotic translation initiation factor 3B (eIF3b) is a subunit of the translation initiation 
factor complex eIF3. Immunohistochemical assessment of 143 bladder cancer samples 
showed that eIF3b overexpression was correlated with a high tumor stage and short 
disease-specific survival in humans.112 The researchers then used siRNAs to inhibit eIF3b 
formation in UMUC3 cells, which resulted in reduced tumor growth of subcutaneous 
xenografts in mice.112 
Some bacterial toxins target the function of proteins during translation. One group used 
diphtheria toxin subunit A to inhibit translation of elongation factor 2.112,113 Expression of 
the toxin was controlled by the promoter of the insulin-like growth factor 2 gene (IGF2) 
and/or the promoter of the long non-coding RNA gene H19. The products of IGF2 and 
H19 are highly expressed in many tumors but not in normal cells. In two studies using 
orthotopic T24 human bladder cancer xenograft models in mice, treatment inhibited 
tumor growth, resulting in tumors that were 86% and 83% smaller than in controls.113,114 
Targeting the translational process has also been investigated in other types of cancer, 
for example by targeting eukaryotic translation initiation factor 4E (eIF4e). After multiple 
promising preclinical studies, a phase  I trial (NCT00903708)114 using an antisense 
oligonucleotide to block expression of eIF4e was completed in 2010.115-118 Patients 
with stage  4 cancer for which no proven therapy existed were included, regardless 
of pathological diagnosis. Included cancer types were mesothelioma, malignant 
melanoma, non-small-cell lung carcinoma and several others. The expression levels 
of eIF4e in tumor biopsy samples taken after treatment were lower than those in pre-
treatment samples. Unfortunately, the study did not show any clinical response, which 
again demonstrates the difficulty of translating preclinical results to the bedside.118 
Cell metabolism
In cancer, cell metabolism is often unbalanced. Metabolism and catabolism are mediated 
and controlled by a multitude of different enzymes, which are therefore other potential 
targets for bladder cancer therapy. In vivo studies that investigated this strategy are 
listed in supplementary table 4. For example, stearoylCoA desaturase 1 is a rate-limiting 
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enzyme in fatty acid desaturation that was targeted by siRNA knockdown or by an oral 
small-molecule inhibitor, both combined with doxycycline therapy. Both strategies led 
to a significant reduction in tumor growth in subcutaneous bladder cancer xenografts 
in mice.119 
Choline kinase  α (ChoKα) is a metabolic enzyme responsible for the generation of 
phosphorylcholine (the hydrophilic polar head group of phospholipids).120 Inhibition 
of this enzyme slowed tumor growth in both subcutaneously as well as orthotopic 
xenografts in mice and prolonged animal survival in the orthotopic mouse model from 
a median of 34 days to 42 days.120 ChoKα is also overexpressed in lung, breast, prostate, 
colon, ovary and hematological malignancies.121 In 2014, a phase I trial testing a ChoKα 
inhibitor in patients with solid tumors, including bladder cancer, finalized recruitment, 
but results have not been published yet.122
Two other studies have tested two other drugs that target metabolic pathways.123,124 
Treatment with a combination of αlipoic acid, which inhibits glycolysis, and 
hydroxycitrate, which inhibits lipid synthesis, was able to improve survival of mice with 
MBT-2 bladder tumor xenografts. Addition of octreotide or cisplatin boosted survival 
even further.123,124
Overall, targeting protein translation seems to be a promising strategy for the treatment 
of bladder cancer, even though the study targeting eIF4e showed the difficulty of 
reproducing favorable preclinical results in a phase I clinical trial.
METASTASIS, IMMUNE SYSTEM AND OTHERS
Other processes that involve potential molecular targets for the treatment of patients 
with bladder cancer include the formation of metastases and the immune response. 
In addition, novel treatment strategies, such as oncolytic viruses, are used to exploit 
tumor-cell-specific molecular mutations. A summary of studies investigating these 
strategies is provided in supplementary table 5.
Potential targets include proteins that interact with the extracellular matrix, for example 
urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor  1 (PAI1) 
and versican core protein. These targets are thought to be important in reducing 
the metastatic potential of bladder cancer cells and, hence, might be employed in 
preventive treatments.125-127 Another promising target is the CD antigen CD24, a cell 
surface protein and cancer stem cell marker that is involved in metastatic progression 
in many cancers.  In three preclinical studies, one group showed the relevance of 
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CD24 in bladder cancer development and metastasis.95,98,128 Inhibition of CD24 with an 
antibody or siRNAs reduced tumor growth in mice with subcutaneous xenografts and 
reduced metastatic load in mice inoculated with tumor cells via their tail vein.95,98,128 
Also, fewer tumors developed in CD24-knockout animals upon administration of 
N-butyl-N-(4-hydroxybutyl)-nitrosamine, which induces bladder tumors.98 Furthermore, 
the researchers found that androgens stimulated CD24 expression in tumor tissue 
and surgical castration of male mice inhibited tumor growth in the subcutaneous 
xenografts.98  As inhibition of CD24 reduced tumor growth in multiple studies, we 
consider this strategy promising as a targeted therapy in bladder cancer (table 1).
Stimulation of the immune system is another way to target cancer cells. If the immune 
system is able to recognize tumor cells as foreign, the immune response might destroy 
the malignant cells.129 One approach investigated the use of IL12 in the treatment of 
bladder cancer, using transfection of EJ bladder cancer cells with a plasmid encoding 
IL12 to force secretion of IL12.130 The hypothesis was that secretion of IL12 would 
stimulate T  lymphocytes and natural killer cells, which should result in increased 
tumor cell killing. Mice were injected subcutaneously with nontransfected EJ cells or 
transfected EJ cells.130 In addition, some mice were treated with injections of pirarubicin, 
a doxorubicin analogue. Combination treatment resulted in significantly smaller tumors 
compared with single treatment or no treatment. Although these results are positive, 
the need to introduce a gene into a high percentage of tumor cells in a solid tumor 
makes this approach unlikely to be translated into clinical application.
Other bladder cancer treatment strategies targeting the immune system are currently 
under investigation in clinical trials.131 These agents have so far not been analyzed in 
animal models of bladder cancer, but have proven their efficacy in clinical trials in other 
types of cancer. Immune checkpoint inhibitors, such as MPDL3280A (atezolizumab) 
pembrolizumab, ipilimumab and nivolumab are examples of such promising therapies 
targeting the immune system. MPDL3280A, an antibody against programmed cell 
death  1 ligand  1 (PDL1), was investigated as a single-agent, second-line therapy in 
a phase  I trial in 68 patients with bladder cancer .132 The objective response rate was 
43% in patients with tumors positive for PDL1 expression upon immunohistochemical 
analysis. Reported overall toxicity was low. In 2014, the FDA granted MPDL3280A the 
breakthrough status for bladder cancer, which will expedite the development and 
review of the drug by the FDA.133, 134 Many clinical trials of MPDL3280A are currently 
ongoing and results are pending.135-142
Finally, three in vivo studies employed oncolytic adenoviruses.130,143,144 The viruses were 
genetically modified in such a way that they specifically attach to a tumor-associated 
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membrane protein or the extracellular matrix and then enter and lyse the tumor cells 
without damaging normal cells. Although this strategy leads to a reduction of tumor 
growth, the infection efficiency of the used viruses is probably not high enough for all 
tumor cells to be are targeted.145 To achieve extensive effectiveness, infection should not 
only result in direct tumor cell killing, but also antigen release and immune stimulation.146 
Thus, since oncolytic viruses have shown suboptimal potency as monotherapies, 
combination treatments with, for example, immune check point inhibitors or immune-
stimulatory molecules should be considered.146,147 For example, in 2012, a phase I trial 
investigating the efficacy of intravesical administration of an oncolytic adenovirus 
expressing granulocyte-macrophage colony-stimulating factor demonstrated tolerable 
safety and a complete response rate of 48.6%.148 However, at the moment, we do not 
consider treatment strategies using oncolytic viruses ready for implementation into the 
clinic. 
CONCLUSIONS
Although targeted therapies have proven effective in other cancer types, none of the 
registered therapies have been approved for the treatment of bladder cancer. The small 
number of clinical trials that included patients with this disease had limited success.12 
With this review, which explores all animal studies investigating targeted therapeutic 
interventions for bladder cancer that were published since 2009, we aimed to provide a 
current, comprehensive overview of this exciting field of research.
We found several animal studies that reported tumor growth inhibition or reduced 
angiogenesis and were replicated by different groups or validated by the same group in 
separate studies (table 1). Inhibition of FGFR3 seemed very successful using the small-
molecule inhibitor PD173074 48,51,52,54 , as well as via the monoclonal antibody R3Mab 
49,50 and in combination with inhibition of EGFR.54 These treatments resulted in tumor 
growth inhibition, reduced angiogenesis and increased apoptosis. Inhibition of EGFR 
alone using erlotinib was also successful, resulting in tumor growth inhibition in some 
heterotopic xenografts and prolonged survival of mice with orthotopic xenograftes.29 
However, the results of clinical trials investigating therapeutic targeting of FGFR3 and 
EGFR have been disappointing,12 most likely owing to the lack of patient stratification 
according to the downstream mutations in the pathways of these receptors.
Inhibition of angiogenesis through blocking VEGF or its receptor reduced tumor growth 
in animal models.30,59-61,149,150 Similarly, inhibition of the cancer stem cell marker CD24 
inhibited tumor growth 95,98,128, which was also the case for treatments targeting mTOR 
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and the PI3K–Akt pathway75-77, STAT3 77,90,151 and the AR.92-95 Most experiments showed 
a cytostatic treatment effect, which suggests that tumor growth probably resumes 
when treatment is stopped. Combining targeted treatment with chemotherapy usually 
enhanced the therapeutic efficacy. In clinical trials, combination treatments have been 
attempted but has not demonstrated an improvement in overall survival and sometimes 
resulted in increased patient toxicity.12
EGFR inhibitors and antibodies have proven to be effective as targeted therapies 
in humans with non-small-cell lung cancer and colorectal cancer.25,26 This work 
demonstrates that activating mutations in the Ras–MAPK and PI3K–Akt pathways 
downstream of EGFR render the tumor resistant to EGFR inhibition. We have identified 
four studies on EGFR inhibition in human bladder cancer cell line xenografts that had 
such mutations in one or both pathways.27,28,30,31 In another study, the researchers 
carefully screened the EGFR downstream pathways of the cell lines before attempting 
to target EGFR.29
One limitation of the studies discussed in this review is the use of cell lines to create 
xenografts. Cell lines might not reflect the entire spectrum of tumor types, especially 
because relatively few bladder cancer cell lines are available. In addition, cell-line-
derived tumors probably lack the tumor heterogeneity observed in most cancers. Thus, 
xenografts established directly from resected tumors might present a better model 
than cell lines. Such tumor models also have human stroma and engage murine stromal 
cells, which is likely to be important in cell–cell interactions and cell proliferation.18 
Furthermore, small-molecule inhibitors, inhibition of cell surface proteins by monoclonal 
antibodies and antibodies against ligands of cell surface receptors have proven their 
efficacy in the clinic. Inhibition or knock down of targets using small, modified RNAs (for 
example, siRNAs), transfection of genes and the use of viral vehicles are efficient in vitro 
but their effectiveness in delivery is still not good enough for systemic treatment of 
tumors and metastases.
Overall, our review shows that a multitude of different targets has been investigated 
and that most of the studies have not been replicated to date. Often, relatively few 
animals were used to register an effect. In addition, almost all studies reported inhibition 
of tumor growth but not increased apoptosis. Also, only five studies reported that the 
investigated treatment had no effect.53,60,96,125,152 This small number suggests a possible 
publication bias. In some papers, the number of treated animals was not reported. In 
2010, the ARRIVE (animals in research: reporting in  vivo experiments) guidelines—
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developed to improve the design, analysis and reporting of animal experiments—
were published.153,154 We suggest that scientists and scientific journals adhere to these 
guidelines in future studies. 
Furthermore, bladder cancer research is consistently underfunded, considering the 
number of life years lost and the costs to health-care systems generated by patients 
with bladder cancer.155 This lack of funding is the major reason why research on novel 
therapies in bladder cancer lags behind that in other tumor types. The community of 
bladder cancer researchers has to invest in reaching out to the different policy makers 
and grant organizations to improve funding.
In conclusion, EGFR, FGFR3, VEGF, mTOR, STAT3, the AR and CD24 represent promising 
and validated targets for the inhibition of bladder cancer growth in animal studies. 
Treatment strategies that combine different modalities and/or targets seem to be most 
promising and clinical studies should continue to pursue these findings. Careful patient 
selection in these clinical studies will be essential in order to demonstrate true benefit. 
Many of the other targets that are under preclinical investigation still need further 
validation.
KEY POINTS
• Over the past 20 years, survival of patients with muscle-invasive bladder cancer has 
not improved
• None of the targeted therapies that are approved for other cancers have been 
approved for the treatment of bladder cancer
• The small number of clinical trials that have been performed in patients with 
bladder cancer had limited success owing to several limitations
• Specific oncogenic mutations in different cell lines used in in vivo research might 
render these cell lines insensitive to the therapy that is being investigated
• Inhibition of EGFR, FGFR3, VEGF, mTOR, STAT3, the AR and CD24 resulted in 
inhibition of tumor growth in multiple in vivo studies
• Careful patient selection in clinical trials based on the molecular profile of the 
tumor will be essential in demonstrating benefit of new targeted therapies
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REVIEW CRITERIA
The Embase, MEDLINE, OvidSP, Web of Science, PubMed publisher, Cochrane CENTRAL 
and Google Scholar databases were systematically searched (date of search: December 
2014). Full search strategy as was conducted in Embase : ('molecularly targeted 
therapy'/de OR 'molecular therapy'/exp OR (target* NEAR/3 (molecul* OR therap* OR 
antibod* OR inhibit* OR mirna* OR microrna* OR treat* OR intervent* OR chemo*)):ab,ti) 
AND ('bladder tumor'/exp OR 'transitional cell carcinoma'/de OR ('carcinoma'/de AND 
'bladder'/de) OR ((bladder OR urothel*) NEAR/3 (tumo* OR cancer* OR neoplas* OR 
carcin* OR metasta* OR transitional)):ab,ti) After the literature search was completed, 
all reviews, expert opinions, editorials, seminar articles, congress abstracts, articles 
published before 2009 and records in languages other than English or Dutch were 
excluded. In total, 93 published animal studies of targeting molecular targets in bladder 
cancer were eligible for review. 
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Supplementary table 1. Receptor tyrosine kinase and angiogenesis
Target N Intervention Conclusion Ref
EGFR 40 total 
heterotopic
PDT and/or intraperitoneal 
injection of monoclonal 
antibody (cetuximab)
Combination therapy gave best 
result: tumor growth inhibition, 
increased apoptosis
1
EGFR 18 total 
heterotopic
Intratumoral injection of 
adenoviral vector-mediated 
transfer of tumor suppressor 
gene LRIG1
Tumor growth inhibition by 
inhibition of cell proliferation 
and angiogenesis
2
EGFR 72 mice (144 
tumors) 
heterotopic
40 total 
orthotopic
Oral gavage of EGFR inhibitor 
(erlotinib) or vehicle
Heterotopic: tumor growth 
inhibition in three cell lines, one 
cell line was resistant and two 
insensitive
Orthotopic: delayed tumor 
detection by echography and 
prolonged survival
3
EGFR
VEGF
60 total 
heterotopic
PDT and/or intraperitoneal 
injection of VEGF monoclonal 
antibody (bevacizumab) and/
or EGFR monoclonal antibody 
(cetuximab)
Combined therapy (PDT + 
one or both antibodies was 
comparable): Tumor regression 
due to regression of tumor 
vessels
4
EGFR
ERBB2
40 total 
heterotopic 
(double-sided)
Oral EGFR and ERBB2 inhibitor 
(afatinib) and/or intraperitoneal 
injection of EGFR monoclonal 
antibody (cetuximab)
Combination therapy gave best 
result, tumor growth inhibition 
and overcome cetuximab 
resistance
5
ERBB2 Not available 
(heterotopic)
Gene gun delivered ERBB2 
DNA vaccine with or without 
intraperitoneal injection of Ling 
Zhi-8
Tumor growth inhibition and 
induction of immune responses
6
FGFR-3 Unknown total 
heterotopic
Oral selective FGFR inhibitor
(PD173074)
Tumor growth inhibition, 
apoptosis induction
7
FGFR-3 80 total 
heterotopic
Intraperitoneal injection of 
specific monoclonal antibody 
(R3Mab) or non-targeting human 
IgG
Tumor growth inhibition, 
promotes tumor cell lysis
8
FGFR-3 128 total 
orthotopic
Intraperitoneal injection of 
specific monoclonal antibody 
(R3Mab) or non-targeting human 
IgG
Antibody therapy gave dose 
dependent growth inhibition, 
reduced proliferation
9
FGFR-3 72 total 
heterotopic
Intraperitoneal injection of 
selective FGFR inhibitor
(PD173074)
Dose dependent tumor growth 
inhibition in SW780 xenografts, 
but not in J82 xenografts. 
FGFR3 fusion proteins enhance 
sensitivity to the inhibitor
10
FGFR-1
FGFR-3
48 total 
heterotopic
Intraperitoneal injection of 
selective FGFR inhibitor
(PD173074)
Delayed tumor growth, cell cycle 
arrest, no apoptosis
11
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Target N Intervention Conclusion Ref
FGFR-1 
FGFR-3
14 total 
orthotopic
Oral selective FGFR-1,2,3 
inhibitor
(BGJ-398)
No inhibitory effect on tumor 
growth, but blockage of tumor 
cell extravasation into the 
vasculature and metastasis
12
FGFR-3 
EGFR
Experiment 
1: 30 total 
heterotopic
Experiment 2: 
Not available
Experiment 1:
Intraperitoneal injection of FGFR 
inhibitor PD173074 and/or oral 
EGFR inhibitor gefitinib
Experiment 2:
Intraperitoneal injection of 
FGFR inhibitor PD173074 and/or 
cetuximab
Experiment 1: Combination 
therapy gave best result in 
tumor growth inhibition, but was 
poorly tolerated (weight loss)
Experiment 2: Combination 
therapy gave best result in tumor 
growth inhibition and was well 
tolerated.
On stopping treatment single-
treated resumed growth, 
combination-treated sustained 
tumor control
13
VEGFR Not available 
(metastatic)
Intraperitoneal injection of 
tyrosine kinase receptor inhibitor 
(sunitinib) and/or chemotherapy
(epirubicin)
Combined therapy: Marginal 
reduction of tumor burden
epirubicin alone gave best 
survival outcome
14
VEGF-A
VEGF-C
VEGFR-3
22 total 
heterotopic
Intratumoral injection of anti-
VEGF-A or anti-VEGF-C and anti-
VEGFR-3 siRNA
Tumor growth inhibition, 
reduced angiogenesis, lymph-
angiogenesis and metastasis
15
VEGF-C
VEGF-D
TAM
18 total 
orthotopic
Intravenous injection of 
adenoviral vector carrying 
extracellular domain of VEGFR-3 
or intraperitoneal injection of 
clodronate liposome
No influence on tumor growth, 
reduction of lymphatic vessels 
and lymphatic metastasis
16
VEGF
EphB4
32 total 
heterotopic
Intraperitoneal injection of 
EphB4 inhibitor (sEphB4-HAS) 
and/or VEGF monoclonal 
antibody (bevacizumab)
Combined therapy gave the 
best result, complete tumor 
regression
17
Flk-1 (= 
VEGFR-2) 
C3d3
48 total 
heterotopic
Intramuscular injection of DNA 
vaccine (recombinant plasmid 
encoding Flk-1 and C3d3 fusion 
proteins or plasmid encoding 
Flk-1 alone or control)
Best result with fusion protein 
DNA vaccine; Tumor growth 
inhibition, prolonged survival 
and decreased angiogenesis 
(vessel density)
18
ADM 48 total 
heterotopic
Intratumoral injection of AMD-
shRNA and/or intraperitoneal 
injection of cisplatin
Combined treatment gave best 
result in tumor growth inhibition
19
All compounds target the RAS-MAPK signaling pathway (figure 1). EGFR: epidermal growth factor receptor, PDT: 
photodynamic therapy, LRIG1: leucine-rich repeats and immunoglobin-like domains 1, VEGF(R): Vascular Endothelial 
Growth Factor (Receptor), ERBB2: V-ERB-B avian erythroblastic leukaemia viral oncogene homolog 2, Ling Zhi-8: fungal 
immunomodulatory protein, FGFR: fibroblast growth factor receptor, siRNA: small interfering RNA, TAM: tumor associated 
macrophages, EphB4: Ephrin type-B receptor 4, C3d3: a degradation product of the third complement component C3, 
ADM: adrenomedullin
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Supplementary table 2. Signal transduction
Target Pathway N Intervention Conclusion Ref
mTORC1 PI3K 37 total renal 
graft model
Knockdown of P53 and 
PTEN +
intraperitoneal injection 
of mTORC1 inhibitor 
(rapamycin) or control
Tumor growth inhibition 
and reduced cell 
proliferation
1
mTOR PI3K 40 total 
heterotopic
Intraperitoneal injection 
of mTOR inhibitor 
(rapamycin) and/or
chemotherapy (cisplatin)
Combined therapy gave 
best result: inhibited 
cell proliferation and 
enhanced effectiveness 
of cisplatin, prolonged 
survival
2
mTOR PI3K 40 total 
heterotopic
Intraperitoneal injection 
of mTOR inhibitor 
(rapamycin) and/or PI3K 
inhibitor (wortmannin)
In UM-UC3 xenografts, 
combined treatment 
inhibited tumor growth 
best. In UM-UC14 
xenografts, both 
therapies led to tumor 
growth inhibition, 
but combination of 
both therapies did not 
enhance this effect.
3
COX-2 PI3K 18 total 
heterotopic
Oral COX-2 inhibitors 
(celecoxib and/or 
indomethacin) and/or 
anti-COX-2-cDNA
Tumor growth inhibition 
(cDNA single effect, but 
stronger effect when 
combined with inhibitor)
4
STAT3
EGFR
Jak
Ras
34 total 
heterotopic
Intratumoral injection of 
STAT3 transcription factor 
decoy oligonucleotide 
and intraperitoneal 
injection of EGFR specific 
antibody (cetuximab)
Tumor growth inhibition 
and sensitization 
of resistant cells to 
cetuximab treatment
5
STAT3 
mTOR
MAPK
Jak
PI3K
Ras
Therapy 
cohort
24 total 
orthotopic
Survival cohort
60 total 
orthotopic 
transgenic
Intraperitoneal injection 
of mTOR inhibitor 
(rapamycin) and/or 
MAPK inhibitor (UO126) 
and/or STAT3 inhibitor 
(S31-201)
Best result with triple 
therapy, tumor growth 
inhibition and prolonged 
survival
6
STAT3
Survivin
Jak
Apoptosis
35 total 
heterotopic
Intratumoral injection of 
saline, culture medium, 
lipofectamine, vector 
control, STAT3-3 siRNA, 
Survivin-4 siRNA or 
STAT3-Survivin siRNA
STAT3 or Survivin 
silencing led to 
similar tumor growth 
inhibition, combining 
both treatments did not 
enhance this effect
7
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Target Pathway N Intervention Conclusion Ref
NF-κB NF-κB 40 total 
heterotopic
Intraperitoneal injection 
of NF-κB inhibitor 
(DHMEQ)
Tumor growth inhibition, 
reduction in microvessel 
density, reduction in 
VEGF expression and 
induction of apoptosis
8
NF-κB NF-κB 40 total 
heterotopic
Oral pathenolide 
analogue (DMAPT)
Dose dependent tumor 
growth inhibition
9
ILK PI3K
PPARγ
24 total 
heterotopic
Tumor cells transfected 
with a plasmid 
vector based siRNA 
to knockdown ILK 
were implanted 
heterotopically
Tumor growth inhibition, 
lower microvessel 
density and higher 
apoptosis rate
10
ILK PI3K
PPARγ
24 total 
heterotopic
Tumor cells transfected 
with a siRNA to 
knockdown ILK 
were implanted 
heterotopically
Tumor growth inhibition, 
reduced angiogenesis 
and inhibition of 
spontaneous metastasis
11
AR Jak
PI3K
Ras
18 total 
heterotopic
Intratumoral injection 
of siRNA and 
electroporation to silence 
AR
Tumor growth inhibition, 
decreased proliferation 
and increased apoptosis
12
AR Jak
PI3K
Ras
10 total 
heterotopic
Androgen deprivation 
(castration)
Tumor growth inhibition 
(not significant)
13
AR Jak
PI3K
Ras
18 total 
heterotopic
Electroporation with 
negative-siRNA or AR-
siRNA
Tumor growth 
inhibition and a reduced 
proliferation index
14
Jak2 Jak
Angiogenesis
15 total 
heterotopic
Intragastric injection of 
methylsulfonylmethane 
(MSM) or MSM combined 
with a Jak2 inhibitor 
(AG490)
Combined treatment 
gave best result; tumor 
growth inhibition, 
increased necrosis and 
reduced metastatic load
15
Hsp70-2 12 total 
heterotopic
Intratumoral injection of  
HSP70-2 shRNA to 
knockdown  
HSP70-2
Tumor growth inhibition 16
Hsp-90
FGFR-3
Ras 32 total 
heterotopic
Intravenous injection 
of HSP90 inhibitor 
(ganetespib) and/or oral 
FGFR inhibitor (BGJ398)
Both treatments 
inhibited tumor growth 
similarly, combining 
treatment enhanced this 
effect.
17
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Target Pathway N Intervention Conclusion Ref
DEPDC1-
ZNF224 
complex
15 total 
heterotopic
Intratumoural injection 
of cell permeable 
peptide corresponding 
to the ZNF224-
interacting domain in 
DEPDC1
Complex formation 
inhibition, tumor growth 
inhibition and increased 
apoptosis
18
Src Ras Unknown 
total 
heterotopic
Oral multi-targeted 
kinase inhibitor 
(dasatinib) and/or 
intraperitoneal injection 
of chemotherapy 
(cisplatin)
Combination therapy 
gave best result; Tumor 
growth inhibition, 
proliferation inhibition 
and increased apoptosis
19
PLCε Ras 15 total 
heterotopic
Tumor cells transfected 
with shRNA to silence 
PLCε were implanted 
heterotopically
Tumor growth inhibition 20
CXCR4 18 total 
BNN-induced 
orthotopic
Subcutaneous injection 
of CXCR4 agonist 
(TF14016)
Lower BC prevalence. 
Therapeutic effect not 
clarified
21
ALB1 16 total 
heterotopic
Intratumoral injection 
of  vehicle delivered 
siRNA or siRNA alone to 
knockdown ALB1
Tumor growth inhibition.
Down regulation of PI3K-
Akt pathway
22
NO 32 total 
heterotopic + 
orthotopic
20 total 
metastatic
No treatment vs  NO 
synthase inhibitor 
L-NAME in drinking water
Tumor growth inhibition 
in both heterotopic 
and orthotopic mouse 
models. Reduced 
angiogenesis and 
metastasis.
23
RHAMM 12 total 
heterotopic
Xenografted with BC cells 
with or without prior 
lentiviral knockdown of 
RHAMM
Reduced tumor 
growth and decreased 
proliferation
24
HDAC-1 Transcription
105 total 
BNN-induced 
orthotopic
Intraperitoneal histone 
deacetylase inhibitor 
(valproic acid)
Delayed incidence of 
bladder tumors when 
given as prevention, no 
therapeutic effect
25
mTOR: mammalian target of rapamycin, COX-2: cyclooxygenase-2, STAT3: signal transducer and activator of transcription 
3, MAPK: mitogen-activated protein kinase, NF-κB: nuclear factor-κB, ILK: integrin-linked kinase, AR: androgen receptor, 
siRNA: small interfering RNA, Hsp70/90: heat shock protein 70/90, DEPDC1: DEP domain containing 1 gene, ZNF224: 
zinc finger transcription factor 224, Src: tyrosine kinase Src (pronounced “sarc”), PLCε: phospholipase C ε, CXRC4: C-X-C 
chemokine receptor 4,  ALB1: amplified in breast cancer 1, NO: Nitric Oxid, RHAMM:  Receptor of Hyaluronan-Mediated 
Motility, HDAC-1: histone deacetylase type 1
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Supplementary table 3. Cell cycle, apoptosis, translation and metabolism
Target Pathway N Intervention Conclusion Ref
Livin Apoptosis Not 
available 
heterotopic
Intratumoral injection of 
Livin antisense (ASODN) 
oligonucleotides or Livin 
missence oligonucleotides 
(MSODN)
Tumor growth 
inhibition and 
increased apoptosis
1
AATBC Apoptosis 8 total 
heterotopic
Tumour cells with lentiviral-
mediated AATBC knockdown 
were implanted heterotopically
Tumor growth 
inhibition
2
miRNA-
449a
Cell cycle 8 total 
heterotopic
Intratumoral injection of 
liposome-encapsulated 
miRNA-449a
Tumor growth 
inhibition due to 
cell cycle arrest and 
cell proliferation 
suppression
3
Chk1 Cell cycle 28 total 
heterotopic
Intraperitoneal injection of 
chemotherapy (gemcitabine) 
and/or Chk1 inhibitor 
(PF477736)
Tumor growth 
inhibition, combined 
therapy gave best 
result
4
P53 P53 84 total 
orthotopic 
transgenic
Oral P53-stabilizing agent 
CP-31398
Tumor growth 
inhibition, tumor 
invasion inhibition, 
increased apoptosis
5
GLIPR1 P53 Unknown 
total 
heterotopic
Intratumoral injection of 
adenoviral vector-mediated 
GLIPR1 gene therapy and/or 
radiotherapy
Combination therapy 
gave best results; tumor 
growth inhibition and 
prolonged survival
6
Bcl-xL NF-κB 16 total 
heterotopic
Intraperitoneal injection of a 
specific Bcl-xL inhibitor  
(bafilomycin A1)
Tumor growth 
inhibition and 
increased apoptosis
7
Aurora 
kinase A
Cell cycle 16 total 
heterotopic 
(double-
sided)
Oral selective Aurora kinase 
A inhibitor (MLN8237 = 
millennium)
Tumor growth 
arrest and reduced 
proliferation index
8
PIM 
kinase
Cell cycle
Apoptosis
Translation
24 total 
heterotopic
Oral PIM kinase inhibitor TP-
3654 or vehicle
Tumor growth 
inhibition
9
eEF2 Translation 24 total 
heterotopic
16 total 
orthotopic
Intratumoral injection or 
intravesical instillation with 
a double promotor DTA 
expressing vector (H19-DTA-
P4-DTA)
Tumor growth 
inhibition in both 
tumor models
10
eEF2 Translation 24 total 
heterotopic
16 total 
orthotopic
Intratumoural injection or 
intravesical instillation with 
a double promotor DTA 
expressing vector (P4-DTA-P3-
DTA, DTA = diphtheria toxin A 
fragment)
Tumor growth 
inhibition in both 
tumor models
11
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Target Pathway N Intervention Conclusion Ref
Ribosome Translation 10 total 
heterotopic
Intravenous injection of anti-
Fn14 monoclonal antibody 
conjugated to recombinant 
gelonin (rGel)
Tumor growth 
inhibition, increased 
apoptosis
12
eIF3b Translation 10 total 
heterotopic
20 total 
metastatic
Transfection with siRNA to 
deplete eIF3b, injection of 
transfected tumor cells
Fewer tumors, tumor 
growth inhibition, 
reduced lung 
colonization
13
Arginine
Folate
Urea cycle 44 total 
heterotopic
Intraperitoneal injection of 
ADI-PEG20 and/or
Pemetrexed (PEM)
PEM alone had no 
effect. ADI-PEG20 
treatment resulted in 
reduced tumor growth. 
Combining ADI-PEG20 
with PEM increased this 
effect.
14
ChoKα Phosphoryl-
choline 
metabolism
40 total 
heterotopic
37 total 
orthotopic
Intraperitoneal injection of 
a specific ChoKα inhibitor 
(MN58b)
Tumor growth 
inhibition and 
prolonged survival
15
PDHK1
ATP 
citrate 
lyase
IGF1 
IGFBP
Glucose 
metabolism
30 total 
heterotopic
Intraperitoneal injection of 
hydroxycitrate (HCA) and/
or α-lipoic acid (ALA) and/
or octreotide (OCT) vs 
chemotherapy (cisplatin)
Combination of 
three drugs gave 
best results, tumor 
growth inhibition and 
prolonged survival
16
PDHK1 
ATP 
citrate 
lyase
Glucose 
metabolism
36 total 
heterotopic
Intraperitoneal injection of 
hydroxycitrate (HCA) and/
or α-lipoic acid (ALA) and/or 
chemotherapy (cisplatin) 
Combination of three 
drugs gave best 
results, tumor growth 
inhibition (NS) and 
prolonged survival
17
SRC-3 Glycolysis 14 total 
heterotopic
Tumor cells transfected with or 
without shRNA to silence SRC-3 
were implanted heterotopically 
Tumor growth 
inhibition in SRC-3 
knockdown tumors
18
SCD1 Fatty acid 
metabolism
76 total 
heterotopic
Doxycycline-inducible 
knockdown of SCD1 or
oral SCD1 small molecule 
inhibitor (A37062)
Tumor growth 
inhibition, increased 
apoptosis
19
Livin: inhibitor of apoptosis protein (IAP family), AATCB: Apoptosis-Associated Transcript in Bladder Cancer, Chk1: Checkpoint 
kinase 1, GLIPR1: glioma pathogenesis-related protein 1,  Bcl-xl: B-cell lymphoma-extra-large, PIM kinase: proviral intergration 
site for moloney murime leukemia virus kinase, eEF2: elongation factor-2, DTA: diphtheria toxin A fragment, eIF3b: eukaryotic 
initiation factor 3b, ChoKα: choline kinase-α, PDHK1: pyruvate dehydrogenase kinase 1, ATP: adenosine triphosphate, IGF1: 
insulin growth factor 1, IGFBP: insulin growth factor binding protein, SRC-3: Steroid receptor coactivator-3, SCD1: stearoyl 
CoA desaturase 1
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Supplementary table 4. Metastasis, immune system and miscellaneous
Target
Process or 
pathway N Intervention Conclusion Ref
CD24 Metastasis 16 total 
heterotopic
44 total 
metastatic
Intravenous CD-24 
monoclonal antibody 
(ALB9)
Tumor growth inhibition, 
reduction of metastatic 
load and prolonged 
survival
1
CD24
HIF-1α
Metastasis
Angiogenesis
40 total 
heterotopic
32 total 
metastatic
Tumor cells transfected 
with shRNA to silence 
CD24 or HIF-1α 
were implanted 
heterotopically + 
intravenously injected 
(metastatic model)
Tumor growth inhibition 
and reduction in 
metastasis (CD24 
downstream of HIF-1α)
2
CD24 
AR
Metastasis
Jak
PI3K
Ras
190 total 
orthotopic
20 total 
heterotopic
CD24 knockout mice or 
androgen deprivation 
(castration)
Less tumor development 
(CD24 knockout), tumor 
growth inhibition 
(castration)
3
Integrin 
α3β1
Metastasis 30 total
heterotopic
72 total
orthotopic
Heterotopic (orthotopic): 
Intraperitoneal injection 
(intravesical instillation) 
of monoclonal integrin 
α3β1 antibody 
(BCMab1) or monoclonal 
integrin α3β1 antibody 
conjugated with 
immunotoxin Ra 
(BCMab1-Ra) or mIgG
BCMab1 led to tumor 
growth inhibition, 
BCMab1-Ra led to 
complete tumor 
regression
4
Integrin 
αv
Metastasis 20 total 
intraosseous 
metastatic 
40 total 
intracardiac 
metastatic 
Intraosseous inoculation 
of either UMUC3 cells 
or UMUC3 integrin αv 
knockdown cells
Preventive protocol: 
daily intraperitoneal 
injections of either vector 
or GLPG187 during 28 
days, after 1 day a single 
intracardiac inoculation 
of UMUC3 cells
Curative protocol: 
inoculation of UMUC3 
cells 3 weeks prior to 
daily intraperitoneal 
injection of either vector 
or GLPG187 during 15 
days
Intraosseous inoculation 
of  Integrin αv knockdown 
led to lower bone and 
total tumor burden (NS)
Preventive protocol: 
significantly decreased 
number of metastasis and 
total tumor burden
Curative protocol: No 
significant effects
5
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Target
Process or 
pathway N Intervention Conclusion Ref
TM
NF-κB
Metastasis 40 total 
orthotopic
40 total 
heterotopic
Tumor cells transfected 
with or without shRNA to 
silence TM were instilled 
intravesically
Tumor cells transfected 
with or without shRNA to 
silence TM were instilled 
intravesically and treated 
with intraperitoneal 
injection of NF-κB 
inhibitor CAPE
Tumor cells transfected 
with or without shRNA to 
silence TM were injected 
heterotopically
Tumor cells transfected 
with or without shRNA 
to silence TM were 
injected heterotopically 
and treated with 
intraperitoneal injection 
of NF-κB inhibitor CAPE
Orthotopic: TM silencing 
led to a higher tumor take 
and larger tumor size, 
CAPE treatment reduced 
tumor development
Heterotopic: TM silencing 
resulted increased tumor 
growth, CAPE treatment 
significantly reduced 
tumor growth
6
IL-12 Immune 
system
40 total 
heterotopic
Intraperitoneal injection 
of IL-12 gene plasmid 
and/or chemotherapy 
(pirarubicin = THP)
Best result with combined 
treatment, tumor growth 
inhibition
7
CD40 
ligand
Immune 
system
30 total 
heterotopic
Intratumoral (it) or 
intravenous (iv) injection 
of either vvdd or vvdd-
hCD40L
Tumor growth inhibition 
of both viruses, increased 
anti-tumor activity by 
CD40 expressing virus via 
intratumoral injection, 
no difference between 
viruses via intravenous 
injection.
8
T cells Immune 
system
16 total 
heterotopic
Intratumoral injection of 
an oncolytic adenovirus 
(PPE3-SEA)
Tumor growth inhibition, 
increased presence of 
infiltrating CD3+ T cells
9
TRIAL Immune 
system
32 total 
heterotopic
Intratumoral injection 
of oncolytic adenovirus 
encoding TRAIL 
(ZD55-TRAIL) and/
or chemotherapy 
(gemcitabine)
Combined therapy gave 
best result, increased 
tumor growth reduction 
and increased apoptosis
10
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Target
Process or 
pathway N Intervention Conclusion Ref
uPA Extracellular 
matrix
30 total 
orthotopic
Intravesical PAI-1 Tumor growth inhibition, 
reduced invasion 
depth and decreased 
angiogenesis (less 
microvessels)
11
PAI-1 Extracellular 
matrix
30 total 
heterotopic
Oral gavage of small 
molecule inhibitor 
tiplaxtinin or vehicle
Treatment with tiplaxtinin 
resulted in tumor growth 
inhibition, angiogenesis 
inhibition, reduced 
proliferation index and 
increased apoptosis 
(no major differences 
between dosage)
12
PSCA Cell signaling Unknown 
total 
heterotopic
Doxycycline regulated 
shRNA against PSCA, 
mice were fed sucrose 
plus doxycycline
Tumor growth inhibition 13
Malat 1
Suz 12
TGF-β 9 total 
metastatic 
27 total 
heterotopic
Injected or xenografted 
with BC cells with or 
without prior knockdown 
of Malat1 or Suz12
Malat1 and Suz12 
inhibition led to a lower 
metastatic load then in 
controls (less metastasis 
and smaller metastasis, 
both gave comparable 
effects) 
14
Versican
CCL2
CCR2
Extracellular 
matrix
Immune 
system
80 total 
metastatic
Intravenous injection of 
tumor cells transfected 
with a siRNA against 
Versican.
CCL2/CCR2 knockout 
mouse or intraperitoneal 
injection of CCL2 
antibody
Reduced metastatic load 
(in both experiments)
15
IDO Immune 
system
Not 
available 
heterotopic
Skin delivery of 
IDO-specific siRNA to 
dendritic cells
Tumor growth inhibition 
and prolonged survival
16
IgG Immune 
system
25 total 
heterotopic
Intratumoral injection 
of polyclonal 
antihuman goat IgG 
antibody with/without 
intraperitoneal injection 
of chemotherapy 
(mitomycin C = MMC)
Combination therapy 
gave best result, tumor 
growth inhibition and 
increased apoptosis.
17
Unknown Unknown 
total 
orthotopic 
rat
Oral Allyl isothiocyanate 
(AITC)-rich mustard seed 
powder (MSP-1)
Tumor growth inhibition 
and inhibition of muscle 
invasion
18
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Target
Process or 
pathway N Intervention Conclusion Ref
Unknown 38 total 
orthotopic 
rat
Oral N-acetylcysteine 
conjugate NAC-AITC
Tumor growth inhibition 
and inhibition of muscle 
invasion
19
Cells 
without 
P53 and 
Rb
30 total 
orthotopic
Single intravesical 
instillation of an 
oncolytic adenovirus; 
AxCAZ3-F/RGD, 
AxdAdB-3 or AxdAdB3-F/
RGD 
AxdAdB3-F/RGD gave 
best result in tumor 
growth suppression, 
bladder weight reduction 
and survival
20
CD24: cluster of differentiation 24, HIF-1α: hypoxia inducible factor - 1α, AR: androgen receptor, BNN: N-butyl-N-(4—
hydroxybutyl)-nitrosamine, TM: thrombomedulin, CAPE: caffeic acid phenethyl ester, IL-12/24: interleukin 12/24, TRIAL: 
tumor necrosis factor (TNF)-related apoptosis-inducing ligand, uPA: urinary plasminogen activator, PAI-1: plasminogen 
activator inhibitor -1, PSCA: prostate stem cell antigen, Malat1: metastasis associated lung adenocarcinoma transcript 1, 
Suz1: suppressor of zeste 12 homolog (Drosophila), CCL2: CC chemokine ligand 2, CCR2: CC chemokine receptor 2, siRNA: 
small interfering RNA, IDO: indoleamine 2,3-dioxygenase
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Supplementary table 5. Studies using KU-7 animal models
Target Pathway
Biological 
mechanism N Intervention Conclusion Ref
EGFR
PPARγ
RAS RTK 40 total 
heterotopic
Oral EGFR 
inhibitor 
(gefitinib) and/
or PPARγ agonist 
(DIM-C)
Growth 
inhibition, 
combination 
therapy can 
overcome 
EGFR therapy 
resistance
1
Met-AP2 RAS RTK 11 total 
orthotopic
Oral Met-
AP2 inhibitor 
(nitroxoline)
Tumor growth 
inhibition
2
COX-2
CK2α
PI3K Signal 
transduction
12 total 
orthotopic
Oral COX-
2 inhibitor 
(meloxicam)
Tumor growth 
inhibition 
and reduced 
invasion depth
3
Hsp27
tubulin
Signal 
transduction
28 total 
orthotopic
Intravesical 
antisense 
oligonucleotides 
targeting Hsp27 
(OGX427) and/
or intravesical 
hemiasterlin 
synthetic 
analogue (HTI-
286)
Combination 
therapy 
inhibited tumor 
growth
4
NGFI-Bα Signal 
transduction
10 total 
heterotopic
Oral activator of 
NGFI-Bα  
(DIM-C-
pPhOCH3)
Tumor growth 
inhibition and 
induction of 
apoptosis
5
c-MYC Ras
Wnt
Signal 
transduction
10 total 
orthotopic
Intravesical 
administration 
of c-MYC small 
molecule 
inhibitor (KSI-
3716) or control
Tumor growth 
inhibition
6
Eg5 Cell cylce Cell cycle and 
apoptosis
40 total 
heterotopic
N metastatic 
model not 
available
Intraperitoneal 
injection of 
Eg5 inhibitors 
(KPYC10728, 
S(MeO)TLC and 
STLC)
S(MeO)TLC 
(high dose) 
performed best; 
tumor growth 
inhibition. 
Prolonged 
survival and 
metastasis 
regression in 
the metastatic 
model
7
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Target Pathway
Biological 
mechanism N Intervention Conclusion Ref
Survivin
PLK1
Apoptosis Cell cycle and 
apoptosis
16 total 
orthotopic
Intravesical 
instillation of 
siRNA to silence 
survivin and 
PLK1
Tumor growth 
inhibition
(PLK1 siRNA > 
survivin siRNA)
8
Survivin Apoptosis Cell cycle and 
apoptosis
12 total 
orthotopic
Intravesical 
instillation 
of oncolytic 
adenovirus 
adenovirus 
using the 
surviving 
promoter 
(Ad5E1-
apsurvivinE4) or 
vehicle
Tumor growth 
inhibition
9
Syndecan-1 Adhesion, 
cytoskeletal 
organization, 
cell-matrix 
interactions 
and others
Miscellaneous 19 total 
orthotopic
Intravesical 
siRNA to silence  
Syndecan-1 
(CD138)
Tumor growth 
inhibition 
and increased 
apoptosis
10
EGFR: epidermal growth factor receptor, PPARγ: peroxisome proliferator-activated receptor gamma, Met-AP2: type 2 
methionine aminopeptidase, COX-2: cyclooxygenase-2, CK2α: casein kinase 2α, Hsp27: heat shock protein 27, NGFI-Bα: 
nerve growth factor-induced Bα, c-MYC: transcription factor c-MYC, Eg5: kinesin-related motor protein EG5 (also known as 
kinesin family member 11 or kinesin-like protein KIF11), Survivin: inhibitor of apoptosis protein (IAP family), siRNA: small 
interfering RNA, PLK1: polo-like kinase 1
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ABSTRACT
Purpose. We determined whether FGFR3 mutation analysis of voided urine samples 
would be cost-effective to partly replace cystoscopy in the surveillance of patients 
treated for non muscle invasive urothelial carcinoma.
Materials and methods. In this decision analytical study we analyzed data on 70 
Dutch patients with FGFR3 positive primary tumors and a median follow-up of 8.8 
years. Surveillance strategies were compared in a Markov model. Modified surveillance 
consisted of FGFR3 mutation analysis of voided urine samples every 3 months, and 
cystoscopy at 3, 12 and 24 months. Standard surveillance was defined as cystoscopy 
every 3 months and minimal surveillance was defined as cystoscopy at 3, 12 and 24 
months. Analysis was stratified for 3 risk profiles, including surveillance after 1) the 
primary tumor, 2) the first to third recurrence and 3) the fourth recurrence or more. 
Sensitivity analysis was performed to evaluate the impact of variations in cost, sensitivity 
and specificity.
Results. The probability of no recurrence after 2 years of surveillance after a primary 
tumor was higher for modified surveillance than for standard and minimal surveillance, 
e.g. after primary tumors (95.7% vs 95.0% and 93.9%, respectively). The total cost of 
surveillance after the primary tumor was lower for minimal and modified surveillance 
(€2,254 and €2,558, respectively) than for standard surveillance (€5,861). Results were 
robust to changing inputs over plausible ranges and consistent for each of the 3 risk 
profiles.
Conclusions. Surveillance in which cystoscopy is partly replaced by FGFR3 mutation 
analysis of urine seems a safe, effective and cost-effective surveillance strategy. Further 
validation in larger cohorts is required.
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INTRODUCTION
Although the 5-year survival rate of NMIBC is high at 80% to 90%,1 surveillance for 
recurrent disease places a major burden on patients and the health care system in 
general. More than half of these patients have 1 or more recurrences and must be 
monitored for the rest of their lives to detect recurrence and progression to muscle 
invasive cancer (10% to 20%).2 Progressive disease leads to bladder loss via cystectomy 
and possibly to death. Therefore, an intensive surveillance protocol is generally followed.
Surveillance relies on regular cystoscopy, which is an invasive procedure associated with 
anxiety, dysuria, urinary tract infection and financial costs.3– 6 Moreover, cystoscopy can 
only detect recurrence inside the bladder and not in the renal pelvis or ureters, where 
these UCs may also recur. Thus, the diagnosis of such upper urinary tract recurrences 
may be delayed since they are only detected if symptoms occur. Therefore, substantial 
efforts have been made to design surveillance strategies that could decrease the 
frequency of cystoscopy in patients with NMIBC without compromising early detection. 
Approximately two-thirds of NMIBCs are FGFR3 mutant. These mutant tumors grow 
less aggressively and only few progress to muscle invasive disease.7–10 A decrease 
in cystoscopy frequency in these patients is an attractive option with cystoscopy 
replaced by FGFR3 mutation analysis of voided urine samples. We determined the cost-
effectiveness and safety of such a surveillance strategy compared to those of standard 
surveillance and a minimal surveillance variant.
MATERIALS AND METHODS
Patient data
We studied a consecutive series of 70 patients with primary nonmuscle invasive UC 
(pTa or pT1) treated at our medical center in The Netherlands, as previously described 
in detail.11 All patients had a FGFR3 positive primary tumor and were retrospectively 
examined for recurrence and progression between 1983 and 2007 (see table 1). 
Recurrence was defined as a tumor removed at TUR with histopathological confirmation 
and without muscle invasion. Progression was defined as muscle invasive UC, i.e. pT2 
or greater. All tumors were staged and graded according to the 1997 TNM12 and 1973 
WHO13 classifications.
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Table 1. Characteristics of 70 patients
No. gender (%)
 Male 46  (65.7)
 Female 24  (34.3)
Median age at primary tumor (range) 66  (32–84)
No. primary tumor stage (%)
 Ta 61  (87.1)
 T1 9  (12.9)
No. primary tumor grade (%)
 G1 36  (51.4)
 G2 30  (42.9)
 G3 4  (5.7)
No. CIS (%)
 Yes 2  (2.9)
 No 68  (97.1)
Median months follow-up (range) 106.1  (42.7–270.9)
Recurrence
 No. 207
 No. pts without (%) 19  (27.1)
 No. pts with (%) 51  (72.9)
 Median No./pt (range) 3  (1–18)
No. progression 4
No. death (%)
 Yes 21  (30)
 No 49  (70)
 Disease 8  (11.4)
 Other cause 13  (18.6)
No. cystectomy (%)
 Yes 4  (5.7)
 No 66  (94.3)
Decision model
We adapted a Markov decision model from a previously published model used to 
evaluate the cost-effectiveness of partly replacing cystoscopy by microsatellite analysis 
in the follow-up of patients with NMIBC.14 Patients started in the well health state and 
eventually died (dead state). Other states related to recurrence and progression in the 
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bladder or UUT (fig. 1). The Markov model had a time horizon of 2 years with 3 monthly 
cycles. Patients were modeled by tumor, that is for each detected recurrence a new 
surveillance course began. Markov cohort analysis of 1,000 cases was performed to 
compare the surveillance strategies.
Model outcomes included the fraction of patients per health state, including a well state 
for those without recurrence, progression or a bladder, and cumulative financial costs 
for up to 2 years.
Surveillance strategies
We modeled 3 strategies (fig 2). 1) A standard surveillance arm included cystoscopy 
every 3 months. 2) A minimal surveillance arm was defined as a lower end reference and 
included cystoscopy at 3, 12 and 24 months. 3) A modified surveillance arm consisted of 
FGFR3 mutation analysis of voided urine samples every 3 months. Follow-up cystoscopy 
was scheduled at 3, 12 and 24 months. Additional cystoscopy was performed when 
FGFR3 mutation analysis had a positive outcome.
If recurrence was found at cystoscopy, it was assumed to be removed by TUR. This 
patient then restarted surveillance. In cases of progression to muscle invasive bladder 
cancer, the bladder was removed via cystectomy. If the outcome of FGFR3 mutation 
analysis was positive but follow-up cystoscopy remained negative for 2 subsequent 
visits, CT of the abdomen was performed to rule out any UUT recurrence. When a UUT 
tumor was detected, unilateral nephroureterectomy was performed.
Transition probabilities and cost data
We determined the 3-month probability of recurrence and progression using data on 
70 patients in a Dutch cohort by Cox proportional hazards regression analysis with 
SPSS®, version 15. We analyzed 207 recurrences and 4 progressions that occurred 
during a median follow-up of 8.8 years. The 3-month probability of progression was 
subsequently estimated, conditional on recurrence. Three sets of transition probabilities 
for recurrence and progression were analyzed, i.e. after 1) the primary tumor, 2) the first 
to third recurrence and 3) the fourth recurrence or more. 
Sensitivity and specificity of the included tests were obtained from the literature, as 
were all remaining transition probabilities (supplementary table 1.1,14,15 The specificity of 
FGFR3 mutation analysis was set at 100% because mutations do not occur in the urine 
samples of nonpatients.
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Cost data were based on Dutch sources (supplementary table 1). Costs were determined 
using the micro-costing method using detailed hospital sources.16 These bottom-up 
cost analyses included the costs of employment, material, equipment and overhead. 
For FGFR3 mutation analysis we assumed that the assays were done in a volume of 48 
analyses at the same time. The cost of the FGFR3 tissue test on the primary tumor was 
included in the model. This test was done once in all patients in the modified surveillance 
arm (supplementary tables 1 and 2).
Model assumptions
We made certain structural model assumptions. 1) Only 1 recurrence developed per 
surveillance cycle. 2) Progression occurred after recurrence. 3) Only patients with tumor 
progression at a certain moment were at higher risk for death than the background 
mortality rate. 4) Cystoscopy never revealed recurrence or progression that originated 
in the UUT and invaded the bladder. 5) In case of progression to muscle invasive UC, 
the next step was cystectomy. 6) After cystectomy, surveillance stopped. 7) In case 
of positive CT of the abdomen, the next step was nephroureterectomy. 8) CT of the 
abdomen had 100% specificity and false-positive results were not possible. 9) The 
health state recurrence in the UUT after nephroureterectomy did not exist, preventing a 
second possible nephroureterectomy in the model.
Sensitivity analysis
One-way sensitivity analyses were performed to evaluate the effect of varying costs, 
sensitivity and specificity of the FGFR3 mutation test and cystoscopy. Cost estimates were 
halved or doubled, and FGFR3 mutation test and cystoscopy sensitivity and specificity 
were increased and decreased based on the literature to determine a plausible range 
(supplementary table 1).1,9,14,15,17,18 
RESULTS
Input data
The 3-month risk of recurrence during the first 2 years of surveillance ranged from 1% to 
3% after a primary tumor (supplementary table 3Patients at risk after a fourth recurrence 
were at 2.5 times higher 3-month risk (supplementary table 3). The risk of progression 
was substantially lower, e.g. less than 0.3% per 3 months, after the primary tumor.
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Surveillance strategy comparison
After a primary tumor and 2 years of modified surveillance, 95.7% of patients were 
expected to be in the well state. This fraction was lower after 1 to 3 and 4 or more 
recurrences (95% and 93.6%, respectively). Standard and minimal surveillance led 
to lower results in 95% and 93.9% of patients, respectively, in the well state and on 
surveillance after a primary tumor (supplementary table 4The expected mortality rate 
was less than 3% for any strategy in each risk group, reflecting death from nonbladder 
cancer causes.
Minimal surveillance after the primary tumor led to more patients in the recurrence health 
state (bladder plus UUT) than standard or modified surveillance (3.1% vs 2.0% and 1.3%, 
respectively) and only 0.01% to 0.02% in the progression state (supplementary table 
4The probability of achieving the no bladder health state (cystectomy after progression) 
was higher for modified and minimal surveillance (minimal 0.06% to 0.34%, standard 
0.04% to 0.22% and modified 0.05% to 0.29%). Standard surveillance led to a slightly 
better detection rate of bladder recurrence during 2 years. However, with modified 
surveillance UUT recurrences were also detected that would have been missed by 
minimal or standard surveillance (UUT recurrence health state, supplementary table 4).
Costs
The cumulative diagnostic plus therapeutic costs during 2 years of surveillance were 
lowest for minimal surveillance after the primary tumor (€2,254) or after recurrences 1 
to 3 and 4 (€2,287 and €2,363, respectively, supplementary tables 1 and 2). The costs of 
modified surveillance were similar. Therapeutic costs were higher than diagnostic costs 
for all surveillance strategies and all 3 risk profiles (supplementary table 2).
Surveillance burden
An average of almost 8 cystoscopies per patient was expected on standard surveillance, 
in contrast to approximately 3 and 4 for minimal and modified surveillance, respectively 
(supplementary table 5). For modified surveillance this would be an average of 1 
cystoscopy in addition to the planned control cystoscopies at 3, 12 and 24 months. 
Patients in the modified surveillance arm would undergo almost another 8 urine tests.
Sensitivity analysis
Changing the model parameter values over plausible ranges did not make modified 
surveillance less effective than standard or minimal surveillance. The difference in the 
percentage of patients ending in the well health state after 2 years of surveillance varied 
from 0.14% to 3.0% for modified and standard surveillance, and from 0.84% to 8.1% 
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for modified and minimal surveillance, respectively. Differences in cumulative costs 
between standard and modified surveillance varied from €1,440 to €5,458 during 2 years 
of surveillance and from €217 to €1,345 between modified and minimal surveillance 
(data not shown).
DISCUSSION
The modified surveillance strategy showed promising results for FGFR3 positive UC, 
in which cystoscopy is partly replaced by the FGFR3 mutation test in voided urine. 
We considered 3 risk profiles, including surveillance after the primary tumor, after the 
first to third recurrence and after the fourth or higher recurrence. The effectiveness 
of modified surveillance was similar to that of standard surveillance and greater than 
the effectiveness of minimal surveillance. The costs of modified surveillance were 
substantially lower than those of standard surveillance and similar to those of minimal 
surveillance.
Studies have shown good potential for urine marker tests during surveillance for 
NMIBC.19,20 However, those groups looked at urine tests in general. Many marker tests 
have been developed for this purpose.21 We specifically tested the potential of the FGFR3 
urine test.
We previously found that cross-sectional sensitivity of the FGFR3 test was 58% using 
cystoscopy as the gold standard.1 This relatively low sensitivity may possibly be explained 
by the imperfect sensitivity of cystoscopy. Urine markers may detect recurrence 
earlier than cystoscopy.1 In addition, awareness of a positive urine test significantly 
improves the recurrence detection rate using cystoscopy.22 This anticipatory effect 
was not included in the current model. Consequently, a combination of urine tests 
and subsequent cystoscopy, as represented by modified surveillance, may significantly 
improve recurrence detection. It may even lead to stage regression when recurrence is 
detected earlier, as observed for hexaminolevulinate cystoscopy.23
A strength of our study was the relatively long follow-up of the patients enrolled, which 
was needed to reliably estimate the transition probabilities of the different risk profiles. 
Long follow-up is especially needed to detect some progressions since the progression 
rate is low in FGFR3 positive cases. This explains why simply decreasing the number of 
cystoscopies, as in the minimal surveillance strategy, had only minor implications for 
overall effectiveness. However, decreasing cystoscopies and partly replacing them with 
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urine tests has a benefit in effectiveness. It also results in a substantial cost reduction 
compared to standard surveillance and has only a slightly higher cost than minimal 
surveillance. 
We counted the average number of tests that would be performed per patient as 
the burden of a surveillance strategy. The burden of cystoscopy is mainly discomfort 
from introducing the scope. The burden of the urine test is mainly the time spent 
waiting for results.4,21 In the modified surveillance strategy we halved the number of 
cystoscopies but increased the total number of tests performed. How-ever, since we 
consider cystoscopy a safety net, it is still required in a modified surveillance strategy 
using FGFR3 mutation analysis. Perhaps logistics and patient perception of urine tests 
can be improved, such that the burden of waiting time for test results can be decreased.
A number of limitations must be considered. Transition rates were based on relatively 
few patients and events, and on retrospective data. How-ever, others have confirmed 
the low recurrence and progression rates.7,8
We only modeled 2 years of follow-up, while surveillance may be required for the entire 
patient life-time. A longer time horizon might provide a stronger comparison among 
alternative strategies.
We also only modeled a limited number of potential surveillance strategies. Alternative 
strategies may consider whether a tumor recurs in the first year of surveillance. If not, it 
might be reasonable to reduce the intensity of surveillance in such patients. In that way 
the first year of surveillance would act as a stratification year to an adjusted surveillance 
strategy per patient.
Although false-positive results of FGFR3 analysis are highly unlikely, the assumption 
of 100% specificity of the test may be an overestimation. Theoretically, false-positive 
findings may occur due to laboratory contamination.
We calculated the costs of FGFR3 analysis based on an efficient practice of genetic 
testing in a non-profit laboratory in Europe. Commercial testing may be done at quite 
higher prices. Also, FGFR3 tissue analysis of all primary tumors implies an increase of 
approximately €14 for all patients with NMIBC.
We analyzed only 1 specific urine test. Other tests have been developed, e.g. microsatellite 
analysis, ImmunoCyt™, CYFRA 21.1, cytokeratin 20 and UroVysion®.21 A combination of 
different tests might show even more potential.
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Modeling implies a simplification of clinical practice and the natural disease course. The 
assumptions made to make modeling possible are themselves a limitation. However, 
this study is meant as guidance for further clinical research.
Overall, our study shows the promising possibilities of urine tests in the surveillance of 
patients treated for NMIBC. FGFR3 positive tumors are exemplary for the detection of 
tumor specific markers in voided urine samples. Further research is needed to continue 
the development of urine tests that perform well, especially for more aggressive tumor 
types.
CONCLUSIONS
For FGFR3 positive tumors a modified surveillance strategy in which cystoscopy is partly 
replaced by FGFR3 mutation analysis of voided urine samples seems safe, effective 
and cost-effective. However, further validation of these results is required to support 
implementation in clinical practice.
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Supplementary table 1. Input data for the Markov decision model to evaluate the cost-
effectiveness of FGFR3 mutation analysis on voided urine samples.
Sensitivity and specificity
Test Location Sens / Spec Estimate (%) [plausible range] Source
FGFR3 Bladder Sens 58 [28 – 86] 1
Spec 100 [75-100] 1, expert opinion
UUT Sens 58 [28 – 86] 1
Spec 100 [75-100] 1, expert opinion
Cystoscopy Bladder Sens 78 [46 – 86] 15
Spec 65 [31 – 93] 15
UUT Sens 0 14
Spec 100 14
CT Abdomen Sens 89 24
Spec 100 Expert opinion
Transition probabilities
Description
3-month 
probability (%) Source
Recurrence probability See table 2 Individual patient data
Recurrence probability UUT * 10 14
Recurrence probability bladder after nefro-ureterectomy 12 25
Progression after recurrence probability See table 2 Individual patient data
Dead after progression probability Year 1 12 14
Year 2 8.5 14
Costs
Description Costs (€) [plausible range] Source
FGFR3 urine analysis ^ € 23 [12 – 46] Dept. of Pathology, Erasmus MC (NL)
FGFR3 tissue analysis † € 14 Dept. of Pathology, Erasmus MC (NL)
Cystoscopy ^ € 273 [137 – 546] Dept. of Finance, Erasmus MC (NL)
CT abdomen ^ € 185 Dept. of Urology, Erasmus MC (NL)
TUR # € 1,324 Dept. of Finance, Erasmus MC (NL)
Cystectomy # € 2,451 Dept. of Finance, Erasmus MC (NL)
Nephroureterectomy # €2,328 Dept. of Finance, Erasmus MC (NL)
* given there is a recurrence, ^ diagnostic costs, # therapeutic costs, † included in modified surveillance
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Supplementary table 2. Transition probabilities for recurrence and progression based on 
Cox regression analysis in 70 patients with primary non muscle invasive UC who had a FGFR3 
positive primary tumor
Description Cycle  Month
3-month probability (%)
after primary tumor after recurrence 1 – 3 after recurrence 4+
Recurrence 
probability
1 3 0.90 1.30 2.20
2 6 2.80 4.10 7.00
3 9 3.50 5.10 9.00
4 12 3.10 4.50 7.80
5 15 1.80 2.60 4.50
6 18 1.10 1.60 2.70
7 21 1.70 2.40 4.20
8 24 1.70 2.40 4.20
Progression 
probability  
after 
recurrence 
1 3 0.08 0.11 0.19
2 6 0.24 0.35 0.61
3 9 0.30 0.44 0.77
4 12 0.27 0.39 0.67
5 15 0.16 0.23 0.39
6 18 0.09 0.13 0.23
7 21 0.15 0.21 0.36
8 24 0.14 0.21 0.36
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Supplementary table 3a-c. Expected average health outcomes in percentages (%) over two 
years of follow-up with minimal surveillance, standard surveillance, or modified surveillance 
based on the Markov decision model and Markov cohort analysis with 1,000 fictional patients.
A. Primary tumor
Health state Standard surveillance Minimal surveillance Modified surveillance
Well 95.04 93.92 95.69
Recurrence* 1.98 3.07 1.33
Bladder 0.41 1.53 0.67
UUT 1.58 1.54 0.66
Progression* 0.01 0.02 0.01
No bladder 0.04 0.06 0.05
Dead 2.93 2.93 2.93
*(Bladder + UUT)
B. 1st  – 3rd recurrence
Health state Standard surveillance Minimal surveillance Modified surveillance
Well 94.14 92.58 95.08
Recurrence* 2.83 4.33 1.88
Bladder 0.57 2.15 0.94
UUT 2.26 2.18 0.94
Progression* 0.02 0.04 0.01
No bladder 0.07 0.12 0.10
Dead 2.98 2.95 2.93
*(Bladder + UUT)
C. Recurrence 4+
Health state Standard surveillance Minimal surveillance Modified surveillance
Well 91.96 89.45 93.59
Recurrence* 4.81 7.11 3.14
Bladder 0.97 3.53 1.58
UUT 3.83 3.58 1.56
Progression* 0.07 0.10 0.03
No bladder 0.22 0.34 0.29
Dead 2.94 2.99 2.95
*(Bladder + UUT)
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Supplementary table 4. Diagnostic, therapeutic and cumulative costs (€) per patient over 
two years of follow-up with standard, minimal or modified surveillance based on the Markov 
decision model.
Surveillance strategy Costs (€) Primary tumor 1st  – 3rd recurrence recurrence 4+
Standard Diagnostic 2,148 2,147 2,145
Therapeutic 3,713 3,742 3,810
Cumulative 5,861 5,889 5,955
Minimal Diagnostic 806 806  805
Therapeutic 1,448 1,482 1,558
Cumulative  2,254 2,287 2,363
Modified Diagnostic  1,057 1,072 1,105
Therapeutic 1,514 1,578 1,724
Cumulative 2,572 2,650 2,829
Supplementary table 5. Average number of cystoscopies and FGFR3 urine tests per patient 
over two years of follow-up with standard surveillance, minimal surveillance or modified 
surveillance based on the Markov decision model. 
Surveillance 
strategy Risk profile
Average no. 
Cystoscopies
Average no. FGFR3 
urine tests
Standard Primary tumor 7.87 0
1st  – 3rd recurrence 7.86 0
recurrence 4+ 7.86 0
Minimal Primary tumor 2.95 0
1st  – 3rd recurrence 2.95 0
recurrence 4+ 2.95 0
Modified Primary tumor 4.05 7.87
1st  – 3rd recurrence 4.08 7.86
recurrence 4+ 4.15 7.86
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The incidence of bladder cancer (BC) in the Netherlands has increased over 1.5-fold 
since the 1990s, with currently more than 7,000 new cases each year 1, 2. Around two 
thirds of new patients are diagnosed with NMIBC, the remaining one third of patients 
are diagnosed with MIBC. The 5-year survival of NMIBC patients is very good (>90%), 
however recurrence rates are high (>50%) and progression to MIBC may occur 3-5. 
Consequently, NMIBC necessitates long and costly surveillance. On the other hand, 
the prognosis of MIBC is very poor; the 5-year survival rate is around 60% for stage cT2 
and only 6% for stage cT4 disease 6. A total of 1,304 patients died of BC in 2016 in the 
Netherlands 2. Treatment options for MIBC are limited and the survival rates have not 
improved much over the past 20 years, although recently introduced immune therapies 
present promising results. 
The high incidence and recurrence rate of NMIBC, together with the poor survival rate 
of MIBC and the immense costs make BC a serious public health problem. Still, BC is 
understudied and awareness in the general population is shortcoming. A lack of funding 
opportunities is a major cause of this problem 7. 
The general aim of this thesis was to evaluate and validate the use of (epi)genetic 
biomarkers in personalized BC management; including diagnosis of primary disease, 
prognosis of disease, tools for treatment allocation and their use in individualized 
surveillance regimens. In part I of this thesis, molecular urine markers are described 
that can detect BC in a population of hematuria patients. The proposed diagnostic urine 
assay was successfully validated in two independent patient cohorts. Part II of this thesis 
contains research on prognostic and predictive biomarkers: i) for the risk of progression 
of NMIBC to MIBC; ii) for the response to preoperative chemotherapy in MIBC patients 
undergoing radical surgery; and iii) for the presence of lymph node-positive disease 
at radical cystectomy. We were able to identify two genes that stratified EAU high-risk 
patients into three different risk groups for progression; good, moderate and poor. In 
addition, we investigated the neutrophil-to-lymphocyte ratio and a 20-gene expression 
signature as prognostic biomarkers in MIBC patients. In part III, an overview is given of 
in vivo research describing new molecular targets for therapy. We attempted to deduce 
reasons for a lack of efficacy of new therapies for BC in human studies. Also, a cost-
effectiveness study was done to illustrate the clinical effects and monetary impact of 
implementation of urinary biomarker assays in a BC surveillance setting.
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TOWARDS A REDUCTION OF CYSTOSCOPIES?
The vast majority of patients with a bladder tumor present with asymptomatic gross 
hematuria although bladder tumors can sometimes also cause other symptoms 
mimicking urinary tract infections, such as dysuria, frequency and urgency. Patients 
with hematuria represent an important burden in urology clinics (20%) and no definite 
consensus exists in current clinical guidelines on what the diagnostic work-up of patients 
with hematuria should be 8-14. Mostly, it is recommended to do a visual inspection of the 
bladder by cystoscopy to rule out a bladder tumor. The prevalence of BC is estimated 
to range from 3% in microscopic hematuria cases to 28% in gross hematuria cases 9. 
Consequently, most patients presenting with hematuria will not have BC, however, 
almost all of these patients undergo an invasive diagnostic cystoscopy 9.
In the primary diagnostic setting, a molecular urine assay could be employed as a 
rule-out assay for cystoscopy. The low prevalence rate in patients presenting with 
microhematuria necessitates a high NPV in order to not subject patients to unnecessary 
invasive procedures. In Sweden, none of the microhematuria patients undergo routine 
cystoscopies, however, we have shown that a small proportion of patients presenting 
with microhematuria can still harbor high risk tumors 14, 15.  Therefore, employing urine 
analysis as a rule-in assay is feasible when a highly sensitive biomarker assay is available. 
In addition, a molecular urine assay could also be employed in the primary diagnostic 
setting especially in women. A possible diagnostic delay in women is reported more 
frequently because  UTIs are thought to be the cause of hematuria 16.
We developed a urine assay that combines methylation of the genes ONECUT2, OTX1 
and TWIST1, together with mutation markers in FGFR3, TERT and HRAS, and the clinical 
variable age 17. In a retrospective discovery series, the assay performed well with a 
sensitivity of 97% and 83% specificity. The NPV proved 99.6-99.9% for an estimated 
5-10% prevalence of BC in the investigated population 17. The assay was validated in 
an independent retrospective case-enriched series, resulting in 93% sensitivity and 
86% specificity 18. Again, the NPV proved very high (99%). We estimated that the 
implementation of this assay could lead to a 77% reduction of cystoscopies in a primary 
diagnostics setting 18. Since both development and validation cohorts consisted of 
retrospective, case-enriched series, we continued to validate the assay in a prospective 
natural cohort (n=1003) 15. This was important since most patients presenting with 
hematuria will eventually not be diagnosed with BC. This prospective cohort was 
collected over a 1.5-year period in the Rotterdam region. All patients with microscopic 
or gross hematuria that would undergo a diagnostic cystoscopy were eligible for 
inclusion. The assay performed very well, with a sensitivity of 93%, a specificity of 81% 
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and a NPV of 99%. The predictive capacity of the assay was 95% 15. We strongly believe 
that this study provides the evidence to convince clinicians to embrace implementation 
of the assay in clinical practice. 
The assay will provide valuable information for clinical decision making; firstly, the 
performance of the cystoscopy will be enhanced with additional information provided 
by the urine assay. We have previously reported that the sensitivity of cystoscopy 
increases if the urologist is aware of a positive urine test 19. Secondly, cystoscopy is used 
to inspect the bladder and urethra but cannot diagnose tumors in the upper urinary 
tract. A major advantage of a urine assay is the ability to detect both upper and lower 
urinary tract localizations of a urothelial tumor. A positive urine test combined with a 
negative cystoscopy, will encourage accelerated upper tract imaging leading to shorter 
delay in upper tract tumor diagnoses. Moreover, a negative urine assay can potentially 
reduce non-informative cystoscopies. A non-invasive ultrasound could be employed as 
an alternative in the search for other causes of hematuria. 
Several other urine biomarker assays have been suggested in the literature over the 
years (eg NMP22®, Immunocyt™, Aura Tek FDP Test™, BTA stat®, Urovysion™ and 
Cxbladder™) 20-32. Most assays did not prove to be sufficiently sensitive and/or specific to 
be able to replace cystoscopy 33. As a result, none have been incorporated into clinical 
guidelines. In 2014, the prospective evaluation of the accuracy of the NMP22® test in a 
cohort of patients referred for hematuria evaluation was published 34. In 381 patients, 
of whom 6% were diagnosed with BC, the predictive accuracy of the test was 80.2%. 
Unfortunately, this study maintained strict exclusion criteria; urinary tract infections, 
urinary retention or stone disease, kidney failure, ureteral stents, nephrostomy tubes, 
bowel interposition or recent genitourinary instrumentation. In contrast, in our studies 
the only exclusion criteria were; younger than 18 years of age and/or a prior history of BC. 
This closely resembles the true population of hematuria patients and is therefore more 
suitable for implementation into clinical practice. Furthermore, very different laboratory 
techniques are at the bases of these different urine assays. For instance, the NMP22® test 
is a protein-based assay, BTA stat® is an immunochromatographic assay, Urovysion™ is a 
FISH test and Cxbladder™ is a mulitiplex evaluation of a RNA gene expression signature 
31. Comparing all assays in a surveillance setting, Cxbladder™ performed best with an 
overall sensitivity of 91% and NPV of 96% 30. 
The performance of most urine assays is based on comparison with the gold standard: 
cystoscopy.  Importantly, sensitivity (68% to 84%) and specificity (31% to 91%) of 
standard white light cystoscopy are not perfect 35. Blue-light cystoscopy is thought to 
improve this performance, however, most clinics do not have both techniques available 
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36. Therefore, the performance of most urine assays is probably underestimated. Further, 
cystoscopy is a point-of-care test. On the contrary, urine assays take several days 
to produce a test result. Therefore, application of a urine assay in acute macroscopic 
hematuria cases will, for now, not be feasible. However, there are patients who would 
prefer to have a urine test first and a cystoscopy only in case the urine test is positive. On 
the other hand, it is questionable how urgently a patient with macrohematuria should 
be evaluated by cystoscopy. Given the lead time of bladder tumors a diagnostic delay of 
4 days seems acceptable. Furthermore, in our prospective validation study, we showed 
that the assay only missed very low risk TaG1 tumors in the microscopic hematuria 
patients. Therefore, we are convinced that performing urine analysis in microhematuria 
patients is very safe. Lastly, technological advances could overcome the time-to-result 
issue in the future, if urine biomarker assays become available as ‘over the counter’ tests, 
much like a urine dipstick analysis. 
Implementation of urine assays could even be extended beyond the Urology-practice 
into the General Practitioners’ office. Offering urine biomarker diagnostics in the General 
Practitioners’ office may reduce the diagnostic delay of BC by increasing early referral. 
Before a urinary tract infection is treated with a course of antibiotics, the urine could be 
evaluated to see if a malignancy is causing the e.g. dysuria and microhematuria 16. Ideally, 
this would shorten the time to diagnosis, potentially leading to downstaging of BC at 
time of diagnosis and eventually an increase in overall survival rate. Would technology 
allow for urine diagnostics to be an over-the-counter assay; this would revolutionize 
clinical practice. One could furthermore imagine urine diagnostics to be employed in a 
national screening program for BC 37. A high risk population would be most eligible for 
inclusion in a national screening program, e.g. a population aged 50-70 years, tobacco 
smokers or chemical industry employees. Screening could entail analyzing a voided 
urine sample every 2-5 years. Again, a shorter time to diagnosis and downstaging would 
be the ultimate goal of such a screening program, thereby eventually increasing overall 
survival rate and reducing the need for invasive local treatment.
Overall, urine assays show great promise for clinical use. Ideally, the urine assays will be 
included in the guidelines for hematuria management. The assays are non-invasive, cheap 
and have the ability to detect upper tract malignancies. Combining urine diagnostics 
with established diagnostics, such as cystoscopy and ultrasound will probably be the 
best way to move the field forward in convincing clinicians of their added value to the 
clinic. A study on cost-effectiveness would be especially interesting. For instance, a 
registration study on microhematuria patients in the General Practitioner’s office could 
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be performed, leading to better allocation of imaging diagnostics or cystoscopies. 
Another interesting option, as mentioned previously, would be a screening study in a 
high-risk population.
CAN MOLECULAR BIOMARKERS IMPROVE RISK STRATIFICATION 
FOR PROGRESSION OF NMIBC?
The prognosis of patients with NMIBC is mostly dependent on progression to MIBC, 
since survival of MIBC is far worse than NMIBC (5-year survival rate 60% for stage T2, 6% 
stage T4 disease versus >90% for NMIBC) 6. The prognosis of NMIBC can be estimated 
by the EORTC risk tables and the EAU risk stratification 3, 38. Several clinicopathological 
parameters are included in this risk score; the size, stage, grade of the tumor, the presence 
of concomitant carcinoma-in-situ (CIS), whether the tumor is primary or recurrent, and 
the prior recurrence-rate. The EAU guidelines advocate different adjuvant treatment 
protocols and surveillance schedules according to the risk stratification 38. Patients can 
be appointed to either a low, intermediate or high-risk category. Even though molecular 
insight in bladder tumors has increased dramatically over the past years, no molecular 
markers have been added to this clinical risk stratification. We analyzed the added 
effect of several molecular markers to the known EAU risk stratification 39. Interestingly, 
based on mutation status of FGFR3 and methylation status of GATA2, the EAU high-
risk patients could be stratified into three distinct risk categories; good, moderate 
and poor. The moderate risk group represented the same overall risk of progression 
to MIBC as the original EAU high-risk group 39. The good sub-class had a much lower 
risk of progression and overtreatment could be reduced in this group. A lesser invasive 
surveillance regimen could be applied to this cohort of patients. Importantly, a group of 
patients with a very high risk of progression could be distinguished, the poor sub-class, 
with a 1.8 times higher risk of progression than the original EAU high-risk patient group 
39. This finding suggests that these patients should receive more intensive surveillance 
and additional treatments or should even be considered for early cystectomy. This sub-
classification increases the accuracy of the EAU risk stratification, potentially leading to 
better treatment allocation and a reduction in overtreatment.
Another study, based on the same patient cohort, proposed a progression score based 
on a 12-gene expression signature, which was shown to add prognostic information 
beyond the EORTC risk score 3, 40. This progression score performed particularly well in 
patients with an EORTC risk score > 6 points. Within this group of patients a high and 
a low-risk of progression sub-group could be appointed with a significantly different 
progression-free survival (p=0.035 or p=0.041, depending on the cutoff used) 40. In 2010, 
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van Rhijn et al, compared a molecular grade with the EORTC risk scores 41. The suggested 
molecular grade was based on FGFR3 mutation status and MIB-1 expression. In a cohort 
of 230 primary NMIBC patients, both the EORTC risk score and the molecular grade 
showed independent predictive capacity for progression to MIBC. The EORTC risk score 
prediction improved by 6.8% to 81.7% predictive capacity when combined with the 
molecular grade 41. Biomarkers to predict progression of NMIBC to MIBC independent 
of the EORTC or EAU risk scores have been suggested as well. Beukers et al presented 
a stratification tool based on methylation of TBX2 and TBX3 42. The three presented 
molecular grades differentiated patients with Ta-tumors into three different risk groups 
for progression (with a 5-year progression rate of 8, 29 and 63% respectively) 42.
While interpreting the results of the earlier EORTC progression score, the methylation-
mutation progression sub-classification, the 12-gene progression score and different 
molecular grades, several important differences between the studies should be 
noted. First of all, the patient cohort on which the EORTC progression score was based 
originates from the years 1979-1989 3. At that time, treatment and follow-up of NMIBC 
patients differed a lot from the current practice. The first EAU NMIBC guideline was 
published in the year 2000 and BCG instillations were only FDA (U.S. Food and Drug 
Administration) approved in 1990. Thus, BCG instillations and the mandatory re-TUR for 
high-risk tumors were not common practice at that time. The recent prospective cohort 
on which the methylation-mutation sub-classification and the 12-gene risk signature 
were developed showed a much lower overall progression rate that the cohort 
described for EORTC risk score development. It is apparent, that the different treatment 
and follow-up of NMIBC has improved patient outcome considerably over the past 
decades. The low progression rate (approximately 5%) reported in the current study will 
complicate prospective replication studies because larger numbers of patients need 
to be included to obtain sufficient numbers of progressing cases. Further, the EORTC 
and EAU risk classification depend on pathological stage and grade of the initial tumor. 
In many studies, pathology reports are revised by a reference pathologist in order to 
reduce the considerable inter-observer variability inherent to pathological staging 
and grading. However, when we try to analyze an outcome that has been influenced 
by treatment or follow-up, such as progression-free survival, this may not be a good 
strategy because treatment and follow-up were based on the original pathology report. 
Revising pathology may stratify patients to other risk groups. It is our opinion that, 
as long as there is no expert pathology review up front, one should use the original 
pathology classification. Lastly, the 12-gene risk score was based on a qRT-PCR analyses 
and the methylation-mutation sub-classification and suggested molecular grades on a 
Snapshot analysis 39, 40. In general, Snapshot analysis is less laborious and less costly than 
qRT-PCR analysis, although both techniques can be performed in a molecular pathology 
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laboratory. Overall, we can conclude that both the 12-gene progression score as the 
methylation-mutation sub-classification show great promise to improve the precision 
of the EAU and EORTC risk scores.
Ideally, our suggested risk stratification should be prospectively validated. Performing 
a randomized controlled trial will probably not be feasible, due to the low number of 
progressing cases and the duration of required follow-up. An alternative approach would 
be to perform a large retrospective study in progressing cases versus non-progressing 
NMIBC cases. Alternatively, a prospective registration study could be commenced. In 
such a study, molecular analyses could be performed on all EAU high-risk tumors. In this 
way, a sufficient number of progressing cases could be collected over the years to proof 
the principle of molecular sub-classification into good, moderate and poor subclasses. 
Eventually treatment allocation and surveillance intensity could be adjusted to these 
enhanced EAU risk profiles. 
CAN MOLECULAR BIOMARKERS AID IN THE PREDICTION OF 
RESPONSE TO CHEMOTHERAPY AND THE RISK OF DISEASE 
PROGRESSION?
The prognosis of MIBC patients is highly dependent on the extent of the disease 
(local and distant) and the outcome of treatment interventions. Depending on 
clinical and pathological characteristics, standard treatment for non-metastatic MIBC 
consists of neoadjuvant chemotherapy followed by radical cystectomy and pelvic 
lymph node dissection. Bladder sparing treatment options are chemo-radiation or 
external beam radiotherapy. Unfavorable clinical and pathological characteristics are 
presence of hydroureteronephrosis, cT3b-T4a disease, and/or lymhovascular invasion, 
neuroendocrine or micropapillary aberrant histology on dTURBT 43. Still, even patients 
with tumors that harbor favorable cliniclopathological features, almost 50% will be 
upstaged on final pathology 43. Further, CT-imaging is known to be unreliable as a 
staging tool for BC and pathology reports are highly dependent on the experience of 
the pathologist 44. This shows the difficulty of using clinical and pathological parameters 
as prognostic tools for MIBC. 
Surprisingly, reports show that only 12-37% of patients actually receive NAC 45, 46. The 
controversies on applying NAC can be appointed to the only modest 6% increase in 
10-year survival 47. Response rates to NAC treatment differ highly between patients. 
Approximately 30% of patients do not respond, but are exposed to treatment-related 
toxicity and may even be subjected to upstaging of disease or positive nodal disease 
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at time of cystectomy 48-50. On the other hand, 25% of patients receiving NAC will 
have a complete response with no detectable tumor left at time of cystectomy. These 
complete responders have a 5-year survival rate of 80%, which is much better than the 
overall survival-rate 51, 52. Further, only applying NAC in a subgroup of MIBC patients 
may also reduce cost of treatment, since hospital admission is necessary to administer 
chemotherapy. Up to now, no decision tools are available to select patients upfront for 
NAC that will respond or select patients that will not respond in order to withhold NAC. We 
evaluated the usefulness of the neutrophil-to-lymphocyte ratio, as a measure to predict 
poor outcome after pre-operative chemotherapy. The inflammatory microenvironment 
is an essential component of tumors and their behavior 53. The NLR is a marker of 
systemic inflammatory response that indicates the balance of the inflammatory system 
and immune system respectively 54. It is known that cancer cells can induce neutrophils 
to form a microenvironment that is beneficial to the malignant cells 55. Therefore, an 
elevated NLR would be an indicator of potentially poor outcome. Although we found 
an association between a high pre-treatment NLR and poor outcome in terms of non-
response and shorter PFS and OS, this result was nullified when corrected for lymph 
node status and clinical T stage 56. Therefore, we had to conclude that the NLR is probably 
insufficient to predict response to NAC in MIC patients. A study from 2015 also showed 
no association between the NLR and pathological response to NAC in MIBC patients (OR 
= 0.69, 95%-CI: 0.36–1.32, p = 0.26) 50. The authors of this publication, however, did use 
a different definition of response to NAC. The authors defined a pathological response 
as T0 or Tis and N0 disease together with down staging to T1 and N-positive to N0, 
whereas in our study a complete response to pre-operative chemotherapy (POC) was 
only defined as ypT0N0M0. Probably, the sample size of only 26 patients was too small 
to draw any meaningful conclusions. In our study of 123 patients, the sample size was 
perhaps still too small. In other malignancies, such as esophageal cancer, the NLR did 
prove a significant predictor for response to NAC (p<0.01) 57. Perhaps other molecular 
predictive markers like ERBB2 and ERCC2 mutation status could be combined with the 
NLR and thereby potentially enhance the overall predictive capacity in MIBC patients 58, 
59. 
Another approach to allocate NAC is to select patients based on the probability of 
node-positive disease at time of cystectomy. In these patients, NAC could be employed 
to eradicate micrometastases and thereby reduce the risk of node-positive disease 
at radical cystectomy. Previously, a 20-gene expression signature was developed 
to predict the presence of lymph node metastases at radical cystectomy in clinically 
node-negative MIBC patients 60. Smith et al identified differentially expressed genes 
by microarray from three different cohorts of cystectomy specimens. Since the TURBT 
represents the starting point for treatment decisions in MIBC patients, in our validation 
265
General discussion
10
study we used RNA isolated from a large cohort of dTURBT and not radical cystectomy 
specimens. In addition, we aimed to validate the 20-gene expression signature on a 
qRT-PCR platform, which is an easier to use technology than microarray analysis. 
Unfortunately, for this approach we also had to conclude that the 20-gene expression 
signature was clinically not applicable and cannot serve as a tool to guide treatment 
decisions on NAC in MIBC patients 61. A different gene expression signature to predict 
the presence of lymph node metastases at time of cystectomy was developed in 2016 
62. Seiler et al used RNA isolated from cystectomy specimens for a whole transcriptome 
approach. This resulted in a 51 K-nearest neighbor classifier (KNN51). Of the 51 genes 
included in this signature, none overlapped with the 20 genes from the earlier 20-gene 
expression signature of Smith et al. However, Seiler et al did attempt to validate the 20-
gene expression signature. The 20-gene expression signature had an AUC of 0.46 and 
a non-significant OR of 1.39 versus an AUC of 0.82 and an OR of 2.65 (p<0.01) for the 
KNN51 model 62. An important difference between our study and the study by Seiler 
et al, was the platform used for analyses. The whole transcriptome expression analysis 
described by Seiler et al is somewhat laborious and not widely available for standard 
diagnostic procedures in contrast to the qRT-PCR technology we used. Further, Seiler et 
al like Smith et al used radical cystectomy for their analysis and not dTURBT specimens 
we used. As the authors stated in their conclusions, the KNN51 expression signature 
should also first be validated on dTURBT specimens before implementation in clinical 
practice is possible. Even though the validation of the KNN51 signature is yet to be 
performed, we can conclude that the 20-gene expression signature is unfortunately 
not sufficient enough to predict the presence of nodal metastases in clinically node-
negative MIBC patients.  
As described in the introduction, chapter 1 of this thesis, clustering of MIBC tumors 
based on their gene expression profile revealed different gene expression subclasses. 
Several research groups have published different and partly-overlapping suggestions 
for classification 63-68. In a meeting in 2016 several researchers attempted to facilitate 
progress and stimulate collaboration between the different research groups, with the 
ideal of eventually reaching agreement on a consensus taxonomy 69. In 2017, Seiler 
et al described differences in response to NAC based on these different molecular 
subclasses 70. Further, a single-patient genomic subtyping classifier was developed to 
predict subtypes with the highest clinical impact in the context of NAC. Albeit not yet 
prospectively validated, this publication demonstrates the promising impact of the 
discovery of the various molecular subclasses 70. 
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WHAT NEW POTENTIAL TREATMENTS FOR MIBC LIE ON THE 
HORIZON?
In other cancer types, targeted therapies have been long established. These therapies 
aim to interfere with cellular processes that are essential to cancer cell survival at the 
molecular level — for example, by blocking proteins involved in tumor cell proliferation 
or tumor cell metabolism, or by delivering toxic compounds to tumor cells. Well-known 
targeted therapies include gefitinib, a small-molecule EGFR inhibitor used for the 
treatment of chemotherapy-refractory non-small-cell lung cancer, and cetuximab, an 
EGFR antibody used for the treatment of head and neck cancer and advanced colorectal 
cancer 71, 72. Other well-known targeted therapies are VEGF inhibitors (e.g. sunitinib) 
or VEGF antibodies (e.g. bevacizumab) that have been widely used to treat cervical, 
colorectal, lung, ovarian and renal cancer 73-77. However, up to 2016 none of the known 
targeted therapies were approved for the treatment of BC. Perhaps, the magnitude of 
synchronous somatic mutations renders BCs more prone to targeted therapy resistance 
78. 
As of 2016, rapid developments in the field of immunotherapies have led to the 
accelerated approval by the FDA of five new immunotherapies for the treatment of 
BC, namely; atezolizumab, nivolumab, durvalumab, avelumab and pembrolizumab 
79. All immunotherapies are approved for the treatment of locally advanced or 
metastatic urothelial carcinoma patients with disease progression after chemotherapy. 
Pembrolizumab is the only drug that is additionally approved for patients with locally 
advanced or metastatic BC who are ineligible for second line cisplatin-containing 
chemotherapy. All above-mentioned compounds are immune checkpoint blockade 
therapies involved in the interaction between the programmed death-ligand 1 (PD-
L1) and the programmed-death 1 receptor (PD-1). Avelumab, atezolizumab and 
durvalumab are PD-L1 antibodies, opposed to nivolumab and pembrolizumab, 
which are PD-1 antibodies. PD-1 is expressed on T cells and pro-B cells and can bind 
two ligands, PD-L1 and PD-L2. PD-L1 is found on tumor cells, PD-L1/PD-1 interactions 
result in an immunosuppressive effect beneficial for a pro-tumor environment 80. Phase 
2 studies have shown promising effectiveness of all immunotherapies, with overall 
response rates varying between 13.3% and 28.6%. Importantly, many patients suffered 
only mild side effects, although 40-50% of patients reported grade 3/4 side effects. 
In a successful phase 3 study, pembrolizumab showed a significantly longer overall 
survival of approximately 3 months compared to investigator’s choice of chemotherapy 
as a second-line treatment for platinum-refractory MIBC 81. Furthermore, significantly 
fewer severe side-effects of treatment were registered compared to chemotherapy 
(15% vs 49%) 81.  In May 2017, Roche (pharmaceutical company) reported unexpected 
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disappointing results from a phase 3 study on atezolizumab 82. The phase 3 study was 
intended to confirm the results from the earlier phase 2 study, which resulted in the 
accelerated FDA approval of atezolizumab. However, the phase 3 study failed to reach 
its primary endpoint of improving overall survival in MIBC patients with high PD-L1 
expression 83. Perhaps an indication to restrain the enthusiasm somewhat and wait 
further confirmation from other studies.
In this thesis, we tried to elucidate reasons for the relative lack of targeted therapies in 
BC. Apart from immunotherapies, the small number of clinical trials in BC had limited 
success. To investigate whether promising new targets for therapy were being developed, 
we evaluated the results from animal studies published since 2009. It appeared 
that many potential targets had been investigated. In case of receptor inhibition or 
blockade, we concluded that the disappointing results from clinical trials were most 
likely due to the lack of patient stratification according to the downstream mutations 
in the pathways of the targeted receptors. For instance, activating mutations in the 
Ras–MAPK and PI3K–Akt pathways downstream of EGFR will render the tumor resistant 
to EGFR inhibition. We identified four studies on EGFR inhibition in human BC cell line 
xenografts that had such mutations in one or both pathways. In addition, in some cases 
a cytostatic effect was observed, which suggests that tumor growth probably resumes 
when treatment is stopped. Combining targeted treatment with chemotherapy usually 
enhanced the therapeutic efficacy in the mouse models. In clinical trials, combination 
treatments have been attempted but did not demonstrate an improvement in overall 
survival and sometimes resulted in increased toxicity in patients 84-86. Furthermore, all 
xenografts included in our review were created by use of cell lines. Cell lines might not 
reflect the entire spectrum of tumor types, especially because relatively few BC cell lines 
are available. Also, there is a real risk of contamination amongst these cell lines 87. In 
addition, cell-line-derived tumors probably lack the tumor heterogeneity observed in 
most cancers. A recent publication showed that N-butyl-N-(4-hydroxybutyl) nitrosamine 
(BNN)-induced BCs might still be a good option to use in animal studies. Although BNN-
induced BCs are in fact mouse BCs, they do represent certain molecular characteristics 
similar to human MIBC 88. Alternatively, xenografts established directly from resected 
tumors might present a better model than cell lines. Such tumor models also have 
human stroma and engage murine stromal cells, which is likely to be important in cell–
cell interactions and cell proliferation 89. Since 2015, several studies were published 
that describe the establishment of patient-derived xenografts for BC research 90. This 
development will surely improve pre-clinical studies on new targeted therapies. 
With the increasing knowledge of the biology of bladder tumors, biomarkers will 
continue to play an important role in identifying certain subgroups of patients. As was 
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initiated by the TCGA, combining different laboratory techniques to interpret overall 
tumor architecture is the next level of science 91. For the future, it is to be expected that 
collaboration between different (inter)national laboratories will gain importance as the 
origin of tumor heterogeneity becomes clearer. Ideally, biomarker assays will combine 
different molecular test modalities. For instance, copy-number-variations combined 
with mutation data, to more precisely identify certain subgroups. Also, in the future 
more complex clinical studies will reveal the ideal momentum of administering certain 
treatments. Should immunotherapy be reserved for end-stage disease? Or should 
we start each patient on immunotherapy, with chemotherapy as a second option? 
Perhaps tumors can be sensitized to certain treatments, by for instance hyperthermia or 
sensitizing agents. Eventually, a continuous switchover strategy might be the ultimate 
solution.
IS IMPLEMENTATION OF URINE ANALYSIS FOR THE SURVEILLANCE 
OF NMIBC PATIENTS FEASIBLY?
Patients remain a minimal of five years under surveillance after treatment for BC, 
however, since BC recurs often, many patients will be kept under surveillance lifelong. 
Surveillance of patients treated for MIBC includes regular CT-scans and laboratory 
work-up, whereas surveillance after treatment for NMIBC entails regular cystoscopies 
92. Since, cystoscopies are time-consuming, expensive and an invasive procedure, 
urine diagnostics has great potential to reduce the burden of surveillance for NMIBC. 
In a simulated follow-up study we evaluated the safety and monetary impact of 
implementation of urine biomarkers assays in clinical practice 93. Implementation of 
urine analyses proved safe as well as cost-effective. It is suggested that in the detection 
of recurrent BC a lower sensitivity and specificity of urine tests are achieved compared to 
primary BC detection 94. A complete urine-based surveillance scheme seems therefore 
unfeasible. However, follow-up of patients treated for very low risk tumors seem good 
candidates for a surveillance scheme in which part of the cystoscopies are replaced by 
urine analysis. Further, analysis of multiple urines from one patient might be a manner 
to increase sensitivity and specificity 95. Furthermore, one could argue that recurrences 
of low-risk tumors tend to be very small and low-risk as well. Missing such a recurrence 
at one surveillance time-point might not be too troublesome. Finally, in higher risk 
tumors urine biomarkers assays could enhance the accuracy of surveillance. Definitely, 
by implementing urine analysis in low-risk categories, a major cost-reduction could be 
achieved. 
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GENERAL CONSIDERATIONS AND CONCLUDING REMARKS
Several challenges remain for the research in NMIBC patients. Firstly, the content of 
urine is influenced by both fluid intake, as well as the coincidence of tumors shedding 
cells. Secondly, with well disseminated guidelines and improved treatments resulting in 
very low progression rates, prospective research on the risk of progression of NMIBC will 
be nearly impossible, due to the magnitude of the number of required study subjects. 
Finally, with differences in recurrence rates, prior treatments may vary between study 
subjects, resulting in a very heterogeneous patient population. Likewise, challenges 
remain while doing research in MIBC patients. Of all BCs, MIBC is particularly known to 
be a heterogeneous cancer in terms of biological behavior. Even in similar histological 
subtypes, the biological profile and behavior of the tumor may differ greatly. Even within 
one patient tumors at different time-points and locations (metastasis) show substantial 
heterogeneity 96. In general, published studies are aimed at developing new hypotheses 
resulting in a lack of high quality validation studies. Further, as described in chapter 8, 
there is a superiority of positive findings in the literature, suggesting that publication 
bias does play a significant role.
The field of BC research is propelling forward with exciting new discoveries in recent 
years and no doubt more discoveries are on the horizon. Patients with BC and their 
treating physicians will have more diagnostic and treatment options in the future, 
improving clinical practice. Although new discoveries are essential in the ongoing 
research field, the lack of validation studies is a concern. Research funding is mostly 
available for studies aiming at new, out-of-the-box hypotheses. Still, to offer patients 
high-quality assays and treatments, we need to (independently) validate our results 
accordingly. 
The BC research field is small compared to other tumor types. It is promising to see 
many publications in recent years coming from major international collaborations. The 
launch of collaboration-stimulating consortia, such as the International Bladder Cancer 
Network (IBCN) shows the great intentions of researchers interested in the field of BC. 
When the field continues to join forces, we will unquestionably be able to significantly 
enhance BC management in the end. 
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SUMMARY
The general aim of this thesis was to evaluate the value of genetic and epigenetic 
biomarkers in the management of BC patients. 
In chapter 1, a short introduction about the structure and function of the urinary tract 
is given and background information on BC is discussed. It covers the epidemiology, 
histological classification, diagnostic procedures, prognostic stratification, treatment 
regimens, and surveillance schedules of BC. BC is a very prevalent disease, which 
occurs three times more often in males than females and cigarette smoking is the most 
important known risk factor. However, awareness of the disease among the general 
population is still scant. Bladder cancer can either occur as NMIBC or MIBC, which results 
in very different treatments and survival outcomes. Although the survival of NMIBC is 
very good, the clinical challenge lies within the high recurrence rates and in identifying 
patients who are at risk of progression to invasive disease. Therefore, strict regimens for 
surveillance are mandatory, making BC the most costly cancer to manage. In contrast, 
the survival of MIBC patients is poor and new decision tools to allocate treatment, as 
well as new treatments are desperately needed. 
In the first part of the thesis, several studies are described that comprise the discovery 
and the validation of a diagnostic urinary biomarker assay to select patients for 
cystoscopy. First, in chapter 2, the discovery of a methylation-mutation urine assay 
is described in a case-enriched series of 154 patients presenting with hematuria. 
The assay contained the variable age, methylation of the genes OTX1, ONECUT2 and 
TWIST1, together with mutations of the FGFR3, TERT and HRAS genes. The assay was 
able to distinguish benign causes of hematuria and urothelial carcinoma as the cause 
of hematuria with 97% sensitivity and 83% specificity, resulting in a 99.6-99.9% NPV, 
with an estimated BC prevalence of 5-10%. In chapter 3, this assay was validated in 
an independent international case-enriched series of 200 hematuria samples. Again, 
the assay proved to be able to select patients with urothelial carcinoma as the cause 
of the hematuria with 95% accuracy as represented by the optimism-corrected AUC. 
Furthermore, we described the potential of a 77% reduction in the need for diagnostic 
cystoscopies when implementing such a urine-based selection tool in hematuria 
patients. We then proceeded in chapter 4, to further validate the rule-in urine assay 
for cystoscopy in a large prospectively collected cohort of 1003 patients presenting 
with either macroscopic or microscopic hematuria to the urology clinic. The previously 
described urine assay performed very well, with a sensitivity of 93% and a specificity of 
81%. The assay had a NPV of 99% and all upper tract tumors were identified. 
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In part two of this thesis several studies are described in which the value of biomarkers 
in determining the prognosis of BC patients is evaluated. In chapter 5, the added value 
of several previously discovered methylation and mutation markers to the known 
clinical EAU risk classification were determined. In this study, a total of 1,239 patients 
in follow-up for NMIBC were prospectively included in hospitals in Denmark, Germany, 
Serbia, Spain, Sweden, and The Netherlands. The primary endpoint was progression to 
MIBC. With a median follow-up of 27 months, 4.6% patients had disease progression 
and we found that the EAU risk classification for patients at high-risk for progression 
was significantly improved by adding FGFR3 mutation and GATA2 methylation status. 
Our study resulted in a re-classification of the EAU risk classification into different high-
risk sub-classes, with large differences in incidence rates for progression, namely 0.86 
versus 4.32 versus 7.66. We conclude that implementation of these biomarkers into 
the EAU risk classification will increase its predictive capacity and may enable more 
personalized treatment. In chapter 6, the prognostic value of the derived neutrophil-
to-lymphocyte ratio (dNLR) in MIBC was investigated in a retrospective cohort of 123 
patients treated with platinum-based pre-operative chemotherapy (POC) and radical 
cystectomy. Analogue to what has been described in other tumors, an elevated dNLR 
corresponded with poor outcome in terms of survival and non-response to POC. 
However, after correction for well-known prognostic factors, such as positive lymph 
node status at diagnostic imaging and clinical T stage, the correlation for the dNLR was 
nullified. Therefore, we concluded that the dNLR is insufficient to predict response to 
POC in MIBC. In chapter 7, the clinical applicability of a previously reported 20-gene 
expression signature that might predict lymph node-positive disease in clinically node-
negative MIBC patients was determined. This 20-gene expression signature could have 
potential as a decision tool to allocate NAC, since the presence of micro-metastasis 
would be reason to give NAC. We included 150 dTURBT samples of MIBC patients who 
were subsequently treated by radical cystectomy and pelvic lymph node dissection. In a 
univariate regression analysis, the expression level of none of the 20 genes significantly 
correlated with node-positive disease. The overall 20-gene expression signature 
resulted in an non-significant AUC of 0.54. Therefore, we concluded that this 20-gene 
expression signature is clinically not applicable and cannot serve as a tool to guide 
treatment decisions on NAC in MIBC patients. 
The third part of this thesis entails studies in which the use of biomarkers in therapy 
and surveillance of BC patients is discussed. Up to January 2017, none of the targeted 
agents that were approved for cancer therapy were approved for the treatment of BC 
and the few clinical trials that have been performed had limited success, often owing to 
a lack of efficacy and toxic effects. In chapter 8, a comprehensive overview is given of 
targeted therapies for BC that have been investigated in animal models, some of which 
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have potential for clinical application. In this chapter, we provided insight into both the 
challenges and the promises of the preclinical development of targeted agents. We 
concluded that EGFR, FGFR3, VEGF, mTOR, STAT3, the androgen receptor and CD24 are 
molecular targets that can be efficiently inhibited, resulting in reduced tumor growth, 
and that these have been investigated in multiple independent studies. Several other 
targets, e.g. COX-2, IL, Bcl-xL, Livin and ChoKα, have also been observed to inhibit tumor 
growth, but these findings have not been replicated to date. Limitations of several 
studies included the use of cell lines with mutations downstream of the target, providing 
resistance to the tested therapy. Furthermore, certain technologies, such as interfering 
RNAs, although effective in vitro, are not considered ready for clinical applications. In 
chapter 9, we performed a cost-effectiveness analysis of the potential implementation 
of FGFR3 mutation analysis on voided urine samples in the follow-up of NMIBC patients. 
A Markov decision model was created to analyze three different surveillance strategies; 
standard, minimal, and modified surveillance. Since risk of recurrence increases when 
the prior recurrence rate increases, we stratified the analysis of surveillance into three 
different risk profiles; after the primary tumor, after the first to third recurrence, and 
after the fourth recurrence or more. The probability of being without recurrence is 
higher for modified surveillance that for standard or minimal surveillance (surveillance 
after the primary tumor 95.7% versus 95.0% and 93.9%, respectively). The total two-
year cost of surveillance is lower for minimal and modified surveillance compared to 
standard surveillance (€2,254 and €2,558, compared to €5,861). We conclude that partly 
replacing cystoscopies by FGFR3 mutation analysis is not only safe, but also a cost-
effective strategy. 
Part four of this thesis, contains the general discussion and elaboration on future 
perspectives. In chapter 10, the results that are presented in the thesis are discussed 
and placed in the context of the global BC research field. Limitations of the different 
studies are elucidated and potential clinical implications of this thesis are summarized. 
Finally, challenges and aspirations for future studies are mentioned. In general, the field 
of BC research is steps behind other fields of cancer research (e.g. colon, breast, lung, 
and prostate). Also, BC is a very heterogeneous disease, complicating study design and 
clinical protocols. As awareness of BC increases, more funding will become available, 
aiding in the discovery of new targets and biomarkers for BC management. Over the 
past four years, major discoveries have propelled the field forward. Most important 
milestones include; the discovery of different molecular profiles of MIBC, and the 
development and approval of the new checkpoint inhibitors for metastatic BC. Now it 
is important to keep the momentum going, resulting is an ever brighter future for BC 
research and management.
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De algemene doelstelling van dit proefschrift is het evalueren van de waarde van 
genetische en epigenetische biomarkers in de aanpak van blaaskanker.
In hoofdstuk 1, wordt een korte introductie gegeven over de opbouw en functie van 
de urinewegen. Tevens wordt er achtergrond informatie gegeven over blaaskanker. 
Het omvat de epidemiologie, histologisch sub-classificatie, diagnostiek, prognostische 
stratificatie, behandel strategieën, en follow-up schema’s van blaaskanker. Blaaskanker 
is een erg prevalente ziekte, welke drie keer vaker voorkomt bij mannen dan vrouwen. 
Het roken van sigaretten is de meest bekende risicofactor. Desondanks is de bekendheid 
van de ziekte onder de bevolking schaars. Blaaskanker komt voor als niet-spierinvasieve 
blaaskanker (NSIBK) of als spierinvasieve blaaskanker (SIBK), welke beide een heel andere 
behandeling en overleving hebben. Alhoewel de overleving van NSIBK erg goed is, ligt 
er een grote klinische uitdaging bij de hoge recidiefkansen en het identificeren van 
patiënten welke een verhoogd risico hebben op progressie naar spier-invasie. Daarom 
zijn strikte follow-up schema’s noodzakelijk, deze maken de aanpak van blaaskanker tot 
meest kostbaar van alle kankertypes. De overleving van SIBK patiënten is daarentegen 
matig en nieuwe beslismodellen om de juiste behandeling te kiezen, als ook nieuwe 
behandel strategieën zijn hoog noodzakelijk. 
In het eerste deel van dit proefschrift worden verschillende studies beschreven die 
gaan over de ontwikkeling en validatie van een diagnostische urine biomarker test 
voor de selectie van patiënten voor het ondergaan van een cystoscopie. Als eerste, in 
hoofdstuk 2, wordt een studie beschreven over de ontwikkeling van een methylatie-
mutatie urinetest in een casus-verrijkte serie van 154 patiënten welke zich presenteren 
met hematurie. De test bevat de variabelen leeftijd, methylatie van de genen OTX1, 
ONECUT2 en TWIST1, samen met de mutaties van FGFR3, TERT en HRAS genen. De 
test was in staat om onderscheid te maken tussen benigne oorzaken van hematurie 
en urotheelcelcarcinoom als oorzaak van de hematurie met een sensitiviteit van 97% 
en specificiteit van 83%, welke resulteerde in een 99.6-99.9% negatief voorspellende 
waarde, bij een geschatte blaaskanker prevalentie van 5-10%. In hoofdstuk 3, werd 
deze test gevalideerd in een onafhankelijk internationaal casus-verrijkte serie van 
200 hematurie patiënten. Opnieuw bleek de test in staat om patiënten aan te wijzen 
welke urotheelcelcarcinoom als oorzaak van hun hematurie hadden met een 95% 
zorgvuldigheid zoals weergegeven door de optimisme-gecorrigeerde oppervlakte 
onder de curve. Verder beschrijven we de mogelijkheid om een 77% reductie van 
diagnostische cystoscopieën te bereiken wanneer deze op urine gebaseerde selectie 
wordt geïmplementeerd in hematurie patiënten. Dan gaat dit deel van het proefschrift 
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verder in hoofdstuk 4, waar de urinetest verder wordt gevalideerd als selectie-test voor 
het ondergaan van een cystoscopie. De testeigenschappen worden geanalyseerd in 
een groot prospectief verzameld cohort van 1003 patiënten welke verwezen zijn naar 
de uroloog met micoscopische of macroscopische hematurie. De eerder beschreven 
urine test gaf goede resultaten, met een sensitiviteit van 93% en een specificiteit van 
81%. De test had een negatief voorspellende waarde van 99% en alle tumoren in de 
hogere urinewegen werden gedetecteerd.
In deel twee van dit proefschrift worden verschillende studies beschreven welke de 
waarde van biomarkers voor het bepalen van de prognose van blaaskanker patiënten 
evalueren. In hoofdstuk 5, wordt de toegevoegde waarde van eerder ontdekte 
methylatie en mutatie markers aan de bekende klinische EAU risico classificatie 
onderzocht. In deze studie werden in totaal 1239 patiënten in follow-up voor NSIBK 
prospectief geïncludeerd in ziekenhuizen in Denemarken, Duitsland, Servië, Spanje, 
Zweden en Nederland. De belangrijkste uitkomst van de studie was ziekteprogressie 
naar spier-invasie. Bij een mediane follow-up van 27 maanden, had 4.6% progressie 
van ziekte naar spier-invasie en we ontdekte dat de EAU risico classificatie voor 
patiënten met hoog risico voor progressie sterk kon worden geoptimaliseerd door de 
toevoeging van FGFR3 mutatie en GATA2 methylatie status. Onze studie resulteerde 
in een re-classificatie van de EAU hoog-risicoclassificatie in verschillende hoog-risico 
sub-classes, met zeer verschillende incidentie cijfers en progressie cijfers, namelijk 0.86 
versus 4.32, versus 7.66. We concluderen dat de implementatie van deze biomarkers in 
de EAU risicoclassificatie de precisie zal doen toenemen en dat dit kan leiden tot meer 
gepersonaliseerde behandeling. In hoofdstuk 6, wordt de prognostische waarden van 
de afgeleide neutrofiel-lymfocyt ratio (aNLR) in SIBK onderzocht in een retrospectief 
cohort van 123 patiënten behandeld met platinum-houdende pre-operatieve 
chemotherapie (POC) en radicale cystectomie. Zoals dit ook eerder al beschreven was 
in andere soorten tumoren, correspondeerde een verhoogde aNLR met een slechte 
uitkomst wanneer gekeken werd naar overleving en achterblijven van respons op POC. 
Echter, na correctie voor bekende prognostische factoren zoals positieve lymfklierstatus 
op diagnostische beeldvorming en klinisch T stadium, verdween de correlatie met 
de aNLR. Daarom concluderen we dat de aNLR onvoldoende functioneert om de 
kans op respons op POC in SIBK te voorspellen. In hoofdstuk 7 wordt de klinische 
toepasbaarheid onderzocht van een eerder beschreven 20-genen expressie panel 
welke de aanwezigheid van positieve lymfklieren in klinische lymfklier-negatieve SIBK 
patiënten zou kunnen voorspellen. Dit 20-genen expressie panel zou eventueel als 
beslishulp kunnen dienen in de afweging om wel of geen neoadjuvante chemotherapie 
(NAC) te geven, aangezien de aanwezigheid van micrometastasen reden zou zijn 
voor NAC. We includeerden 150 diagnostische transurethrale resectie monsters van 
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blaastumoren van SIBK patiënten welke daaropvolgend werden behandeld middels 
radicale cystectomie en pelviene lymfklierdissectie. In een univariate regressie analyse 
bleek het expressie niveau van géén van de 20 genen significant gecorreleerd met de 
aanwezigheid van positieve lymfklieren. Het totale 20-genen expressie panel resulteerde 
in een niet-significante oppervlakte onder de curve van 0.54. Daarom concludeerden 
we dat dit 20-genen expressie panel klinisch niet toepasbaar is en dat het daarom niet 
kan dienen als beslishulp voor het al dan niet toedienen van NAC in SIBK patiënten.
Het derde deel van dit proefschrift bevat studies welke het gebruik van biomarkers in 
de behandeling en follow-up van blaaskanker patiënten beschrijven. Tot januari 2017 
waren geen van de gerichte therapieën welke goedgekeurd waren voor behandeling van 
andere kankerpatiënten goedgekeurd voor de behandeling van blaaskanker patiënten. 
De spaarzame klinische studies die waren uitgevoerd waren weinig succesvol, vaak ten 
gevolge van een gebrek aan effectiviteit en de aanwezigheid van schadelijke bijeffecten. 
In hoofdstuk 8 wordt een uitgebreid overzicht gegeven van gerichte therapieën voor 
blaaskanker welke onderzocht zijn in diermodellen, waarvan sommigen de potentie 
hebben om klinisch toepasbaar te zijn. In dit hoofdstuk geven we een overzicht van 
zowel de uitdagingen als de potentie van de preklinische ontwikkeling van gerichte 
middelen. We concludeerden dat EGFR, FGFR3, VEGF, mTOR, STAT3, de androgeen 
receptor en CD24 moleculaire aangrijpingspunten zijn welke effectief kunnen worden 
afgeremd, wat resulteert in een afname van tumor groei. Bovendien waren deze 
moleculen onderzocht in meerdere studies. Verschillende andere aangrijpingspunten, 
zoals COX-2, IL, Bcl-xL, Livin en ChoKα, hebben ook een afname van tumorgroei 
laten zien, echter deze bevindingen zijn nog niet herhaald in andere studies. Enkele 
tekortkomingen van verschillende studies waren onder andere het gebruik van cellijnen 
welke mutaties hadden in moleculen verderop in de communicatie cascade, leidend 
tot resistentie van de onderzochte therapie. Daarnaast zijn verschillende onderzochte 
technologieën, zoals het aangrijpen op bepaalde types RNAs, alhoewel effectief in vitro, 
nog niet klaar voor klinische toepassingen. In hoofdstuk 9 hebben we een kosten-
effectiviteitsstudie uitgevoerd waarin we de potentiele implementatie van een FGFR3 
mutatie analyse op uitgeplaste urinemonsters in de follow-up van NSIBK patiënten 
hebben onderzocht. Een Markov beslismodel werd gebruikt om drie verschillende 
follow-up strategieën met elkaar te vergelijken: een standaard, minimaal en aangepaste 
follow-up strategie. Aangezien het risico op een recidief tumor toeneemt wanneer het 
voorgaande recidiefcijfer hoger wordt hebben we de analyses gestratificeerd voor drie 
verschillende risicoprofielen: na de primaire tumor, na de eerste tot derde recidief, na 
het vierde recidief of meer. De waarschijnlijkheid om zonder tumor te zijn is hoger 
voor de aangepaste follow-up strategie dan voor de standaard of de minimale follow-
up strategie (95.7% na de primaire tumor versus 95.0% en 93.9%). De totale tweejaars 
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kosten van de follow-up is lager voor de minimale en aangepaste follow-up strategie 
in vergelijking met de standaard follow-up strategie (€2,254 en €2,558, in vergelijking 
tot €5,861). We concluderen dat het deels vervangen van cystoscopieën door FGFR3 
mutatie analyse niet alleen veilig is, maar ook een kosten-effectieve strategie.
Deel vier van dit proefschrift bevat de algemene discussie en een uiteenzetting van 
ontwikkelingen in de toekomst. In hoofdstuk 10 bediscussiëren we de resultaten die 
beschreven staan in dit proefschrift en plaatsen we die resultaten in de context van 
het wereldwijde blaaskanker onderzoek. Tekortkomingen van de verschillende studies 
worden toegelicht en potentiele klinische implicatie van dit proefschrift worden 
samengevat. Tot slot benoemen we de uitdagingen en de na te streven toekomstige 
studies. In het algemeen loopt het onderzoek naar blaaskanker achter op andere takken 
van kankeronderzoek (zoals darm, borst, long en prostaat). Daarnaast is blaaskanker een 
erg heterogene ziekte, welke het bestuderen ervan bemoeilijkt en het ontwikkelen van 
klinische protocollen ingewikkeld maakt. Wanneer de bewustwording van blaaskanker 
toeneemt, zal er meer onderzoekssubsidie beschikbaar komen, wat zal bijdragen aan 
de ontdekking van nieuwe aangrijpingspunten voor therapie en biomarkers voor de 
aanpak van blaaskanker. Gedurende de laatste vier jaar hebben verschillende grote 
ontwikkelingen in het onderzoek naar blaaskanker het hele onderzoeksveld stappen 
vooruit gebracht. De meest belangrijke mijlpalen zijn de ontdekking van verschillende 
moleculaire profielen van SIBK en de ontwikkeling en goedkeuring van verschillende 
immunotherapieën voor gemetastaseerd blaaskanker. Het is nu vooral belangrijk om 
deze impuls vast te houden, wat ongetwijfeld zal leiden tot een steeds zonnigere 
toekomst voor blaaskanker onderzoek en de aanpak van blaaskanker.
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LIST OF ABBREVIATIONS
Akt  serine/threonine-protein kinase
ACR  American College of Radiology
AI  Allelic Imbalance
AR  Androgen Receptor
ARF  tumor suppressor ARF
AUA  American Urological Association
AUC   Area Under the Curve
BAX  apoptosis regulator BAX
BC   Bladder Cancer
BCG   Bacillus Calmette-Guerin
Bcl-xL  Bcl-2-like protein 1 expressed from BCL2L1
BNN  N-butyl-N-(4-hydroxybutyl) nitrosamine
B-raf  serine/threonine-protein kinas B-raf
CD24  signal transducer CD24
cDNA  complementary DNA
CI   Confidence Interval
CIS   Carcinoma In Situ
CMV   Cisplatin, Methotrexate and Vinblastine
CNA  Copy Number Alterations 
CNV  Copy Number Variations
CR   Complete Response
CT  Computed Tomography
ddNTP  Dideoxynucleotide triphosphates
DNA  Deoxyribonucleic acid
dNLR   derived Neutrophil-to-Lymphocyte Ratio
dTURBT   diagnostic Transurethral Resection of a Bladder Tumor
E2F  transcription factor of the E2F family
EAU   European Association of Urology
ECM   Extracellular Matrix
EGFR  Epidermal Growth Factor Receptor
eIF  Eukaryotic translation Initiation Factor
EORTC   European Organisation for Research and Treatment of Cancer
EphB4  Ephrin type-B Receptor 4
EPI   Epirubicin
FDA   United States Food and Drug Administration
FFPE   Formalin-fixed Paraffin-embedded
FF   Fresh Frozen
FGFR   Fibroblast Growth Factor Receptor
GDP  Guanosine Diphosphate 
List of abbreviations
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GFR   Glomerular Filtration Rate
GTP  Guanosine Triphosphate 
HB   Hemobglobin
HIF-1α  Hypoxia-Inducible Factor 1α
HR   Hazard Ratio
HRAS  Harvey rat sarcoma viral oncogene homolog 
IAP  Inhibitors of Apoptosis Proteins
IGF  Insulin-like Growth Factor
IL  Interleukin
IR   Incidence Rate
KRAS  Kirsten rat sarcoma viral oncogene homolog
LN   Lymph Node
LOH  Loss of Heterozygosity
LVI   Lymphovascular Invasion
Mab  Monoclonal antibody
MAPK  Mitogen-activated protein kinase
MDM2  E3 ubiquitin-protein ligase Mdm2
MEK  dual specificity MAPK kinases 1 and 2
MIBC   Muscle Invasive Bladder Cancer
MMC   Mitomycin C
MSP   Methylation Specific PCR
mTOR  mammalian Target of Rapamycin
MVAC   Methotrexate, Vinblastine, Doxorubicin and Cisplatin
NA  Not Applicable
NAC   Neoadjuvant Chemotherapy
NF-κB  Nuclear Factor κB
NLR   Neutrophil-to-Lymphocyte Ratio
NMIBC   Non-Muscle Invasive Bladder Cancer
NPV  Negative Predictive Value
NR   Non-response
NRAS  Neuroblastoma RAS viral (v-ras) oncogene homolog 
OR   Odds Ratio
OS   Overall Survival
P21  cyclin-dependent kinase inhibitor 1
P53  cellular tumor antigen p53
PAI  Plasminogen Activator Inhibitor
PCR  Polymerase Chain Reaction
PD-L1  Programmed cell Death 1 ligand 1
PCR   Polymerase Chain Reaction
PFS   Progression Free Survival
PI3K  Phosphatidylinositol 3 Kinase
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PIK3CA  Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
POC   Pre-operative Chemotherapy
PPV   Positive Predictive Value
PR   Partial Response
PUNLMP   Papillary Urothelial Neoplasm of Low Malignant Potential
qRT-PCR   quantitative real-time PCR
ROC   Receiver Operating Characteristic 
RPS6  40S ribosomal protein S6
RTK  Receptor Tyrosine Kinase
SD   Standard Deviation
shRNA  small hairpin RNA
siRNA  small interfering RNA
STAT  Signal Transducer and Activator of Transcription
TCGA   The Cancer Genome Atlas
TERT   Telomerase Reverse Transcriptase
TNM   Tumor Nodes Metastasis
TUNEL  Terminal deoxynucleotidyl transferase dUTP nick end labeling
TUR   TransUrethral resection
TURB   Transurethral Resection Bladder
TURBT   Transurethral Resection of a Bladder Tumor
UBC   Urinary Bladder Cancer
uPA  Urokinase-type Plasminogen Activator
VEGFR  Vascular Endothelial Growth Factor Receptor
VUC   Voided Urinary Cytology
WBC   White Blood cell Count
List of abbreviations
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